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ABSTRACT 
 
 
Background: Le mutazioni nonsenso, dando origine ai codoni di stop UAA, 
UGA, UAG all’interno della sequenza codificante degli mRNA, promuovono la 
terminazione prematura della traduzione e causano circa il 30% delle malattie 
ereditarie, fra cui fibrosi cistica, distrofia muscolare di Duchenne, talassemia.  
Attualmente, due sono gli approcci per la potenziale cura di malattie causate da 
mutazioni nonsenso: la terapia genica, intesa come introduzione di un gene 
esogeno, e il proseguimento della lettura da parte dei ribosomi (o tecnica read-
through) indotto dagli aminoglicosidi, i quali diminuiscono l’accuratezza della 
fase di allungamento e riducono l’efficacia del complesso di terminazione della 
traduzione. Recenti pubblicazioni hanno descritto composti disegnati e prodotti 
per sopprimere la terminazione prematura della traduzione, inducendo il 
proseguimento della lettura da parte del ribosoma oltre codoni di stop prematuri, 
senza alterare il riconoscimento dei normali codoni di terminazione. Dall’altro 
lato, negli ultimi anni, numerosi gruppi di ricerca sono stati impegnati nello 
sviluppo di vettori lentivirali sicuri, cercando di eliminare effetti collaterali quali 
l’attivazione di oncogeni e il silenziamento del transgene.   
 
Scopo della tesi:  Il nostro obiettivo è stato quello di verificare gli effetti e 
l’utilità clinica nella β0-talassemia della correzione a livello traduzionale delle 
mutazioni nonsenso tramite read-through e della terapia genica. 
 
Metodi: Come prima cosa, siamo partiti dallo sviluppo di un modello cellulare 
della mutazione talassemica β039, utilizzabile per lo screening di un elevato 
numero di aminoglicosidi e molecole analoghe. Abbiamo prodotto due vettori 
lentivirali contenenti il gene β globinico wild type o β039 sotto il controllo di una 
regione di controllo LCR minimale e usato tali costrutti per la transduzione di 
cellule K562, successivamente subclonate, con lo scopo di ottenere numerosi cloni 
cellulari con un diverso numero di costrutti integrati. Questi cloni sono stati, 
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quindi, trattati con geneticina (G418) e altri aminoglicosidi e l’eventuale 
produzione di β globina analizzata tramite citofluorimetro.  
In secondo luogo, abbiano effettuato lo screening di numerosi pazienti 
talassemici e isolato le cellule progenitrici eritroidi da quegli individui risultati 
omozigoti per la mutazione talassemica β039. Abbiamo, quindi, trattato tali cellule 
con la geneticina e analizzato l’eventuale produzione di β globina ed emoglobina 
adulta (HbA) tramite FACS e HPLC, rispettivamente. 
Infine, abbiamo sottoposto i precursori eritroidi β039 alla terapia genica, 
utilizzando il vettore lentivirale esprimente il trascritto wild type della β globina, 
con lo scopo di verificare l’aumento della HbA tramite analisi con HPLC. Inoltre, 
trattando le cellule trasdotte con la mitramicina, abbiamo voluto verificare gli 
effetti combinati della terapia genica e dell’induzione dell’emoglobina fetale. 
 
Risultati: Abbiamo ottenuto e caratterizzato 6 cloni contenenti il gene β 
globinico mutato β039 e sette contenenti il gene β globinico wild type, da usare 
come controllo. Abbiamo, quindi, scelto 2 cloni, uno βwt e uno β039, che 
mostravano un’espressione simile del gene globinico, e li abbiamo usati per testare 
svariati aminoglicosidi, per verificarne l’attività di read-through. La geneticina 
(G418) e la gentamicina hanno mostrato la maggiore capacità di indurre la 
correzione traduzionale della mutazione nonsenso, sebbene l’effetto prodotto dal 
G418 sia stato maggiore di quello provocato dalla gentamicina. Un aumento 
significativo del numero di cellule contenenti β globina è stato, inoltre, rilevato in 
cellule progenitrici eritroidi β039 trattate con G418. Quest’ultimo risultato è stato 
confermato anche tramite HPLC, la quale ha mostrato un aumento nella 
concentrazione relativa di HbA rispetto alle emoglobine totali. 
Infine, abbiamo ottenuto un forte incremento nella percentuale di HbA quando 
gli stessi precursori eritroidi sono stati sottoposti a terapia genica, tramite 
trasduzione con il vettore lentivirale contenente il gene β globinico wild type, ed 
un netto incremento di HbF è stato, inoltre, evidenziato dopo trattamento con 
mitramicina. 
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Conclusione: Entrambi gli approcci terapeutici per la cura delle β0-thalassemie 
analizzati in questo lavoro, e cioè il proseguimento della lettura o read-through e la 
terapia genica, sebbene presentino ancora numerosi svantaggi, fra cui la tossicità 
degli aminoglicosidi e l’incertezza degli effetti dei vettori lentivirali sui geni 
endogeni, possono essere considerati tecniche con un elevato potenziale curativo. 
Naturalmente, nel caso della strategia read-through è augurabile l’identificazione 
di nuovi composti con un effetto terapeutico maggiore di quello degli 
aminoglicosidi, con minore tossicità e possibile somministrazione orale, mentre 
nel caso della terapia genica, ulteriori ricerche dovrebbero essere effettuate per 
eliminare i suoi ben noti svantaggi, fra cui in primo luogo la possibile attivazione 
di oncogeni.  
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ABSTRACT 
 
 
Background: Nonsense mutations, giving rise to UAA, UGA, UAG stop 
codons within the coding region of mRNAs, promote premature translational 
termination and are the leading cause of about 30% of inherited diseases, 
including cystic fibrosis, Duchenne muscular dystrophy, thalassemia.  
Currently, there are two approaches to directly overcome diseases caused by 
nonsense mutations: gene therapy, meaning introduction of an exogenous gene, 
and translational read-through induced by aminoglycosides, which decrease the 
accuracy of translation elongation and reduce the efficacy of the translation 
termination machinery. Interestingly, recent papers have described drugs designed 
and produced for suppressing premature translational termination, inducing a 
ribosomal read-through of premature but not normal termination codons. On the 
other hand, in recent years, many investigators have been studying the 
development of safe lentiviral vectors to avoid the side effects as activation of 
oncogenes and transcription silencing.  
 
Aim: Our purpose was to verify the effects and clinical utility in β0-
thalassemia of translational read-through and gene therapy. 
 
Methods: First, we started the development of a cellular model of the β039-
thalassemia mutation that could be used for the screening of high numbers of 
aminoglycosides and analogous molecules. We produced two lentiviral vectors 
containing the βwt- or β039-thalassemia globin gene under a minimal LCR control 
region and used such constructs for the transduction of K562 cells, subsequently 
subcloned, with the purpose to obtain several K562 clones with different copy-
number of the integrated constructs. These clones were then treated with geneticin 
(G418) and other aminoglycosides and the production of β-globin was analysed by 
FACS analysis.  
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Secondly, we screened several thalassemia patients and isolated erythroid 
progenitors from such individuals resulted homozygous for the β039 mutation. 
Then, we treated the cells with geneticin and analysed the production of β-globin 
and adult haemoglobin (HbA) by FACS and HPLC analysis, respectively. 
Finally, we subjected the β039 erythroid precursor cells to gene therapy, 
through the use of the lentiviral vector expressing the βwt-globin mRNA, with the 
aim to verify the increase of HbA through HPLC analysis. Moreover, by treating 
the transduced cells with mithramycin we wanted to verify the combined effects of 
gene therapy and fetal haemoglobin (HbF) induction. 
 
Main results: We obtained and characterized six clones carrying the β039-
globin gene and seven clones carrying the βwt-globin gene, to be used as a 
control. We then chose two clones, a βwt and a β039, showing similar content of 
mRNA and used them to test various aminoglycosides to verify their read-through 
activity. Geneticin (G418) and gentamicin showed the highest capacity to read-
through of nonsense mutation, although the effect of G418 was found to be higher 
than that displayed by gentamicin. A significant increase in β-globin containing 
cells was also detected when β039 progenitor cells were treated with G418. This 
last result was confirmed by HPLC analysis, which showed an increase in the 
relative concentration of HbA compared to total Hbs. 
Finally, we obtained a high increase in the proportion of HbA when the same 
progenitor cells were subjected to gene therapy, through transduction with the 
lentiviral vector containing the βwt-globin gene, and a clear increment of HbF was 
detected after treatment with mithramycin. 
 
Conclusion: Both the therapeutic approaches for the cure of β0-thalassemias 
analysed in this work, namely translational read-through and gene therapy, while 
still presenting many disadvantages, including toxicity of aminoglycosides and the 
uncertainty of the effects of lentiviral vectors on endogenous genes, can be 
considered techniques with a high curative potential. Naturally, in the case of 
translational read-through is hoped the identification of new compounds with a 
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therapeutic effect similar to but greater than that of aminoglycosides, with less 
toxicity and oral bioavailability, while in the case of gene therapy, further 
investigations should be made to eliminate its well known disadvantages, 
primarily including the possible activation of oncogenes. 
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 GLOSSARY 
 
 
Amp:  ampicillin 
ASL:  anticodon stem-loop 
ATM:  ataxia-teleangiectasia  
BFUe:  burst-forming unit(s) 
bp:  base pair 
BSA:  bovine serum albumine 
CFTR:  cystic fibrosis transmembrane conductance regulator 
CFUe:  colony-forming unit(s) 
CMV:  cytomegalovirus 
cPPT:  central polypurine tract 
Ct:  threshold cycle 
DMD:  Duchenne’s muscular dystrophy 
D-MEM: Dulbecco’s modified eagle medium 
dNTP:  triphosphate deoxyribonucleotide 
DPBS:  Dulbecco’s phosphate buffered saline 
EF:  elongation factor(s) 
E-MEM: essential minimum eagle medium 
EPO:  erythropoietin 
FBS:  fetal bovine serum 
FSC:  forward light scatter 
GFP:  green fluorescent protein 
GTP:  guanosine triphosphate 
GVHD:  graft versus host disease 
HbF:  fetal haemoglobin 
HbA:  adult haemoglobin 
HbA2:  type 2 adult haemoglobin 
HIV-1:  human immunodeficiency virus 
HPLC:  high performance liquid chromatography 
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HS:  hypersensitive site(s) 
IF:  initiation factor(s) 
I-MDM: Iscove’s modified Dulbecco’s medium 
HSC:  hematopoietic stem cell(s) 
LCR:  locus control region 
LTR:  long terminal repeat 
MCV:  average globular volume 
MCH:  average globular content of Hb 
MEL:  murine erythroleukemia cells 
MoAb:  monoclonal antibody 
mRNA:  messenger RNA 
NMD:  nonsense mediated decay 
nt:  nucleotide 
NTP:  triphosphate ribonucleotide 
PABPC1: major cytoplasmatic PABP (poly(A)-binding protein 
PBS:  phosphate buffered saline 
PE:  phycoerythrin 
PEG:  polyethylene glycol 
PTC:  premature termination codon 
RCL:  replication competent lentivirus 
RF:  release factor(s) 
RGO:  resistance globular osmotic 
RNP:  ribonucleoprotein 
RPMI:  Roswell park memorial institute medium 
RRE:  rev responsive element 
rRNA:  ribosomal RNA  
DS:  standard deviation 
SDF:  small DNA fragment(s) 
SFHR:  small fragment homologous replacement 
SIN:  self-inactivating transfer vector 
S/MAR: scaffold/matrix attachment region 
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SMG1-7: suppressor with morphological effect on genitalia (trans-acting factor 
involved in NMD) 
SSC:  sideward light scatter 
tRNA:  transfer RNA 
UPF1-3: upframeshift 1-3 (trans-acting factor involved in NMD) 
VSV-G: G glycoprotein of vesicular stomatitis virus 
WPRE:  Woodchuck hepatitis virus post-transcriptional regulatory element  
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INTRODUCTION 
 
 
Haemoglobin 
 
The haemoglobin (Hb) (figure 1a) is a globular tetramer, with a molecular 
weight of 64,500 dalton, located within the red cells of vertebrates, where it has 
the function to transport oxygen from the lungs to the tissues. This tetramer is 
composed of two pairs of identical α and β subunits. The four subunits have the 
same tertiary folding and they each contain eight α helices, which are identified as 
A through H [Fronticelli et al, 1995]. These helices are connected to one another 
by short loop regions and arranged so to form a pocket where the active site of the 
group, essential to bind the heme group, is located (figure 1a). The α helices wrap 
up the central core in different directions, so that helices adjacent in sequence 
become distant in structure [Branden & Tooze, 2001]. 
The ability to bind oxygen of the haemoglobin depends on the presence of a 
prosthetic group called heme, which contains an iron ion in a large heterocyclic 
ring called porphyrin (figure 1a). When the oxygen binds to the iron ion of the 
deoxy-haemoglobin, it pushes this ion inside the heme, and since the ion is linked 
to an amino acid of the protein, a histidine, this also is pushed through the plan 
(figure 1b). This conformational change is transmitted to the peptidic skeleton 
with consequent change in the three-dimensional structure of the subunits and 
variations in the level of interactions with adjacent subunits, which include the 
destruction of salt bonds and the formation of new hydrogen bonds and 
hydrophobic interactions. All this contributes to the formation of a new quaternary 
structure. The variations in the interactions between the different subunits are 
transmitted from the surface to the heme group of a second subunit and cause a 
more facilitated access of the oxygen to the ion iron, leading, so, a greater affinity 
of the haemoglobin for a second molecule of oxygen. 
A normal individual owns four different types of haemoglobin: embryonic Hb, 
the first to be produced during the haematopoiesis; HbF (fetal Hb) typical of the 
 19 
a)
o2
b)
Figure 1 – Haemoglobin. a) Haemoglobin is a tetrameric globular protein, composed of two pairs of identical α and β
subunits, having the same tertiary structure, consisting of eight α-helices connected to one another by short loop region and 
arranged so to form a pocket where the active site of the group, essential to link the heme group, is located. The ability to 
bind oxygen depends precisely on heme prosthetic group, which contains an iron ion in a large heterocyclic ring called 
porphyrin. b) When the oxygen binds to the iron ion of the deoxy-haemoglobin, it pushes the ion inside the heme plan and 
since the ion is bound to a histidine of the protein, this also is pushed through the plan, resulting in a conformational change 
of the entire subunit and variations in the level of interaction with the adjacent subunits. These variations are transmitted 
from the surface to the heme group of a second subunit, causing an easier access of the oxygen to the iron ion.
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intrauterine life and present only in trace after birth; HbA (adult Hb), which is 
about the 98% of an adult subject haemoglobin; HbA2, present only after birth and 
corresponding to the remaining 2%. 
 
Globin clusters 
 
The genes codifying for the α and β-like globin chains are put together in 
clusters (figure 2): the α-globin cluster is located on the short arm of chromosome 
16, while the cluster β spans 80 Kb on the short arm of chromosome 11. In both 
clusters, the globin genes are arranged in the order in which they are expressed 
during development [Joy et al, 2000]. 
In the cluster β, upstream of the globin genes is the locus control region (LCR), 
a major regulatory element containing four erythroid-specific hypersensitive sites 
present at all stages of erythroid development (HS1–4) and a constitutive site 
(HS5) located further upstream. Two further HSs have been described by 
Routledge et al [2002]: HS6 and HS7, upstream of HS5. 
The cluster β (figure 2) includes the embryonic block composed of ε gene, 
active until the 8th week of gestation; the fetal block with Gγ and Aγ genes, which 
produce globin chains that differ by one amino acid at position 136, namely 
glycine in Gγ and alanine in Aγ, and are active from the 8th week of gestation until 
the 3rd month after birth; finally, the adult block with the δ and β genes producing 
globin chains different only for 10 amino acids including between the positions 22 
and 115. These genes are activated gradually, as the activity of genes γ decreases 
(switch HbF – HbA) and expressed fully only after birth. The genes present in 
cluster β produce during the embryonic period the haemoglobins Gower I (ζ2ε2), 
Portland (ζ2γ2) and Gower II (α2ε2); in the fetal period HbF (α2γ2) and in the adult 
period HbA (α2β2) and HbA2 (α2δ2 ) [Bianco Silvestroni, 1998]. 
The cluster α (figure 2) includes an embryonic gene (ζ), a fetal-adult block 
consisted of the α1 and α2 genes, a few pseudo-genes (ψξ, ψα1, ψα2) and the θ 
gene, which is considered a pseudo-gene, because, while producing a mRNA, does 
not express any globin. 
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Structure of the β-globin genes 
 
The general structure of the β globin gene (figure 3a) is typical of other globin 
loci. The genomic sequence which encodes for 146 amino acids spans 1,600 bp, 
and are divided into three exons (coding regions) by two non-coding intervening 
sequences (introns or IVS). IVS1 interrupts the coding sequence within codon 30, 
and IVS2 between codons 104 and 105. Exon 2 encodes the residues involved in 
heme binding and αβ dimer formation while exons 1 and 3 encode the non-heme 
binding regions of the globin chain. Many of the amino acids involved in globin 
subunit interactions required for the Bohr effect and 2,3-DPG binding are found in 
exon 3. Conserved sequences important for gene function are found in the 5’ 
promoter region, at the exon – intron junctions and in the 3’ untranslated region 
(3’UTR) at the end of the mRNA sequences [Joy et al, 2000]. 
The promoter is an indispensable region for the efficient transcription of the 
gene. It includes several conserved sequences necessary for its efficient 
functioning (figure 3a), as recognized and bound by transcription factors. Among 
these are the sequence ATAA (or ATA-box), located about -30 nucleotides from 
the cap, the sequence CCAAT (or CAAT-box), located between -70 and -80 bp 
and the sequence CACCC, which is duplicated in a proximal and distal sequence, 
which show to exert equal influence on the transcription [Bianco Silvestroni, 
1998]. 
The 5’ untranslated region (5’UTR) occupies a region of 50 nucleotides 
between the very 5’ terminus or ‘cap’ site of the β-globin mRNA and the initiation 
(ATG) codon. There are two prominently conserved sequences in the 5’UTR of 
the various globin genes (both α and β). One is the CTTCTG hexanucleotide 
found 8 through 13 nucleotides downstream from the cap site. The second 
conserved sequence is the CACCATG, in which the last three nucleotides form the 
initiation codon. The 3’UTR constitutes the region between the termination codon 
and the poly(A) tail (figure 3a). It is 132 nucleotides long with one conserved 
sequence, AATAAA, located 20 nucleotides upstream of the poly(A) tail. This 
consensus hexanucleotide serves as a signal for cleavage of the 3’ end of the 
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primary transcript and addition of the poly(A) tail which confers stability on the 
processed mRNA and enhances translation [Joy et al, 2000]. 
 
Locus control region (LCR) 
 
The locus control regions (LCRs) have been identified in at least 36 loci of 
different species of mammals, including human, mouse, rat, rabbit and goat. As 
already mentioned, the LCR is physically defined by the presence of 5 HS (figure 
3b), areas of nucleosomic destruction in which the  DNA is susceptible to 
digestion by the DNase I. These areas make the region accessible to transcription 
and chromatin-remodeling factors [Harju et al, 2002]. 
It has been demonstrated, through the deletion of the LCR in mice and humans, 
that this region is necessary neither for the initiation and maintenance of an open 
chromatin structure, namely transcriptional active, nor for the transcription to 
baseline levels of various globin genes [Reik et al, 1998; Bender et al, 2000]. 
Bender et al [2000] proposed a model where the regulation of these two 
phenomena is attributed to several redundant factors, among which is also 
included the LCR, responsible only of the stimulation of transcription at high 
levels [Bender et al, 2000]. 
Individual HSs within the LCR appear to have different roles in chromatin 
remodeling and control of globin gene switching (figure 3b) [Harju et al, 2002]:  
• HS1, located about 6 kb 5’ to the ε-globin gene, may be dispensable for 
LCR function, since individuals with a deletion that encompasses this region show 
no sign of haematological defect [Hardison et al, 1997].  
• HS2 is a general enhancer element that functions during all three 
developmental stages. Similar to other enhancers, HS2 encodes E-box sequences, 
which are binding sites for the basic helix-loop-helix family of transcription factor 
proteins, such as USF and Tal 1 (SCF). Binding of NF-E2 is directly correlated 
with HS2 enhancer function. However, HS2 does not display enhancer activity by 
itself in single-copy transgenes; it requires the presence of another LCR HS [Harju 
et al, 2002].  
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• HS3 is located upstream of HS2 and seems to have chromatin-opening 
function or chromatin-remodeling activity [Harju et al, 2002]. It causes high level 
expression of the β- or γ-globin genes after stable integration in MEL cells, but it 
does not enhance transient expression of these construct prior to integration. Such 
observations lead to assume that the principal effect of HS3 is on domain opening 
with at best a weak activity as a classical enhancer [Hardison et al, 1997].  
• HS4 has no enhancer function by itself; perhaps it is required during 
development to achieve efficient domain opening by the LCR [Hardison et al, 
1997].  
• HS5 has always been considered as a constitutive hypersensitive site but 
Wai et al [2003] showed, on erythroid and not erythroid tissues of humans and 
mice, that it is, in fact, erythroid-specific. This site presents a unique function, 
namely that of insulator; in fact, it can insulate the β-globin gene from the 
enhancing effect of HS3 when it is positioned between the HS3 and the human β-
globin gene [Li & Stomatoyannopoulos, 1994]. Insulator elements protect against 
the negative effects of neighboring heterochromatin and may serve as boundary 
elements that flank or demarcate an open, transcriptionally active chromatin 
domain. They may also block histone deacetylase activity [Harju et al, 2002] . 
 
β-Thalassemia 
 
The β-thalassemia is an autosomal recessive genetic disease, caused mainly by 
point mutations within and near the β globin gene. Nearly 200 different mutations 
have been described in patients with β-thalassemia and related disorders. Although 
most are small nucleotide substitutions within the cluster, deletions may also cause 
β-thalassemia. All the mutations result in either the absence of the synthesis of β-
globin chains (β0-thalassemia) or reduction in synthesis (β+-thalassemia) [Olivieri, 
1999]. The geographical distribution of these molecular defects is not uniform, 
because each ethnic population have common and rare alterations different from 
those of another population [Le Denmat et al, 1997]. 
Although β-thalassemia is considered, from a clinical point of view, as a 
recessive character, in fact, at haematological level, β-thalassaemic alleles behave 
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as dominant characters because it is well recognizable in heterozygous individuals 
the typical haematological phenotype of microcitemia [Bianco Silvestroni, 1998]. 
 
Classification of β-thalassemias  
 
In β-thalassemias, it is possible to identify 4 different genotypes:  
1) homozygosity with both alleles wild type.  
2) heterozygosity with a wild type allele and one carrying the mutated β-
globin gene: individuals with this genotype were called microcitemic and have the 
ability to transmit the mutated allele to their offspring. The sons of two 
microcitemic individuals, having the same mutation, have a 25% chance of being 
healthy homozygous, 50% being heterozygous, as parents, and 25% to be 
homozygous for the mutation.  
3) heterozygosity for two different mutations of β-globin gene: this genotype 
correlates with thalassaemic phenotypes with various gravity, depending on the 
types of mutation present.  
4) homozygosity for the same genetic defect: in most cases, the condition is 
the most severe thalassemia, called thalassemia major or Cooley's disease. 
Because of the extensive number of mutations that can lead to a defective β-
globin chain, it is possible to identify β-thalassaemic phenotypes of different 
gravity, based precisely on the type of defect present in the gene. Furthermore, 
depending on the fact that this defect could cause a reduction in the production of 
β-globin or its complete elimination, it is possible to subdivide the β-thalassemia 
in two large groups, β+ and β0, respectively. 
Among the many β-thalassemia phenotypes, the most common are: 
1) silent β-thalassemia: this term is used for a mild β-thalassemia condition 
which, in the heterozygote, is difficult to detect because the haematological 
parameters and the HbA2 and HbF levels are essentially normal: only a slight 
imbalance in the in vitro chain synthesis can be observed [Gonzalez-Redondo et 
al, 1989]. These mutations have been usually identified by genetic and molecular 
analysis of families in which a proband was affected by thalassemia intermedia, 
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resulting from a compound heterozygous state for a typical β-thalassemia and 
silent β-thalassemia [Moi et al, 2004]. 
2) β-thalassemia trait (or microcitemia): it manifests itself in individuals 
heterozygous for a mutation in the β-globin gene. They have a mild anemia, 
decreased level of Hb, iperglobulia, reduced average globular volume (MCV), 
reduced average globular content of Hb (MCH), increased resistance globular 
osmotic (RGO) and abnormal erythrocyte morphology. The symptoms may, 
however, have different severity depending on the type of mutation [Bianco 
Silvestroni, 1998]. 
3) β-thalassemia intermedia: in a large number of patients with thalassemia 
intermedia, the reduced disease severity can be explained by the inheritance of 
milder β-thalassemia alleles that allow the production of a significant proportion 
of β-globin chains. A substantial number, however, have β0-thalassaemia, and in 
such cases, the absence of β-globin chains is compensated by an inherent ability to 
produce fetal haemoglobin (HbF). Yet other thalassemic patients have inherited 
only one β-thalassemia allele. Most cases of unusually severe heterozygous β-
thalassemia are due to the co-inheritance of extra α globin genes while others are 
due to the nature of the underlying β-thalassemia mutation itself. Hence, the 
underlying genotypes of β-thalassemia intermedia are extremely heterogeneous; 
the genetic basis can be the inheritance of one or two β-thalassemia alleles 
interacting with other genetic variables [Thein, 2004]. 
4) β-thalassemia major or Cooley’s disease: it is the most serious form of β-
thalassemia, characterized by a very small production of Hb or its total absence. It 
manifests itself in individuals homozygous for a β0- or severe β+-thalassemia 
allele, or in individuals heterozygous for two different β0 and β+ mutations. 
Patients with Cooley's disease have an anemia so severe that they undergo regular 
blood transfusions to survive [Thein, 2004]. 
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Alterations of β-globin cluster 
 
The alterations that may affect the β-globin gene are: deletions, defects of 
transcription, defects of mRNA maturation, defects of mRNA translation and 
defects that impair the stability of the β-globin chain. 
Deletion of the β-globin gene: among genetic factors that give rise, if present in 
heterozygous, to β-microcitemias, deletions are quite rare. The existence of cases 
of microcitemia with a level of HbA2 much higher than in normal β-thalassemia 
heterozygotes, often until 8 to 9%, was known even before the identification of the 
molecular defect. All these varieties have an apparent microcitemic 
haematological phenotype, with  normal or slightly higher HbF and a ratio α/β>1, 
and they are caused by extensive deletions that remove the β-globin gene but leave 
intact the δ-globin gene. Except a few rare exceptions, it is also deleted the region 
immediately upstream of β-globin gene that includes, at -200 bp, a binding site for 
NF-E2 protein. The increase in the proportion of HbA2 is supported by the 
deletion of the 5' upstream of the β-globin gene [Bianco Silvestroni, 1998]. 
Defects of transcription: they are, in the great majority of cases, point 
mutations of the promoter. These mutations affect the various functional blocks of 
the region: the ATA box in which were found mutations in the nucleotides -28, -
29, -30, -31; the proximal CACCC box with mutations in nucleotides -86, -87, -88, 
-90, -92; the distal CACCC box with the mutation -101 (C/T) [Bianco Silvestroni, 
1998]. This last is associated, as those at nucleotides -90 and -92, with a 
phenotype of silent β-thalassemia [Gonzalez-Redondo et al, 1989].  
All mutations in the promoter reduce, but never completely, the transcription 
of β-globin gene and therefore give explanation of the mild β-thalassemias and of 
some β-thalassemias with a silent or sub-silent phenotype [Bianco Silvestroni, 
1998]. 
Defects in the mRNA maturation: these are divided in splicing defects and in 
cut and polyadenilation defects. 
Splicing mutations: they are a very large and important group of mutations that 
cause about half of all β-thalassemias. The defects consist, usually, in point 
mutations that, with various mechanisms, alter the normal process of splicing. 
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These mutations can occur either within an intron or within an exon. In the first 
case, they may cancel a regular site of splicing destroying the donor site GT or the 
acceptor site AG, reduce the efficiency of a splicing site altering its consensus 
sequence or create a new site of splicing, producing a new signal GT or AG in a 
cryptic site. When, however, mutations affecting the exons, the only thing that can 
happen is the creation of a new donor or acceptor site of splicing, thus producing 
an abnormal mRNA [Bianco Silvestroni, 1998]. 
Mutations in the cut and polyadenilation site of the pre-mRNA: if the 
AATAAA sequence is mutated, the cut and polyadenilation process occurs much 
more downstream (i.e. about 20 nt downstream the next AATAAA sequence). It 
produces, thus, mRNA much longer (several hundred nucleotides) and very 
unstable. The resulting phenotype, in heterozygous, is a mild β+ microcitemia with 
a rate of HbA2 little higher than the standard [Bianco Silvestroni, 1998]. 
Defects of mRNA translation: they constitute the third major group of 
mutations that cause β-thalassemia. The most numerous are those affecting exons 
and may be non-sense or frameshift [Bianco Silvestroni, 1998]. 
Non-sense mutations: they consists in the substitution of a base in a codon of 
the codifying DNA, with subsequent creation of a premature stop codon and, thus, 
translation termination. To this group belongs one of the most frequent mutations 
in our country, especially in Sardinia, the β039-thalassemia (figure 4). For 
instance, in β039-thalassemia the CAG (Gln) codon of the β-globin mRNA is 
mutated to the UAG stop codon [Trecartin et al, 1981; Piras et al, 2005], leading to 
premature translation termination and to mRNA destabilization through the well 
described nonsense-mediated mRNA decay (NMD) [Holbrook et al, 2004; Stalder 
& Mühlemann, 2008]. Other examples of stop mutation of the β-globin mRNA 
occurr at position 15 [Ahmed et al, 2001], 37 [Kornblit et al, 2005; Li et al, 2006] 
and 127 [Préhu et al, 2005] of the mRNA sequence. 
Frameshift mutations: they consist of deletions or additions of one or a few 
nucleotides, which cause a shift in the reading frame of the mRNA (frameshift) 
and, therefore, a more or less early termination of the translation. If the shift 
begins in a codon far away from the termination one, the chain, as well as having 
an altered amino acid sequence, is usually much shorter than the normal. If, 
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Pre-mRNA
β039CAG TAG
No β-globin
UAG
AUG
Stop
Translation
AUG UAA
Gln
Normal β-globin
CAG
Splicing
a)
GAGAAGACTC TTGGGTTTCT GATAGGCACT GACTCTCTCT GCCTATTGGT 
CTATTTTCCC ACCCTTAGGC TGCTGGTGGT CTACCCTTGG ACCCAGAGGT 
TCTTTGAGTC CTTTGGGGAT CTGTCCACTC CTGATGCTGT TATGGGCAAC 
CCTAAGGTGA AGGCTCATGG CAAGAAAGTG CTCGGTGCCT TTAGTGATGG 
CCTGGCTCAC CTGGACAACC TCAAGGGCAC CTTTGCCACA CTGAGTGAGC 
TGCACTGTGA CAAGCTGCAC GTGGATCCTG AGAACTTCAG GGTGAGTCTA 
TGGGACCCTT GATGTTTTCT TTCCCCTTCT TTTCTATGGT TAAGTTCATG
TAGb)
Figure 4 – β039 mutation. a) Schematic reppresentation of the maturation and translation of βwt and β039 
transcripts: in the presence of the mutation β-globin chains are not produced. b) Sequence of the second exon (in 
blue) of the human β-globin gene, with the codon 39 (in red) and the mutation CD 39 C/T (β039). 
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however, the mutation is located in a region closer to the end of the translation, it 
is very likely that this will continue beyond the normal stop codon, to meet a new 
termination codon, producing a stretched globin chain [Bianco Silvestroni, 1998]. 
Mutations that cause serious instability of the β-globin chain: these defects are 
frameshift or non-sense mutations or deletions of a few nucleotides, for the most 
part in the 3rd exon. They give rise to a β-globin chain stretched or, more rarely, 
truncated but always highly unstable, which does not have the tendency to form 
tetramers and then falls rapidly, so that the abnormal Hb is not present in the 
circulation. It is distinctive, hence, the data that the synthesis ratio between α and β 
 chains is highly unbalanced, while that between α and β mRNA is normal. 
Because of the instability of the β-globin chain, large quantities of both β-globin 
and α-globin chains remain free [Bianco Silvestroni, 1998]. 
 
Physiopathology of β-thalassemia 
 
The pathophysiology of β-thalassemia relates to a quantifiable deficiency of 
functional β-globin chains, which leads to an imbalanced globin chain production 
and an excess of α-globin chains [Thein, 2004].  
In β-thalassemia, the synthesis of normal α-globin chains from the unaffected 
α-globin genes continues as normal, resulting in the accumulation within the 
erythroid precursors of excess unmatched α-globin. The free α-globin chains are 
not able to form viable tetramers and instead precipitate in red cell precursors in 
the bone marrow forming inclusion bodies. These α-chain inclusions can be 
demonstrated by both light and electron microscopy in  erythroid precursors in the 
bone marrow as well as in peripheral red cells following splenectomy. They are 
responsible for the extensive intramedullary destruction of the erythroid precursors 
and hence the ineffective erythropoiesis that underlies all β-thalassemias [Thein, 
2005]. 
Erythrokinetic and morphologic studies showed that particularly in the β-
thalassemias the major cause of anemia was death of erythroid precursors in the 
bone marrow and other sites of extramedullary erythropoiesis. The cause of this 
ineffective erythropoiesis was unknown until it was showed, that β-thalassemia 
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major erythroid precursors, but not myeloid precursors, underwent accelerated 
apoptosis, as detected by an increase in DNA “laddering,” a sign of enhanced 
nucleosomal cleavage. Quantitative studies subsequently showed that erythroid 
apoptosis in β-thalassemia major was increased about four times above normal. In 
combined erythrokinetic and marrow analyses of patients with moderate to severe 
forms of α- and β-thalassemia, it was shown that there was a fairly tight 
correlation between ineffective erythropoiesis and marrow erythroid apoptosis. 
This lead to the proposal that the mechanism of ineffective erythropoiesis in the 
thalassemias is enhanced apoptosis. 
The level of apoptosis achieved in the bone marrow of β-thalassemia patients 
seems to depend, at least in part, on their level of erythroid expansion. Some 
hypothesis were formulated, trying to explain this dependence: the most accredited 
one says that when a cell line is forced by physiologic or pathologic mechanisms 
to increase its proliferative rate, the chances for errors increase, leading to 
aberrations that are detected by the affected cells, which then turn on their 
apoptotic programs [Centis et al, 2000]. 
The lack of β-globin chains, in β0 homozygous patients, and the consequent 
ineffective erythropoiesis begin a series of events leading to the onset of several 
clinical manifestations of the disease (figure 5). The first and most serious 
manifestation is the anemia, determined primarily by the total absence of HbA. In 
erythroid precursors are present, since the early states of development, inclusion 
bodies formed by the precipitation of α chains, aggregates of ferritin, mitochondria 
loaded with iron, both due to the absence of haemoglobin, and accumulation of 
glycogen. As already explained, most of erythroblasts faces death in bone marrow, 
but a small part of them, containing HbF, enters to the general circulation. They 
are, however, severely damaged, restricted and little elastic and, once in the 
spleen, are unable to cross the splenic sinus and are therefore eliminated by 
macrophages. Few cells, insufficient to compensate the anemic state, less affected 
because containing a fair share of HbF, manage to cross the spleen without being 
destroyed but only undergoing the removal of some precipitates (pitting) and 
finally destroyed in the following steps. The average life of red cells of patients 
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Figure 5 – General physiopathology of β0-thalassemias.
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with thalassemia major which come into circulation is, therefore, very short: the 
destruction is premature and the hyperhemolysis results in sub-icterus, increase of  
indirect bilirubin and urobilin. Moreover, the high work of removal done by the 
spleen leads to one of the predominant features of β-thalassemia patients and that 
is splenomegaly (figure 5) [Bianco Silvestroni, 1998]. 
A direct effect of anemia is the increased production of erythropoietin, which 
leads to intense proliferation and expansion of bone marrow with the resulting 
skeletal deformities. Another important consequence of anemia is the iron loading 
in hearth, liver and spleen that results from the increased gastrointestinal 
absorption and the blood transfusions [Thein, 2004]. These iron deposits are 
responsible for  
many complications that accompany the disease. Among these may include 
osteopenia and osteoporosis, depending also on anemia and growth of bone 
marrow, heart complications, which are the leading cause of death in β-
thalassemia, endocrine disorders, diabetes and liver cirrhosis, limit situation, rarely 
reached even when, in addition to deposits of iron, the liver is infected with 
hepatitis C virus, recruited via blood transfusion. 
 
Therapies  
 
It is possible to divide the therapies for β-thalassemia into two principal 
groups: the maintenance and definitive therapies. 
 
Maintenance therapies 
 
The traditional therapies that have contributed over the last 35 years to 
eliminate, or nearly, manifestations of the disease and to determine the extension 
and improvement of quality of life of patients are blood transfusions and iron 
chelation therapy. 
Blood transfusions: in patients with β-thalassemia major, this therapy is not 
only an alternate remedy that is applied to eliminate or reduce an anemic state, but 
is also a therapy that acts on the main clinical manifestations of disease by 
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changing their pathogenesis. Practiced under the current protocols, the therapy 
eliminates dangerous fluctuations of haemoglobin level and allows the patient to 
have regular growth and development, good living conditions, normal resistance to 
infection. It determines also a drastic reduction in intestinal absorption of iron that 
already with an average level of haemoglobin of 9 g/dl is only 10% higher than the 
normal. Finally, this therapy produces another and even more important effect, 
namely a reduction of bone marrow activity, because it reduces the production of 
erythropoietin and consequently the enormous expansion and hyperactivity of 
bone marrow and the biggest manifestations that this involves. Another effect that 
complements the block of bone marrow is the cessation or marked reduction of the 
ineffective erythropoiesis, with a sharp decline in production of altered 
erythroblasts and precipitated α chains. The consequence of the entry in the 
circulation of a very small number of altered erythroblasts and red blood cells, 
intended to be seized in the spleen, is a slower increase in the volume of this organ 
with a delayed onset of hypersplenism  [Bianoc Silvestroni, 1998]. 
Thanks to new techniques for early detection, the start time of transfusion 
therapy in patients with severe thalassemia major is usually in the second half or 
towards the end of the first year of life. Once started, the transfusion must be such 
as to ensure a level of haemoglobin pre-transfusion of approximately 9 – 10 g/dl, 
and this requires the patient to be transfused every 2 – 3 weeks with an average of 
500 grams of blood, which was previously deprived of all leukocytes, through 
centrifugation, sedimentation, filtration and washing, to avoid feverish reactions. 
The washing with physiological solution can be repeated a second time in the case 
of patients particularly susceptible to plasma proteins, such as cytokines.  
Two risks are associated with transfusion therapy: 1) the use of blood 
containing viruses such as hepatitis B and C viruses, leading to onset of infection 
and, in the specific case, of hepatitis; 2) assumption of large amounts of iron, 
which, added to that taken by gastrointestinal adsorption, leads to the formation of 
large deposits in several organs with the consequences of which has already 
spoken. 
Iron chelation therapy: the first iron chelator introduced in the treatment of the 
β-thalassemia major is deferoxamine (Desferal®), already used since the 1960s but 
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applied with methods and doses truly effective only by the end of the 1970s. This 
is a hexadentate agent that effectively chelates iron, masking all six coordination 
sites so that the complex cannot generate ROS. Deferoxamine does not enter cells, 
so the iron is removed from transferrin or non-transferrin-bound sources of iron in 
blood and bile. The chelated iron is excreted equally in urine and stool. 
Deferoxamine must be given parenterally, either by bolus plus intravenous 
continuous infusion or via prolonged subcutaneous infusion. For best results the 
infusion needs to be continued for 8 – 12 hours using a constant infusion pump 
and must be carried out 250 nights per year in order to prevent the iron buildup 
that occurs in a patient getting RBC transfusions every three weeks. The high cost 
of the drug, pump, and infusion materials, as well as the side effects, limit its 
acceptability and utility [Schrier and Angelucci, 2005]. 
In recent years, new iron chelators, orally active, were developed. Among 
these drugs, the most used is deferiprone (Ferriprox®). As a small, lipophilic 
bidentate molecule, deferiprone would theoretically have the potential to be more 
effective than deferoxamine in removing intracellular iron from some tissues [Piga 
et al, 2003]. The available data appear to demonstrate that deferiprone is an 
effective oral iron chelator able to reduce iron overload and to maintain a safe 
body iron level [Galanello, 2007]. Moreover, a comparative study of the effects of 
the two chelators (deferiprone and deferoxamine) on survival and cardiac 
complications, showed greater activity of deferiprone on deposits of iron in the 
heart, thus improving the conditions of the organ. This action was attributed both 
to the ability of this molecule to enter into the cells and to its longer half-life and 
the opportunity to make an uninterrupted therapy (seven days a week), with more 
frequent doses (three per day) than that achieved with deferoxamine [Piga et al, 
2003]. 
Several are the side effects of these two drugs: in the case of deferoxamine, 
prolonged use can lead to chronic toxicity, with onset of cataracts, damage to the 
retina, optic atrophy, ototoxicity and cartilage dysplasia [Merson and Olivieri, 
2002]; while deferiprone can cause, even in the early stages of use, neutropenia, 
agranulocytosis and arthralgia [Schrier and Angelucci, 2005]. 
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Due to the different distribution of deferoxamine and deferiprone in the cell, a 
combination therapy was proposed, which could bring several benefits through a 
synergistic action of the two drugs. In fact, the deferiprone could act transferring 
the iron from the deposits inside the cell to molecules of deferoxamine in the 
extracellular compartment, with the function to excrete the iron in urine and stool 
[Ding et al, 2002]. 
A new orally active iron chelator is actually been testing in clinical trials: the 
deferasirox (ICL670, Exjade®) is a tridentate iron chelator with a relative long 
circulating half-life of 8 to 16 hours and documented cellular permeability [Walter 
et al, 2008]. Preclinical studies have demonstrated that ICL670 is a highly potent 
and selective chelator, and clinical evaluation in patients with iron overload have 
demonstrated an efficacy and safety profile compatible with long-term use. Six-
month preliminary data from a 1-year comparative study of thalassaemic patients 
with transfusional iron overload suggest that a single daily dose of ICL670 20 
mg/kg is as effective as deferoxamine in the removal of iron from body stores 
[Cappellini, 2005].  
As for the future perspectives of maintenance treatment, in addition to research 
and testing of new oral chelators, investigators have focused their attention to 
substances that can stimulate the production of HbF in order to reduce the annual 
requirement of blood transfusions of thalassemia patients, thus reducing the iron 
contribution. Among the different molecules so far tested in clinical trials, are 
included hydroxyurea (HU) [Bradai et al, 2003] and derivatives of butyrate [Reich 
et al, 2000]. In the case of HU, a general increase in the level of Hb was noticed in 
all patients in the study, while in the case of derivative of butyrate, only two 
patients over 8 showed a marked improvement. In the latter case, it was suggested 
that the stimulating action of the substance may depend in some way on a genetic 
factor responsible for a particular predisposition to the production of HbF and on 
the serum levels of erythropoietin present in patients prior to the administration of 
derivative. Because of the side effects and the low activity of HU and derivatives 
of butyrate, many other molecules capable of inducing the production of HbF are 
under study, among these, are included cytosine arabinoside [Cortesi et al, 1999], 
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mithramycin [Bianchi et al, 1999; Fibach et al, 2003], rapamycin [Mischiati et al, 
2004; Fibach et al, 2006]. 
 
Definitive therapies  
 
This group includes all the therapeutic techniques aimed to resolve the disease, 
including bone marrow and umbilical cord blood cells transplantation. 
Bone marrow transplantation (BMT): the first successful BMT for 
thalassaemia major was performed in 1982 and now over 1500 transplants have 
been performed worldwide with the most experience from Pesaro, Italy [Lawson 
et al, 2003]. Just in Pesaro, in 1989, following analysis of potential negative 
factors such as low quality of chelation therapy before the transplantation, the 
marked hepatomegaly and portal fibrosis, were established three classes of risk, in 
which splitting transplant patients, and, according to them, several protocols of 
action were developed [Lucarelli et al, 1998]. 
Naturally, the essential prerequisite to make bone marrow transplantation is the 
availability of a compatible donor. Only after the identification of the donor, the 
patient is assigned to one of the categories of risk and is therefore subjected to 
ablation of the hematopoietic and immune systems. Once this deletion has taken 
place, the patient is ready to be transplanted by infusion of bone marrow into a 
peripheral vein [Lucarelli et al, 2002]. 
The complications that can arise early after the transplant are different: the 
foremost one is the rejection of the transplant itself, accompanied by the recover of 
thalassemia conditions and dependency on blood transfusions. Another danger is 
the disease known as graft versus host disease (GVHD), which can occur in acute 
and chronic form. In both cases, major events take place at the level of immune 
system and epithelial cells of skin, liver and intestines, with complications that can 
lead to death [Robbins, 1997]. 
Regarding the long-term complications, they include all the consequences of 
the years prior to transplantation, in which the patient has undergone a transfusion 
and chelation therapy, including 1) the accumulation of iron that lead to infertility, 
disturbance of growth and alteration of the endocrine system; 2) chronic hepatitis, 
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mainly due to infection by the hepatitis C virus and 3) liver fibrosis [Lucarelli et 
al, 2002]. 
Unfortunately, in most cases, even after the transplantation it is necessary to 
subject the ex-thalassemic patients to chelation therapy to eliminate all the iron 
overloads formed in the previous period. To do this, the preferred therapeutic 
technique is the phlebotomy, which consists in the removal of 6 ml/kg of blood 
every 14 days and in the administration of autologous plasma or saline solution to 
restore the normal blood volume. Those patients who, for various reasons, can not 
be subjected to this treatment, are treated with subcutaneous infusions of 
deferoxamine [Lucarelli et al, 2002]. 
Umbilical cord blood cells transplantation: it is not a technique widely used in 
the treatment of β-thalassemia major, but has many advantages over bone marrow 
transplantation, including a lower incidence of GVHD and increased survival. In a 
study where 44 patients undergoing a umbilical cord blood transplantation in 
different institutions were analyzed, none of them went to meet death, which 
confirms the high reliability of the technique. It should, however, noted that in all 
cases the period of post-transplantation analysis was of short duration, but the 
prognosis remains, however, favourable for the total absence of chronic GVHD, 
which difficulty occurs after two years [Locatelli at al, 2003]. 
The positive results achieved, until now, in the cure of thalassemia with 
umbilical cord blood transplantation should encourage the use of this technique in 
individuals suffering from haemoglobinopathies and thus stimulate the donation of 
umbilical cord from women at the end of pregnancy. 
 
Gene therapy 
 
In recent years, various approaches have been proposed for the treatment of 
haemoglobinopathies, especially β-thalassemia and sickle cell anemia, based on 
gene transfert, gene targeting or correction of mRNA processing. 
The gene transfer into hematopoietic stem cells is a technique widely studied, 
which has already proved effective in animal models. Since the patient's own cells 
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are used, the need for HLA-identical donor and immunological complications 
associated with bone marrow transplantation are removed. 
This gene strategy has 4 goals: 1) the transfer of a single gene in specific 
hematopoietic stem cells, 2) the endogenous expression of the transgene at high 
levels, 3) the maintenance of that expression over time and 4) the use of not 
pathogenic vectors. Many of the available techniques are not in accordance with 
all four of these expectations. For example, non-viral vectors, which may be in the 
form of naked DNA, cationic lipid binding DNA through electrostatic interactions 
or particles of condensed DNA, have all proved ineffective for in vivo 
transfection; in addition, the gene transfer results in transient expression of genes 
of interest. Increased efficiency can be achieved through the use of adenoviral 
vectors, but, again, the expression is not permanent because of the immune 
response against cells that express low levels of viral proteins. Instead, the vectors 
derived from onco-retrovirus, such as the Moloney murine leukemia virus, have 
proved suitable for gene therapy, thanks to their ability to integrate the gene of 
interest into the genome of target cells without, however, any viral gene transfer 
[Stathopulos, 2003]. 
Recombinant onco-retroviruses were the first viral vectors used to transfer the 
human β-globin gene in mouse hemaopoietic stem cells (HSCs). Early 
experimentation with vectors harboring the β-globin gene resulted in tissue-
specific but low and variable human β-globin expression in bone marrow 
chimeras, usually varying between 0 and 2% of endogenous mouse βmajor RNA 
levels. Initial efforts to incorporate locus control region (LCR) subfragments into 
onco-retroviral vectors resulted in low titers, low expression, or unstable vectors 
prone to sequence rearrangements. Incorporation of the core elements of HS2, 
HS3, and HS4 of the human β-globin LCR significantly increased expression 
levels in murine erythroleukemia (MEL) cells, but failed to abolish positional 
variability of expression. This finding suggested that a minimal LCR comprising 
juxtaposed core elements did not provide full LCR function, but rather acted like 
an erythroid-specific enhancer [Sadelain et al, 2005; Lisowski & Sadelain, 2008].  
As a result of these continuing failures, some investigators have thought of 
using more extensive fragments containing the sites HS2, HS3 and HS4. 
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Unfortunately, incorporation of larger HS spanning elements into onco-retroviral 
vectors is problematic due to the inability of the vector to incorporate large 
quantities of genetic material in a stable manner. Another major limitation of 
onco-retroviral vectors is the obligate requirement of these vectors to transduce 
cells that divide shortly after infection because the vector RNA cannot migrate 
into the nucleus due to the presence of a nuclear membrane, and thus, must wait 
for mitosis to make the transition. Since most HSCs are in a quiescent state, they 
must be induced to divide in order to achieve higher transduction efficiencies and 
overall expression levels. The problem with stimulating quiescent hematopoietic 
stem cells is that they tend to lose long-term repopulating capacities when treated 
with cell division stimulants such as cytokines [Stathopulos, 2003]. 
In view of such difficulties, most investigators began exploring alternative 
vector systems, as lentiviral vectors, and alternative transcriptional control 
elements. Lentiviral vectors are replication-defective retroviral particles containing 
lentiviral core proteins and enzymes, which are pseudotyped with a heterologous 
retroviral envelope or equivalent. Lentiviral vectors derived from HIV-1 and other 
lentiviruses have elicited great interest for their ability to transduce non-dividing 
cells. While onco-retroviral vectors are restricted to cells proceeding through 
mitosis, the preintegration complex of lentiviral vectors can translocate to the 
nucleus and successfully integrate in the absence of cell division. Lentiviral 
vectors can transduce a broad spectrum of target cells, including neurons, retinal 
photoreceptors, dendritic cells, macrophages, hepatocytes, and HSCs. Another 
fundamental attribute of lentiviral vectors is their relative genomic stability and 
their packaging capacity [Sadelain et al, 2005; Lisowski & Sadelain, 2008].  
With the use of lentiviral vectors, some investigators has managed to obtain a 
new construct containing the β-globin gene, the sequences of the promoter and 
proximal enhancers and a region comprising the LCR elements, including the sites 
HS2, HS3 and HS4. Studies comparing this vector, called TNS9 (figure 6), with 
an equal contains, however, only minimal LCR sequence (RNS1) have 
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demonstrated, for TNS9, a dramatic increase in expression of the transgene and 
less dependence from the insertional position [Sadelain, 2002]. 
This dependence is due to the presence in the genome of regions with high, 
low and no expression that affect the transcription not only of the contained 
endogenous genes but also of possible inserted transgenes (figure 7). The 
transcriptional activity of these regions depends on the chromatin structure, which 
can be opened or closed, and that is transmitted to the new inserted genetic 
sequence, unless that contains elements that prevent such influence. Just to avoid 
at all to get different effects depending on the position of the vector insertion, 
some investigators have been looking for possible new regulatory sequences to 
add to the construct. The element that has proved most effective is the insulator 
cHS-4 from the chicken β-globin LCR, thanks to its ability to isolate the coding 
sequence by the influences of the surrounding chromatin [Emery et al, 2002].  
Moreover, the insulators have the additional aim to avoid the insertional 
oncogenesis, depending on the random integration of foreign genetic material, 
whether of viral or non-viral origin. In a mouse study where myeloid leukemia 
was shown to be caused by insertional oncogenesis, the transgene was a truncated, 
but not fully disabled form of the human low-affinity nerve growth factor receptor. 
The risk of insertional oncogenesis has also been established in humans, in the 
context of gene therapy for X-linked severe combined immunodeficiency disease 
(SCID-X1).  
This therapy was remarkably successful in 10 of 11 treated patients, but two 
patients developed a lymphoid leukemia that could be linked to the integration of 
the retroviral vector in or near the LMO-2 oncogene. In both instances, the LMO-2 
oncogene, which is normally silent in T lymphocytes, was transcribed as a direct 
consequence of the neighboring vector insertion [Sadelain et al, 2005; Lisowski & 
Sadelain, 2008].  
Using the TNS9 vector, the Sadelain’s group have first demonstrated efficient 
gene transfer in bone marrow hematopoietic stem cells, tissue-specific transgene 
expression and long-term correction in a mouse model of β-thalassemia 
intermedia. Subsequently, they have produced a mouse model for the most severe 
form of β-thalassemia, the Cooley anemia, demonstrating that mice die as a 
 44 
 
 
a
)
b)
c)
d)
Fi
gu
re
7 
–
Po
sit
io
n
 
ef
fe
ct
s
ha
m
pe
r
re
gu
la
te
d
tr
a
sg
en
e
ex
pr
es
sio
n
.
Ea
ch
qu
ad
ra
n
t
re
pr
es
en
ts
a 
po
ss
ib
le
pa
tte
rn
 
o
f
ex
pr
es
sio
n
fo
llo
w
in
g
v
ec
to
r
in
te
gr
at
io
n
at
 
ra
n
do
m
: 
a) 
hi
gh
-
le
v
el
,
 
er
yt
hr
o
id
-
sp
ec
ifi
c
ex
pr
es
sio
n
; b
) l
o
w
-
le
v
el
,
 
er
yt
hr
o
id
-
sp
ec
ifi
c
ex
pr
es
sio
n
; c
) t
ra
sg
en
e
sil
en
ci
n
g;
 
d) 
dy
sr
eg
u
la
te
d
ex
pr
es
sio
n
[S
ad
el
ai
n
,
 
20
02
].  
a
)
b)
c)
d)
a
)
b)
c)
d)
Fi
gu
re
7 
–
Po
sit
io
n
 
ef
fe
ct
s
ha
m
pe
r
re
gu
la
te
d
tr
a
sg
en
e
ex
pr
es
sio
n
.
Ea
ch
qu
ad
ra
n
t
re
pr
es
en
ts
a 
po
ss
ib
le
pa
tte
rn
 
o
f
ex
pr
es
sio
n
fo
llo
w
in
g
v
ec
to
r
in
te
gr
at
io
n
at
 
ra
n
do
m
: 
a) 
hi
gh
-
le
v
el
,
 
er
yt
hr
o
id
-
sp
ec
ifi
c
ex
pr
es
sio
n
; b
) l
o
w
-
le
v
el
,
 
er
yt
hr
o
id
-
sp
ec
ifi
c
ex
pr
es
sio
n
; c
) t
ra
sg
en
e
sil
en
ci
n
g;
 
d) 
dy
sr
eg
u
la
te
d
ex
pr
es
sio
n
[S
ad
el
ai
n
,
 
20
02
].  
 45 
consequence of extreme ineffective erythropoiesis and that they can be rescued 
and cured by lentivirus-mediated transfer of the human β-globin gene [May et al, 
2002; Rivella et al, 2003].  
In a more recent study, Malik et al [2005] show that a lentiviral vector that 
would express the human β-globin gene under control of its regulatory elements 
and be flanked with chromatin insulator elements upon integration into host 
hematopoietic cells results in (1) high-level transduction of bone marrow 
progenitor cells from four patients with transfusion-dependent thalassemia major, 
(2) complete phenotypic and functional correction of the in vitro model of human 
thalassemia erythropoiesis, (3) levels of β-globin similar to that derived from 
normal bone marrow progenitors, and (4) effective human erythropoiesis with 
circulating β-globin-producing human erythroid cells in genetically corrected 
xenografts, at levels comparable to normal bone marrow xenograft controls. 
Unfortunately, the uncertainties about possible side effects in the long term 
remain numerous and, for this reasons, further studies are required, aimed at the 
development of new vectors and new cellular and animal models. 
The oligonucleotide-based gene targeting strategies, able to correct point 
mutations, include those that use triplex-forming oligonucleotides, RNA/DNA 
hybrid oligonucleotides (chimeraplasty) and small DNA fragments (SDFs), which 
are used in the small fragments homologous replacement (SFHR) strategy. The 
SDFs used in SFHR are composed of either single-stranded (ssDNA) or double-
stranded DNA (dsDNA), contain non-coding sequences, and are essentially 
homologous to target loci. These SDFs effect homologous exchange between 
incoming SDF sequences and endogenous (genomic or episomal) sequences, 
ultimately resulting in phenotypic changes (figure 8) [Gruenert et al, 2003].  
Gene targeting is the only procedure that can produce predefined alterations in 
the genome of eukaryotic cells. As such, gene targeting is an attractive approach to 
gene therapy of genetic diseases because: (1) it can lead to the accurate correction 
of the defect in the target locus of interest; (2) it can correct both recessive and 
dominant mutations, unlike gene augmentation, which is restricted to recessive 
defects; (3) it is not restricted by the size of the mutated gene since only the 
damaged portion need be considered; gene augmentation requires delivery of the
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 entire coding region which may be impractical for large genes; (4) actual 
correction of the faulty gene would permanently reverse the genetic disorder by 
restoring production of the normal protein product; the corrected gene would be 
under the control of its own regulatory sequences, thereby avoiding the potential 
problems of non-physiological gene expression and long-term gene inactivation 
frequently associated with gene augmentation procedures; and (5) it avoids the 
risk, associated with many gene augmentation approaches, of a harmful mutation 
caused by the chance integration of the therapeutic DNA at a sensitive genomic 
site such as an oncogene [Yanez and Porter, 1998].  
A potential drawback of gene correction by gene targeting is that it requires 
previous knowledge about the location and type of mutation to be corrected, and 
may require the use of different therapeutic DNA for different patients with the 
same disease. Also, although it can be a high fidelity procedure, mutations 
associated with gene targeting have been observed. The main handicap, however, 
lies in the inefficiency of gene targeting which typically ranges from 10-5 to 10-7 
targeted cells per transfected cell [Yanez and Porter, 1998].  
In a recent study, a gene targeting approach, based on the introduction of small 
DNA fragments (SDF) into erythroid progenitor cells, was applied to specifically 
modify the β-globin gene sequence at codon 39. The strategy was first tested in 
normal individuals by delivering mutant SDF that were able to produce the β039 
(CT) mutation. Secondly, wild-type SDF were electroporated into target cells of  
β
039-thalassemia patients to correct the endogenous mutation. In the first case, 
with the use of mutated SDF, the efficiency of small-fragment homologous 
replacement (SFHR)-mediated modification was approximately 2.4%, while, in 
the case of thalassemic cells treated with wild type SDF, targeted correction was 
detected in eight of ten different experiments [Colosimo et al, 2007]. 
Unlike the SFHR strategy, the chimeraplasty involves the use of RNA/DNA 
oligonucleotides that, once entering the cell, appear to stimulate the mismatch 
repair machinery resulting in the correction of the defect. These chimeric 
oligonucleotides have been shown to actually be effective both in correcting a 
point mutation and in the insertion of a single base in the genome of mammalian 
cells, both in vitro and in vivo, and were able to correct a thalassemic mutation 
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introduced in MEL cells. But, although the chimeraplasty is an attractive strategy 
for gene therapy, many questions are still unanswered and it will, therefore, 
necessary to deepen the understanding of this approach through further research 
[Li et al, 2001]. 
The last type of gene therapy to be considered is the antisense strategy, which 
allow the correction of mRNA processing and can be used only with a particular 
group of mutations, the splicing mutations. 
In various antisense mechanisms developed over the years, the 
oligonucleotides are used to modulate the transfer of information from gene to 
protein, altering the intermediate metabolism of RNA. Depending on the type of 
oligonucleotide used and the target sequence recognized by it, it is possible to 
produce two different results: silencing a gene or modifying the mRNA 
processing. When the aim is to inhibit gene expression it is necessary to use 
methods that lead to activation of the RNase H or to the arrest of translation. 
A key point of the metabolism of mRNA molecules is the excision of introns. 
Splicing reactions are sequence-specific and require the concerted action of many 
proteins, which form the splicesoma. Antisense oligonucleotides, which bind to 
regions required for the splicing can prevent the binding of necessary factors or 
physically prevent the cutting reactions. This implies, therefore, inhibition of 
production of mature mRNA [Crook, 1999]. In this perspective, many 
investigators thought to use oligonucleotides to correct the effect of mutations that 
cause aberrant splicing, restoring the normal splicing and the function of the 
defective gene. Requests for compounds to be used to change the splicing are 
different from those for the oligonucleotides used in silencing. In particular, they 
should not activate the RNase H, as this would destroy the target pre-mRNA 
before being spliced, and should be able to compete efficiently with the splicing 
factors for access to primary messenger, which is located inside the nucleus of the 
cell [Sazani and Kole, 2003]. 
The early studies, in which antisense oligonucleotides were used to modulate 
splicing, were carried out by Kole and colleagues, who have successfully used 
these molecules to correct the aberrant splicing of pre-mRNA of β-globin, due to 
thalassemic mutations [Dominski and Kole, 1993]. 
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The antisense nucleotides can also be used to regulate the alternative splicing, 
stimulating or inhibiting the production of a protein variant [Mercatante et al, 
2001] and to stimulate the exon skipping, in which the oligonucleotides can be 
used to promote a process of alternative splicing which avoids the incorporation of 
a defective exon in a mature mRNA [De Angelis et al, 2002]. 
 
Lentiviral vectors 
 
Over the years, several types of vectors have been used in gene therapy, to 
introduce the exogenous gene into the target cells, among these vectors the 
lentiviral ones have proven to be of particular interest. Lentiviral vectors, in fact, 
have characteristics that make them particularly suitable for use in gene therapy, 
including their ability to permanently integrate into the genome of cells in vitro 
and in vivo, allowing an expression stable over time [Naldini et al., 1996]. 
Lentiviral vectors derive from lentiviruses, which, being a subfamily of 
retroviruses, are RNA viruses that replicate through a DNA intermediate. All 
retroviruses encode gag, pol, and env genes. The protein products of these genes 
are unique to each type of retrovirus, but they do share basic common features. In 
infected cells, the proviral genome is transcribed into a single precursor mRNA 
from the viral promoter located in the 5’ (upstream) long terminal repeat (LTR), 
with the 3’ (downstream) LTR containing transcription termination and polyA 
signals. The gag gene encodes the viral core proteins, whereas the pol gene 
encodes the viral replication enzymes. These two genes are initially expressed as a 
Gag–Pol fusion polyprotein. The viral protease self-cleaves the Gag–Pol precursor 
and further processes the Pol protein to individual protease (for cleaving viral 
precursor proteins into their mature forms), reverse transcriptase (for replicating 
viral nucleic) and integrase (for integrating the viral genome into chromosomal 
DNA). The env gene encodes the viral envelope glycoprotein, which is cleaved by 
cellular proteases to the external envelope glycoprotein and the transmembrane 
protein. [Buchschacher and Wong-Staal, 2000]. 
In addition to the structural gag, pol, and env genes common to all retroviruses, 
human immunodeficiecy virus (HIV) contains two regulatory genes, tat and rev, 
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essential for viral replication, and four accessory genes, vif, vpr, vpu, and nef, that 
are not crucial for viral growth in vitro but are critical for in vivo replication and 
pathogenesis (figure 9a) [Dull et al, 1998]. 
Infection (figure 9b) begins when a virion enters a susceptible target cell 
through the specific interactions between the envelope glycoprotein and the 
cellular receptors. Viral-cell membrane fusion and virion internalization (by direct 
fusion or endocytosis) result in release of the virus core into the cell cytoplasm. 
Viral RNA is reverse transcribed into double-stranded DNA and transported to the 
cell nucleus. Viral DNA is permanently integrated (hence referred to as the 
provirus) into chromosomal DNA, where it is replicated during the cell cycle, just 
as cellular genes are, and subsequently passed to daughter cells. This feature 
makes retroviral vectors useful for permanently introducing foreign genes into 
cells. Proviral DNA is transcribed into RNA and transported to the cytoplasm, 
where it can be translated into viral proteins. Viral precursor structural proteins 
and replication enzymes assemble with viral RNA to form new virion cores, which 
obtain the viral envelope glycoprotein as they bud from the cellular membrane. 
Further processing of the precursor core proteins result in the formation of mature, 
infectious progeny virus particles [Buchschacher and Wong-Staal, 2000]. 
From their first application, the lentiviral vectors have been strongly developed 
in design, in biosafety and in their ability of transgene expression into target cells. 
The design of viral vectors is based on the separation of cis-acting sequences 
required for the transfer of the viral genome to target cells from the trans-acting 
sequences encoding the viral protein. Vectors particles are assembled by viral 
proteins expressed in trans from construct(s) devoid of most viral cis-acting 
sequence (packaging constructs). The viral cis-acting sequences are linked to an 
expression cassette for the transgene (transfer vector construct) [Vigna and 
Naldini, 2000].  
Over the years, three different generations of lentiviral vectors based on HIV-1 
were developed. In these vectors was, first, gradually reduced the number of viral 
genes present in order to make defective replication in target cells, secondly, the 
remaining genes were separated each other and transferred in many different 
constructs. 
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ψ
Figure 9 – Retroviruses. a) Schematic representation of the HIV-1 genome. There are indicated: two Long Terminal 
Repeat (5’ e 3’ LTR), packaging signal ψ and the structural, regulatory and accessory genes. b) Retroviral replication
cycle. The infection begins when the virus envelope glycoprotein recognizes specific receptor located on the cell surface, 
which mediate the internalization of the core into the target cell; after reverse transcription of the viral RNA, the provirus
integrates into the cellular genome, with a subsequent intense translational activity. Then, the viral RNA passes into the 
cytoplasm, where a part is translated to produce viral proteins while a part associates with viral proteins to form new core
particles [Buchschacher and Wong-Staal, 2000].
viral RNA 
encapsidation
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Due to safety concerns, first generation lentiviral vectors for gene transfer 
employed a three-plasmid expression system and generated a pseudotyped vector 
through transient transfection of packaging cells. The first generation system 
included a packaging construct that had a deleted env fragment (1.4 kb) and vpu 
gene, a partially deleted packaging sequence (DC) and the replacement of the 5’ 
and 3’ long terminal repeat (LTR) regions responsible for the regulation of viral 
gene expression, with a strong cytomegalovirus (CMV) promoter and 
polyadenylation signal of the insulin gene, respectively. A second plasmid 
encoding an alternative envelope protein, the G glycoprotein of vesicular 
stomatitis virus (VSV-G), was controlled by the CMV promoter. The VSV-G 
envelope protein is advantageous due to its higher stability that allows 
concentration by ultracentrifugation and since VSV-G pseudotyped viral particles 
show broad host cell infectivity. Finally, a third plasmid encoding the expression 
cassette for the transgene contained all the cis-acting sequences required for 
encapsidation, reverse transcription, and integration. The transgene plasmid also 
contained the CMV promoter, intact 5’ as well as 3’ LTRs, the portion of the gag 
gene containing the packaging sequence (C) and a sequence known as the rev 
responsive element (RRE) that is involved in the control of splicing. By using a 
multiple plasmid expression system for the construction of the vector and 
minimizing the number of overlapping sequences between plasmids, the 
possibility of producing a replication competent lentivirus (RCL) by 
recombination was greatly reduced [Stathopulos, 2003].  
Second generation HIV-1-derived vectors improved on biosafety by deleting 
HIV-1 genes not required for generating functional vector particles. Second 
generation vectors used multiple plasmids as described for first generation; 
however, the packaging plasmid had the vif, vpr, vpu, and nef genes, as well as the 
entire env gene deleted. In total, five of the nine genes found in wild-type HIV-1 
were deleted in these second generation vectors [Stathopulos, 2003]. 
Third generation lentiviral vectors (figure 10a) were introduced by Dull et al. 
[1998]. The lentiviral vector described in their paper was packaged by three 
nonoverlapping expression constructs, two expressing HIV proteins and the third 
expressing the envelope of a different virus. Moreover, all HIV sequences known 
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Fig. 10 – Lentiviral vectors. a) Example of third generation lentiviral vectors for the gene therapy of
haemoglobinopathies. Three helper vectors (1) carrying the gene sequences of Gag and Pol, Rev and the VSV-G
protein. A SIN (Self-INactivation) vector (2) containing the transgene (β-globin) under the control of the promoter P, 
together with the in cis elements: cPPT, WPRE, β-globin locus control region LCR. It also present the packaging 
sequence, Ψ (∆= partial). b) Mechanism of production of the lentiviral vector. The construct carrying the exogenous
gene and the helper vectors are used for the transfection of packaging cells, where there are the transgene transcription
and the sythesis of the virus-specific proteins: the transgenic RNA is then incapsidated to generate viral particles
carrying the desired genetic information. These particles, release into the supernatant, are finally used to transduce the 
target cells, where the integration in the genome and the expression of the exogenous gene take place, while the virus is
not longer capable of replication [Buchschacher and Wong-Staal, 2000].
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to be required for encapsidation and reverse transcription were absent from these 
constructs, with the exception of the portion of the gag gene that contributes to the 
stem-loop structure of the HIV-1 packaging motif. Secondly, they deleted another 
factor crucial for HIV replication, the tat gene. Its product is one of the most 
powerful known transcriptional activators and plays a pivotal role in the 
exceedingly high replication rates that characterize HIV-induced disease. They 
finally described a core packaging system split in two separated nonoverlapping 
expression constructs, one for the gag and pol reading frames optimized for Rev-
dependent expression and the other for the rev cDNA. This third-generation 
packaging system matched the performance of its predecessors in terms of both 
yield and transducing efficiency. However, it increased significantly the predicted 
biosafety of the vector. 
The biosafety was also improved generating self-inactivating transfer vectors 
(SIN). These constructs duplicate, upstream in the vector, a major deletion in the 
U3 region of the LTR when transduced into target cells. As this region contains 
the viral enhancer and promoter sequences, its deletion results in the 
transcriptional inactivation of the LTR. Self-inactivating lentiviral vectors could 
be produced with infectious titers and levels of transgene expression driven by an 
internal promoter similar to vectors carrying wild type LTRs. Concerning 
biosafety, a self-inactivating vector diminishes the risk of oncogene activation by 
promoter insertion and alleviates substantially the risk of vector mobilization and 
recombination with wild type virus [Vigna and Naldini, 2000; Miyoshi et al, 1998; 
Iwakuma et al, 1999]. 
To increase the transduction efficiency and the expression of transgenes 
delivered by retroviral vectors, some sequences were added to the viral construct: 
• the Woodchuck hepatitis virus Post-transcriptional Regulatory Element 
(WPRE), which stimulate the expression of transgene in a way not depending on 
the cell type or on the species. Its effect is not influenced by the cycling status of 
the transduced cells but the WPRE is only functional when present within a 
transcript in the sense orientation. This element increases the level of nuclear 
transcripts, without influencing the RNA half-life. Moreover, the WPRE may 
facilitate another step in RNA processing, directing RNAs that would normally be 
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degraded within the nucleus to be efficiently expressed. This processing could be 
facilitated at the level of 3’ cleavage and polyadenilation. The WPRE could also 
function to facilitate the generation of RNA-protein complexes which would 
protect newly synthesized transcripts from degradation in the nucleus [Zufferey et 
al, 1999]. 
• The central polypurine tract (cPPT), a cis-acting sequence that is located 
in the pol gene of the wild type HIV-1. This element facilitates the nuclear 
transport of the pre-integration complex through the nuclear membrane of 
quiescent cells. The introduction of the cPPT sequence in the transfer vector 
backbone strongly increased the total amount of genome integrated into the DNA 
of target cells [Follenzi et al, 2000; Vigna and Naldini, 2000; Stathopulos, 2003].  
Another strategy to regulate transgene silencing relies on the addition of 
positive regulatory elements to the expression cassette, such as locus control 
regions (LCRs), chromatin insulators or matrix attachment sites:  
• The discovery of DNaseI hypersensitive sites (HS) far upstream of the 
human β-globin cluster has improved the prospects for gene therapy for human 
haemoglobinopathies. As mentioned above, these HS sites are nucleosome-free 
regions of open chromatin that are highly accessible to trans-acting factors. 
Moreover, this cis-acting DNA element, termed β-LCR, has been reported to 
confer position-independent and copy number-dependent expression. This region, 
which is 20 kb long, has been reduced to shorter forms of a few hundred base pairs 
long that still confer the silencing modulation activity. The insertion of the β-LCR 
sequence within HIV-1 lentiviral vectors has been useful for increasing erythroid-
specific synthesis of the β-globin protein in transgenic mice [Delenda, 2004].  
• Several chromatin insulator boundary elements have also been described 
to protect expression cassettes from position effects. These include the HS4 core 
from the chicken β-globin LCR [Delenda, 2004]. 
• The insertion of a scaffold or matrix attachment region (S/MAR) from the 
immunoglobulin-kappa gene into HIV-1-based SIN transfer vectors has 
significantly increased the liver and hepatocyte transduction efficiency. Moreover, 
the human interferon-β S/MAR element inserted in the same kind of lentiviral 
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vector also resulted in an increase in the duration time of transgene expression in 
human HSCs [Delenda, 2004]. 
Naturally, the four lentiviral constructs produced in the third generation must 
be assembled in virus particles able to infect the target cells. The production of 
lentiviral particles is carried out through co-transfection of packanging cells with 
the different constructs (figure 10b). The use of these cells ensures many 
advantages, such as an increase in the titer and a further reduction of the 
possibility of producing wild type viruses [Buchschacher & Wong-Staal, 2000]. 
Among the different cell lines used for this purpose are included cells of human 
embryonic kidney 293T [Stathopulos, 2003]. 
 
Models for the study of β-thalassemia 
 
The experimental models can reproduce, in the limit of the type of model, the 
clinical and molecular conditions of human β-thalassemia and their use can lead to 
the discovery of therapeutic strategies aimed to treat the disease. 
In addition to the in vitro models, which reproduce a molecular mechanism 
modified by a pathological alteration, were developed more complex models ex 
vivo and in vivo. 
The ex vivo models of β-thalassemia include different types of cell lines that 
can be modified through the introduction of constructs containing the β-globin 
gene, wild type or mutated. Among these cells, of particular importance are the 
human (K562) and mouse (MEL) erythroleukemic lines. 
The erythroid K562 cell line was isolated and characterized by Lozzio and 
Lozzio [1975] from a pleural effusion of a patient with chronic myeloid leukemia 
(CML) in the terminal stage. K562 cells possess all the genes of β-globin locus, as 
the β gene, but this is not expressed, due to trans-active effects or to the presence 
of negative regulatory factors or to the lack of positive regulatory factors for the 
transcription of the gene [Young et al, 1985]. These cells do not produce adult 
haemoglobin and so they do not show some important pathological aspects of β-
thalassemic cells, for example, the excess α chains [Gambari and Fibach, 2007]. 
For this reason, they are widely used for the production of ex vivo models with 
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various purposes: 1) the study of the molecular mechanisms that regulate the 
expression of globin genes [Young et al, 1985; Donovan-Peluso et al, 1987; 
Donovan-Peluso et al, 1991], 2) the study of gene expression after induction of the 
cellular differentiation [Plonczynski et al, 1999]; 3) screening of new compounds 
that induce cellular differentiation [Bianchi et al, 1999, Bianchi et al, 2001], 4) 
development of approaches for gene transfer of human genes [Young et al, 1984], 
5) the production of reporter systems to monitor the activities of the globin genes 
[Vadolas et al, 2002]. 
The erythroid MEL (Mouse ErythroLeukemia or FLC) cell line, of murine 
origin, derives from the transformation of erythroid cells with the Friend virus, 
which arrested them at the proerythrobastic stage [Friend et al, 1971]. These cells 
are used for different types of studies, from the cell differentiation to the 
regulation of globin genes [Chae and Kim, 2002]. They can also be used for the 
study of mutations in the human β-globin gene, following its introduction into the 
cell and subsequent integration into cellular genome. In this regard, Ho et al 
[1999] produced an expression system for ex vivo analysis of β-globin gene 
mutations, based on the transfection of MEL cells with β-globin gene wild type 
and mutated. After being validated, the system was used to examine the effects 
and mechanisms of action of two mutations in the β-globin gene 5' not translated 
region (5'UTR). 
For the study of diseases, as well as ex vivo models, are of particular 
importance in vivo models, because they reproduce as far as possible the disease in 
study. It is essential, however, choose the animal most appropriate for the type of 
disease and the study phase of this, on which to develop clinical protocols. 
With regard to β-thalassemia, investigators have generated several animal 
models based on mice, which present an α-globin cluster, located on chromosome 
11, similar to the human one and, in contrast, a β cluster, on chromosome 7, quite 
different (figure 11). The murine β cluster includes four functional genes under 
the control of the LCR region. Of these, bh1 and εy are the globin genes of the 
embryonic phase, while b1 (βmajor) and b2 (βminor) the globin genes of the adult 
stage, responsible of the production of 80% and 20% β-globin chains of adult 
haemoglobin, respectively [Whitelaw et al, 1990; Shehee et al, 1993]. The 
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Figure 11 – Comparison between human and murine β-like clusters. a) Schematic representation of the human
β cluster, located on the chromosome 11. There are indicated: the structural genes ε, Gγ, Aγ, δ and β, the 
pseudogenes ψβ2 and ψβ1, and the locus control region (LCR), containing the hypersensitive sites (HS1, HS2, 
HS3, HS4 and HS5). b) Schematic representation of the murine β cluster, located on the chromosome 7. There are 
indicated: the structural genes εy, βh1, βmajor e βminor, the pseudogenes ψβh0, ψβh2, ψβh3, and the locus control
region (LCR), containing the hypersensitive sites (HS1, HS2, HS3 and HS4). In figure are, therefore, reported
different types of haemoglobin, produced according to the β-like globin encoded by the different genes. It is
possible to note the lack of fetal haemoglobin in mouse. HbE, embryonic haemoglobin; HbF, fetal haemoglobin; 
HbA, adult haemoglobin; HbA2, type 2 adult haemoglobin.
b)
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different composition of the cluster β, missing a γ-globin gene comparable to the 
human one, initially brought considerable difficulty in developing mouse 
thalassemic models. This genetic limit has, in fact, allowed the production of a few  
models of murine β-thalassemia intermedia, as the complete absence of expression 
of β genes leads to prenatal death. 
The first mouse model produced, called th1, [Skow et al., 1983] had a 
spontaneous deletion of 3.3 kb of DNA, including the βmajor gene and upstream 
regulatory sequences, including promoter. The heterozygous subjects had a 
clinical situation of thalassemia intermedia and analysis of the synthesis of β-
globin chains revealed a production of 95% in heterozygous and of 75% in 
homozygous mice. This event is explained by an increase in the synthesis of βminor 
chains to compensate for the total absence of βmajor chains. This compensatory 
increase is due to a competitive advantage of βminor mRNA compared to α mRNA 
during the start of protein synthesis [Curcio et al., 1986].  
The second mouse model, th2, [Shehee et al., 1993] was generated by 
producing a break in the βmajor gene through the insertion of an exon of the neo 
gene (which confers resistance to the antibiotic G418) and of the relative 
promoter, made by homologous recombination in embryonic stem cells. This 
process does not remove the promoter of βmajor gene and, therefore, the βminor gene 
is to have two promoters that compete with its for the LCR region, with 
consequent reduction in its transcription. In addition, the βminor transcript faces 
strong competition for the translational factors from the mRNAs of the βmajor and 
neo genes, non-coding, however, for functional β-globin chains. For these reasons, 
homozygous subjects faced a prenatal death, while the survival in heterozygous 
was 60% of cases with severe anemia, due to thalassemia intermedia. 
The third mouse model, th3, generated simultaneously in two different 
laboratories, by Ciavatta et al [1995] through homologous recombination, and by 
Yang et al [1995] through gene targeting, results from deletion, in embryonic stem 
cells, of βmajor and βminor genes. Homozygous subjects did not survive birth, while 
heterozygous ones had a clinical phenotype of thalassemia intermedia. This animal 
model of β0 heterozygous thalassemia can be used to test gene therapy, to study 
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the pathophysiology of the disease and to develop treatments that can improve the 
condition of individuals with β-thalassemia. 
The fourth mouse model, th4, [Lewis et al., 1998] was the first animal model 
resulting from a human splicing mutation. It was produced by gene targeting, 
replacing βmajor and βminor genes with a single copy of human β-globin gene 
containing a mutation that causes a splicing defect and that leads to a condition of 
β
0
-thalassemia. The resulting homozygous subject died in prenatal stage, while the 
heterozygote presents β-thalassemia intermediate, caused by aberrant splicing as in 
the human counterpart. This animal model can be used to develop therapies to 
correct defective splicing, as, for example, the use of antisense oligonucleotides. 
The lack of murine models which reproduce β-thalassemia major has long been 
a limit to the characterization of critical physiopathological events, for the 
detection of biological mechanisms and the valuation of genetic and 
pharmacological treatments in this disease [Breda and Rivella, 2003]. For this 
reason, a mouse model of adult β0-thalassemia major was created through the 
introduction, in animals subjected to myeloablation, of fetal liver cells, taken from 
an homozygous embryo of the th3 mouse model, which is devoid of βmajor and 
β
minor
 genes. Already after a few weeks, the mice showed a severe anemia and 
succumbed within 60 days because of the ineffective erythropoiesis [Rivella et al, 
2003]. 
Among the various possible genetic treatments, an approach used by Breda and 
Rivella [2003] was the use of lentiviral vectors, arising from dTNS9 vector, and 
coding for the human β-globin gene. The developed mouse model, in the absence 
of endogenous β-globin gene, proved to be a valuable tool for quantification of the 
globin transgene expression and production of human β chains obtained in vivo. It 
was also demonstrated that the gene transfer through these vectors is a valid and 
applicable approach to study haematopoietic lethal phenotypes in animal models.  
Because there is a significant difference between mouse and human gene 
sequences and it is of vital importance to develop therapeutic strategies that 
targeted the human sequences, Jamsai et al [2004] thought to produce transgenic 
mice by microinjection of extended fragments of human genomic DNA in 
fertilized oocytes. From these assumptions, they began to develop humanized 
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murine models, which, expressing the human gene locus, are more sophisticated 
and better simulate the disease than the earlier models. 
Jamsai et al [2004] generated a humanized mouse model, breeding a transgenic 
mice containing the human β-globin locus, carrying a β0 mutation in the β-globin 
gene, with a heterozygous mouse th3. From this crossbred, it was therefore 
possible to isolate a transgenic heterozygous mouse, which may express, in 
addition to normal βmajor and βminor genes, present in heterozygosity, the γ-globin 
gene during fetal development and the β-globin gene containing the mutation in 
the adult stage, a condition that leads him to have a β-thalassemia intermedia. This 
model can be used to study the corrections of DNA mutations in hematopoietic 
stem cells and the identification of new inducers of fetal haemoglobin.  
The same group [Vadolas et al, 2006] also produced a humanized mouse 
model containing in emizygosity the β-globin locus with a human β+ mutation that 
causes a defect in splicing. The synthesis of human β-globin chains is comparable 
to that of a human β-thalassemic patient with the same mutation. In fact, 
comparing the model containing the mutated transgene with one containing the 
wild type transgene, it is possible to note that the presence of the mutation results 
in a decrease of 90% in the synthesis of human β-globin chains, difference 
attributable to an aberrant splicing. This animal model is an excellent in vivo 
system for the screening of antisense oligonucleotides usable to correct splicing 
mutations. 
 
Cultures of erythroid progenitors 
 
The hematopoietic pluripotent stem cell undergoes a series of developmental 
changes that commit it to a specific cell lineage. The first erythroid-committed 
progenitors are defined functionally as burst-forming units (BFUe). Following 
proliferation and differentiation, these cells give rise to colony-forming units 
(CFUe) which bear on their surface the receptors for erythropoietin. These 
progenitor cells continue to proliferate and differentiate, eventually becoming 
mature red blood cells containing haemoglobin with oxygen-carrying capability. 
Erythroid cell maturation, known as erythropoiesis, is mediated by a combination 
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of regulatory proteins acting in concert to direct the development of progenitor 
cells into mature erythrocytes. 
Erythropoiesis has been studied extensively as a model of gene regulation. 
During human ontogeny, erythropoiesis begins in the embryonic yolk sac 
(primitive erythropoiesis), transfers to the fetal liver, and then to the bone marrow 
before birth (definitive erythropoiesis). As the site of erythropoiesis changes, the 
globin genes being expressed also change, progressing from embryonic to fetal 
and finally to adult. Thus, globin gene regulation serves both as a model for 
developmental gene regulation during ontogeny and for the molecular mechanism 
directing cellular differentiation [Pope et al, 2000]. 
As already mentioned, erythroid cell lines and transgenic animals have been 
used extensively as models to study β-thalassemia and to develop new therapeutic 
strategies. In addition, primary cultures of erythroid cells can be readily 
established from most normal individual and patients and their growth in vitro 
represents more closely than cell lines the in vivo situation. The cells can be 
cultured either in semi-solid medium where they develop into discrete colonies, or 
in liquid medium where they grow as single cells or clusters in suspension. In both 
systems erythropoietin (EPO) is essential for full development of Hb-containing 
erythroid cells [Fibach, 2003].  
 
Semi-solid cultures 
 
In the cloning method, suspensions of single hematopoietic cells derived from 
the bone marrow, peripheral blood or other sources such as fetal liver, neonatal 
cord blood or adult spleen, are dispersed in semi-solid media usually containing 
methyl cellulose or plasma clot. Colonies start to appear after 3 – 4 day incubation, 
and they reach their final size and haemoglobinization after 1 – 2 weeks. Each 
colony represents a clone derived from one erythroid-committed progenitor. Based 
on the final size of the colonies and the time required for their haemoglobinization 
various type of progenitors can be distinguished; the late erythroid colony-forming 
units (CFUe) reach final size and haemoglobinization after 1 week and then 
disappear, while the early erythroid burst-forming units (BFUe) develop after 2 
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weeks. Erythroid colonies can be distinguishes from other (myeloid) colonies by 
their red colour or by their positive reaction with heme-specific reagents. 
The fact that in this culture system the cells are immobilized in semi-solid 
medium results in several disadvantages. The cell yield per colony and the total 
cells per culture are low making it technically difficult to carry out biochemical, 
molecular and immunological characterizations of the developing cells. It is a one-
step continuous culture and addition of the tested agents during the culture is 
difficult. In addition, the proportion of HbF produced in colonies grown in semi-
solid medium is significantly higher than that produced in vivo by the donor of the 
cells [Fibach, 2003]. 
 
The two-phase liquid cultures 
 
The liquid culture procedure overcomes several of these obstacles. It is 
possible to obtain large cultures of relatively pure and synchronized erythroid cell 
population and compounds can be added on different days when the culture 
consists of cells at specific stages of maturation. This culture procedure is 
separated into two phases: in phase I, peripheral blood mononuclear cells were 
cultured for 1 week in the presence of a combination of growth factors, but not 
EPO, and cyclosporine A, able to suppress the lymphocyte activation and 
proliferation (figure 12a). The vast majority of cells in these cultures are small 
lymphocytes and only a minute fraction of the cell population are various 
hemopoietic progenitors. Moreover, during the phase I the early erythroid-
committed progenitors (BFUe), present originally in the peripheral blood, 
proliferate and differentiate into the more mature, CFUe-like, progenitors. In 
phase II (figure 12a), following exposure to EPO, the latter cells proliferate and 
mature within 2 weeks into Hb-containing orthochromatic normoblasts. Shown in 
figure 12b are cytospin preparations of cells at various stages of phase II. Early in 
the phase II (days 0 – 5) lymphocytes continue to present the most abundant cell 
type. Proerythroblasts begin to be discernible on days 4 – 5 as large, round, 
smooth cells which, following staining with Wright-Giemsa, demonstrate deep 
blue cytoplasm and a central large nucleus with abundant chromatin and 2 – 3 
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prominent nucleoli. As these cells multiply they form clusters. During the 
intermediate phase (days 6 – 10) lymphocytes gradually give way to an increasing 
proportion of proerythroblasts and basophilic normoblasts, which when 
indisturbed form aggregates consisting of hundreds of cells. In late phase II (days 
11 – 15), erythroid cells continue to proliferate and mature into polychromatic and 
orthochromatic Hb-containing normoblasts. Within the intermediate and late 
phases, the absolute number and proportion of small lymphocytes diminished 
significantly. 
Globin expression in the maturing erythrocyte in the two-phase system 
recapitulates expression patterns which occur in the fetal to adult haemoglobin 
switch during ontogeny. This is seen in the reciprocal relationship between γ- and 
β-globin gene expression in which γ-globin peaks in early phase II then declines as 
β-globin increases and then peaks in late phase II. As expected, α-globin also 
reaches maximum expression when total haemoglobin increases in the late stage 
[Pope et al, 2000]. 
Pope et al [2000] analysed also the expression of the transcription factors Sp1, 
GATA-1 and EKLF, essential for the primitive and definitive erythropoiesis. They 
observed that Sp1 is expressed at maximum levels in the early stage of phase II. It 
then declines through the intermediate stage to moderately low levels where it is 
maintained, an expression pattern which is consistent with its key role in early 
developmental viability. GATA-1 is expressed at high levels in both the early and 
intermediate stages of phase II and then declines as the cells reach maturity during 
the late stage. This pattern of expression supports the crucial role of GATA-1 in 
the maturation of the primitive erythroblast and in the gene expression as the cells 
continue to develop. The erythoid-specific transcription factor EKLF also reaches 
peak expression during the intermediate stage of phase II preceding a significant 
rise in β-globin expression. 
Since the erythroid cells in phase II are grown in suspension, samples of cells 
can be withdrawn at any time without disturbing the cultures and assayed for 
morphology, size, number, cell viability and apoptosis, cell cycle or expression of 
surface antigens. The Hb content of the developing erythroid cells can be 
measured by a variety of techniques, such as the alkaline denaturation and 
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benzedine staining and high-performance liquid chromatography (HPLC), cation-
exchange HPLC for haemoglobins and reverse-phase HPLC for globin chains. 
Using the HPLC techniques, Hb is measurable in culture as early as 5 days in 
phase II. The mean cellular Hb concentration of erythroid cells are calculated from 
the values of the HPLC determinations divided by the number of benzedine-
positive cells. Moreover, the distribution of the erythroid cell population with 
respect to intracellular content of HbA or HbF can be analysed by flow cytometry 
using monoclonal antibodies directed specifically against HbA or HbF. 
This system has been used to study the effects of several compounds on the 
HbF production. For studying their potential to enhance HbF production, 
compounds can be added to phase I, phase II or both. Non-toxic drugs such as 
cytokines and hemin may be added to the cultures at any time. With cytotoxic 
drugs, such as hudroxyurea and 5-azacytidine, because of their cyto-toxic/static 
effects, they are usually added on day 4 – 8 of phase II [Fibach, 2003]. 
Among the several compounds tested on healthy human and thalassemic-
cultured erythroid precursor cells, mithramycin [Fibach et al, 2003], rapamycin 
[Mischiati et al, 2004], angelicin [Lampronti et al, 2003] and everolimus [Zuccato 
et al, 2007] showed to be potent HbF inducers. 
 
Separation of haemoglobins by high-performance liquid chromatography 
(HPLC) 
 
Human haemoglobin abnormalities have been studied for many years, 
particularly since 1949 when the HbS was discovered in sickle cell anemia. Most 
of the hundreds of variants, discovered during the years, are the result of single 
base substitution in the DNA of either the Gγ-, Aγ-, δ-, β-, α-globin genes, but other 
variants with hybrid chains, extended chains, chains with deletions, etc., have also 
been discovered.  
Numerous procedure have been used to identify and/or characterize the normal 
and abnormal Hbs. Most common are elctrophoretic methods, isoelectric focusing 
(IEF) techniques, and macro-chromatography procedures. Since the early ’80s, 
high-performance liquid chromatography (HPLC) has influenced all aspects of 
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analytical chemistry and it is therefore not surprising that different types of HPLC 
have also been applied to the study of the haemoglobinopathies [Huisman, 1987].  
 
Separation of haemoglobins by anion-exchange HPLC 
 
The anion exchanger SynChropak AX 300 was introduced in early ’80s for the 
separation of normal and variant Hb types. Separation of the Hbs A and F is 
important; however, the elution times of HbF and the minor HbA1 are about the 
same, which prevents the quantification of HbF in adult red cell lysates with a low 
HbF percentage. The Hbs A2 and E also cannot be separated. Identification and 
quantification of adult Hb abnormalities in cord blood samples are possible, 
particularly for the β chain variants HbS and HbC. HbD-Los Angeles and HbS, 
however, can only be incompletely separated by this procedure although a slower 
gradient will improve the separation of these variants. The method is particularly 
useful for the quantification of Hb Kenya which is composed of α chains 
combined with Aγβ hybrid chains [Huisman, 1987]. 
 
Separation of haemoglobins by cation-exchange HPLC 
 
Huisman’s group applied cation-exchange HPLC using many different blood 
samples, taken from patients with different pathologies in order to identify the 
elution time proper of each haemoglobin, so as to identify its position on the 
chromatogram obtained from the analysis.  
Separation obtained using blood samples collected from severely affected, 
uncontrolled, diabetic patient shows large quantities of HbA1c (glycosylated HbA) 
and HbA1d (normally not observed or present in small quantities; this fraction is 
HbA with glucose attached to more than one amino acid residue, including some 
of the α chains). HbA2 elutes after HbA0 and is completely separated from the 
major Hb, thus allowing its quantification. HbE does not separate from HbA2, 
while the minor Hbs elute in front of the major HbE component behind two HbF 
zones, i.e. the major HbF0 and its acetylated derivative HbF1.  
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Using samples from patients with homozygous HbS or HbC conditions, it was 
possible to verify that the elution characteristics of these β chain variants readily 
allow the quantification of HbF (F0+F1) and HbA2 in one chromatographic 
experiment. Figure 13a illustrates the positions of various β chain abnormal Hbs 
in this type of chromatography. It is interesting to note that variants with identical 
substitution (GluLys) but in different position of the β chain (C: β6; E: β26; O-
Arab: β121) elute at completely different elution time, indicating that the 
chromatographic properties of these variants are greatly influenced by the location 
of this GluLys substitution in the β chain.  
The original cation-exchange HPLC methodology was most useful for the 
separation of abnormal Hbs in blood from newborn babies. The major advantage 
of this method is the fast elution of HbF (F0+F1) well separated from HbA and the 
most common β chain variants. Their elution is preceded by that of Hb Bart’s (or 
γ4); the presence of a notable quantity of this unusual variant is indicative for the 
presence of an α chain deficiency or α-thalassemia.  
The excellent separation of HbF and HbA makes cation-exchange HPLC the 
method of choice to analyse and quantitate Hbs F, A and A2 in patients with 
homozygous β0- or β+- or (δβ)0-thalassemia. Figure 13b gives two examples 
[Huisman, 1987]. 
Over the years, HPLC has been extensively used for the prenatal and postnatal 
diagnoses of thalassemia and haemoglobinopathies [Eastman et al, 1996; 
Fucharoen et al, 1998] and the screening of haemoglobin variants [Ou and 
Rognerud, 1993; Clarke and Higgins, 2000]. Moreover, this procedure has been 
used for the quantification of cellular Hb content in samples of erythroid precursor 
cells treated with HbF inducers [Fibach et al, 1993; Fibach et al, 1995;  Lampronti 
et al, 2003; Mischiati et al, 2004]. 
 
Nonsense-mediated mRNA decay 
 
Eukaryotic gene expression involves an intricate chain of complex biochemical 
reactions, starting with the synthesis of mRNA, followed by the production of 
encoded proteins, and ending with the degradation of both the mRNA and the 
 69 
 
b)
Figure 13 – HPLC chromatograms. a) Positions of different adult Hb types in chromatograms of red
cell lysates from newborn babies. b) Separation of Hb types by HPLC cation-exchange methodology. 
This procedure adequately separates HbA, HbA2 and HbS and allows the differentiation between the 
two conditions listed. 
a)
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protein. Tight control of and high accuracy within these processes are absolutely 
required to prevent inappropriate gene expression and to ensure cell survival, and 
cells have therefore evolved mechanisms to control many steps along the chain. 
One of the best-studied quality control mechanisms is nonsense-mediated mRNA 
decay (NMD). NMD was initially described as a mechanism for recognizing and 
degrading faulty transcripts harbouring a premature translation-termination codon 
(PTC); such nonsense transcripts would otherwise result in the production of C-
terminally truncated proteins with potentially dominant-negative effects. PTCs can 
arise either from mutations at the DNA level (e.g. nonsense mutations, frame-
shifting deletions and insertions) or from altered splicing signals that induce 
production of alternatively spliced mRNA isoforms with truncated reading frames. 
Over the last five years, it has become clear that NMD not only degrades faulty 
transcripts but also regulates the steady-state level of many physiological mRNAs 
involved in a variety of different cellular processes, such as DNA repair, the cell 
cycle, and metabolism. Genome-wide screens in budding yeast, Drosophila and 
human cells have revealed that NMD regulates expression of  about 3 – 10% of 
the transcriptome. Furthermore, it has been estimated that about 30% of the known 
disease-associated mutations in humans generate a PTC-containing (PTC+) 
mRNA, and in many of these cases NMD influences the severity of the clinical 
manifestations caused by the mutation [Stalder and Mühlemann, 2008]. 
 
Trans-acting factors involved in NMD 
 
The NMD core factors Upf1p, Upf2p and Upf3p (for ‘‘upframeshift 1-3’’) 
were initially identified in genetic screens in yeast, and SMG1-7 (for ‘‘suppressor 
with morphological effect on genitalia’’) were found to be NMD effectors in C. 
elegans. Sequence alignments revealed that SMG2 is homologous to Upf1p, 
SMG3 to Upf2p, and SMG4 to Upf3p, and that SMG1–7 are present in all higher 
eukaryotes analyzed to date, with the exception of D. melanogaster, which 
contains no clear homolog for SMG7. Additional NMD factors are very likely to 
exist, although they remain to be discovered. Given that they are conserved from 
yeast to humans, UPF1, UPF2 and UPF3 are believed to function at the heart of 
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NMD. UPF1 is the most highly conserved NMD factor, and elucidating its 
structure and function will provide the key to understanding the mechanism of 
NMD. UPF1 interacts with the eukaryotic release factors eRF1 and eRF3, it binds 
to UPF2 through its cysteine and histidine rich (CH-rich) region near the N-
terminus, and it interacts with SMG1, SMG5, SMG6 and SMG7. UPF1 exhibits 
RNA binding, RNA-dependent ATP hydrolysis, and 5’-to-3’ ATP-dependent 
RNA helicase activities, and inhibition of any of these activities suppresses NMD. 
It has been shown in vitro that UPF1 dissociates from RNA after addition of ATP. 
Interaction with eRF1 and eRF3 strongly reduces the ATPase and RNA binding 
activities of UPF1. Vice versa, RNA binding stimulates the ATPase activity and 
leads to a dissociation of UPF1 from eRF1 and eRF3 [Stalder and Mühlemann, 
2008]. 
 
Mechanism of NMD 
 
Actually, there are three different models, which try to elucidate the exact 
mechanism of NMD. 
1. the first, widely accepted, model (figure 14) assumes that in mammalian 
NMD, an intron apparently functions as second signal, besides the premature 
termination codon (PTC), for triggering NMD by leaving a “mark” on the mRNA 
at the exon-exon junction as a consequence of the splicing event. This mark 
known as the exon-junction complex (EJC) enables the NMD RNA surveillance 
pathway to differentiate between PTCs and normal stop condons present in the last 
exon ensuring the degradation only of transcripts containing nonsense codons that 
are followed by an intron. Evidence from a number of studies suggests that during 
the initial rounds of translation, referred as the “pioneer round”, the translating 
ribosome pauses at the PTC. Release factors eRF1 and eRF3, which associate with 
the termination ribosome, recruit UPF1, which subsequently makes contact with 
 UPF2 and UPF3, which are bound to EJC. Formation of this complete 
“surveillance complex” containing UPF1-3 is believed to initiate degradation by 
NMD. In normal transcripts, in which the termination codon occurs in the final 
exon, all EJCs are displaced by the translating ribosome. Thus, the complete 
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surveillance complex cannot form during translation termination because of the 
absence of UPF2 and UPF3, thus NMD is avoided. The mammalian NMD 
surveillance system cannot distinguish PTCs in the penultimate exon that are 
located less than about 55 bp from the final intron. The “55bp-rule” for the 3’end 
of the penultimate exon is believed to reflect the location of the EJC on spliced 
mRNAs; a translocating ribosome would displace an EJC upstream of the last 
exon-exon junction before the ribosome could recognize a stop codon located less 
than about 55 bp from the exon-exon junction. As a consequence, the inability to 
differentiate nonsense codon mutations in the last and 3’end of the penultimate 
exon from the normal termination codon can result in the stable translation of 
mRNAs that contains PTCs located within this “protected” region. Thus, mRNA 
with non-sense codons present in such positions can escape the NMD pathway. 
Such an “escape from NMD surveillance” may cause expression of large amounts 
of aberrant truncated proteins with potential dominant-negative or gain-of-function 
effects in cells [Khajavi et al, 2006]. 
2. The second model is called “the faux 3’UTR model” and suggests that 
proper termination of translation and normal rates of mRNA decay are likely to 
require interactions between a terminating ribosome and a specific 
ribonucleoprotein (RNP) structure or set of factors localized on 3’ to the stop 
codon. Failure to terminate in this manner seems to slow ribosome release and 
facilitate reinitiation. The latter event must only be a symptom of aberrant 
termination, not a cause of NMD, because elimination of reinitiation site AUG 
codons does not alter the decay rate of nonsense-containing mRNAs. However, 
the failure to release a terminating ribosome effectively might be a stimulus for 
NMD, possibly promoted by the ribosome failure to recycle in cis and/or by the 
recruitment of UPF1P to aberrant termination event or to a bound negative 
regulatory factor [Amrani et al, 2004]. 
3. Recently, Stalder and Mühlemann [2008] proposed a new “unified” model 
for PTC recognition (figure 15). This model essentially extends the faux 3’UTR 
model to all species and proposes that, during mammalian NMD, downstream 
EJCs act as an evolutionary adaptation to efficiently recognize nonsense mRNAs 
produced by extensive alternative splicing. Their laboratory showed that the 
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physical distance, rather than the number of nucleotides, between a PTC and the 
poly(A) tail is a crucial determinant in defining a PTC as premature. It was shown 
that UPF1 and PABPC1, the major cytoplasmic PABP (poly(A)-binding protein), 
compete for the interaction with eRF3 in human cells in vitro. The balance of this 
competition enables the cell to distinguish between correct and aberrant translation 
termination. Thus, if a ribosome stalls at a PTC that is too far away from the 
termination-promoting environment (i.e. distant from PABPC1), resulting in slow 
termination kinetics, the balance between the two antagonizing signals is tilted 
toward UPF1 binding (‘marking’ within figure 15b). Notably, binding of UPF1 to 
the stalled ribosome in this context is EJC-independent. Although UPF1 has been 
found to preferentially associate with PTC-containing mRNA in C. elegans, some 
association with PTC-free mRNA was also observed. This suggests that simple 
binding of UPF1 to a terminating ribosome is not sufficient to elicit degradation, 
but rather a ‘second signal’ is required. The second signal might be the binding of 
UPF2 and UPF3 to UPF1, an event that is important for the SMG1-mediated 
phosphorylation of UPF1 in higher eukaryotes, and which stimulates the RNA 
helicase and ATPase activities of UPF1. As a consequence of ATP hydrolysis, 
binding of UPF1 to the RNA might be facilitated. ATPase-defective UPF1 
mutants show enriched co-immunoprecipitation with UPF2 and UPF3b in 
mammalian cells. In summary, Stalder and Mühlemann [2008] postulate that the 
phosphorylation of UPF1 and the stimulation of its ATP hydrolysis and helicase 
activity represent a ‘point of no return’ in the NMD pathway, and they define this 
as the ‘licensing step’ (figure 15b). Contrary to the popular model for mammalian 
NMD, several studies have demonstrated that PTCs can trigger NMD in the 
absence of an EJC further downstream on the mRNA. However, it is apparent that 
the extent of mRNA downregulation in these examples of EJC-independent NMD 
is lower than in corresponding examples of NMD of transcripts with EJCs in the 
3’UTR. Consistent with the idea that EJCs have an important role in NMD, 
knockdown of EJC core-factors in mammalian cells reduced the downregulation 
of many NMD reporter mRNAs. In the light of this, Stalder and Mühlemann 
[2008] propose that, in mammals, the EJC has evolved as a specialized second 
signal to enhance mammalian NMD. This unified NMD model provides a 
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mechanistic explanation for the NMD-enhancing function of EJCs located 
downstream of a PTC. As part of such a 3’UTR-bound EJC, UPF2 and UPF3 are 
ideally positioned for immediate interaction with ribosome-bound UPF1 and 
SMG1. As a consequence, the time window between the binding of UPF1 to the 
terminating ribosome (the marking step) and its SMG1- mediated phosphorylation 
(the licensing step) would be shortened, and thus the competition between PABP 
and UPF1 for binding to the stalled ribosome would tilt toward NMD (figure 
15b). They hypothesize that, in mammals, under the evolutionary pressure to 
efficiently recognize and eliminate the large number of nonsense mRNAs 
produced by extensive alternative pre-mRNA splicing, the EJC as a spatial mark 
of previous splicing events has been incorporated into the mechanism of PTC 
recognition as an enhancer. 
 
Degradation of PTC-containing transcripts 
 
Once aberrant mRNA is targeted for decay by PTC-recognition, its degradation 
will be mediated by several different enzyme complexes involved in different 
NMD pathways. Generally, most aberrant mRNA degradation is initiated from 3’ 
poly(A) by deadenylase complex. Subsequently, there are two pathways involved 
in rapid mRNA decay. In one pathway, deadenylation triggers decapping, and this 
exposes the mRNA body for digestion by the major cytoplasmic 5’-3’ exonuclease 
XRN1. decay of mRNA through this pathway is though to occur in specialised 
cytoplasmic bodies or mRNA decay foci (also known as P-bodies or GW-bodies) 
that are enriched in XRN1, the decapping enzymes and decapping co-activators. 
Besides 5’-3’ mRNA decay pathway, recent work in yeast shows that there is an 
alternative, decapping-independent NMD pathway, involving deadenylation and 
subsequent 3’-5’ exonucleolytic decay [Li et al, 2006].  
 
The role of NMD in regulation of normal gene expression 
 
Probably, the primary role of the NMD pathway is to regulate the stability and 
abundance of physiological transcripts. In all eukaryotes, there is a low but 
 77 
significant level of incompletely spliced pre-mRNA that encode in-frame 
premature termination codons and would therefore be substrates for the NMD 
pathway. Aberrant mRNAs resulting from other natural sources of error, including 
faulty transcription or splicing, would also be subject to the quality control 
imposed by this surveillance system. Another class of transcripts expected to be a 
target of NMD comprises those that contain upstream open reading frames 
(uORFs) in their 5’UTR. These uORFs may be interpreted to be prematurely 
terminated by the scanning machinery, resulting in rapid decay. In theory, there is 
a number of other physiological variants of gene structure that may elicit scrutiny 
by the nonsense surveillance pathway. For example, the growing class of non-
coding RNAs may serve as substrate for NMD. Moreover, a small but significant 
number of mammalian genes contain an intron within the 3’UTR. In theory, the 
corresponding transcripts would be subject to rapid decay if a sufficient distance 
were present between the bona fide termination codon and the splice donor 
[Frischmeyer and Dietz, 1999].  
Further contribution from NMD to physiological gene expression are evident 
in the maturation of the immune system. In B and T cells, the immunoglobulin and 
T-cell receptor genes, respectively, are rearranged extensively, introducing PTCs 
in two-thirds of cases, and transcripts from these genes are degraded by NMD. 
Presumably, at the level of the entire B- and T-cell population, permitting 
expression of only successfully rearranged genes results in a large number of fully 
functional variant immunoglobulin or T-cell receptor protein, greatly increasing 
the ability of the immune system to respond to a variety of antigens [Holbrook et 
al, 2004].  
 
NMD-mediated protection against hereditary disorders 
 
The medical significance of NMD in this respect was first appreciated in β-
thalassemia, and this disorder demonstrates the protective effects of NMD against 
the production of faulty proteins. In the common recessive form of β-thalassemia 
caused by NMD-sensitive PTC mutations, defective β-globin mRNA is degraded 
by NMD and, therefore, synthesis of truncated β-globins is limited. In contrast to 
 78 
homozygotes, heterozygotes with these mutations generally synthesise enough β-
globin from the remaining allele to support near-normal haemoglobin levels and 
are therefore healthy. Rare NMD-insensitive last-exon PTC mutations, however, 
give rise to truncated, nonfunctional β-globin that overwhelms the cellular 
proteolytic system and causes toxic precipitation of insoluble globin chains. This 
stark contrast between asymptomatic heterozygotes with NMD-competent 
mutations and affected heterozygotes with NMD-incompetent mutations shows 
that, for PTC mutations in the β-globin gene, NMD protects most heterozygous 
carriers from dominant disease [Holbrook et al, 2004]. 
 
NMD in acquired genetic conditions 
 
Mutations in tumor-suppressor genes are common steps in the development 
and progression of cancer. NMD degrades transcripts containing PTCs from the 
gene BRCA1 and reduces abundance of mRNAs containing PTCs from the TP53 
and Wilson tumor loci. Studies indicate that if abnormal transcript containing 
PTCs were not degraded by NMD, clinically recessive tumor-suppressor 
mutations could result in the synthesis of truncated, dominant oncoproteins. NMD 
may thus protect heterozygous carriers of tumor-supressor gene containing PTC 
mutations from developing cancer, at least for as long as the other tumor-
suppressor allele remains intact [Holbrook et al, 2004].   
 
Protein synthesis (Translation)  
 
The translation is the process by which the nucleotide sequence of a mRNA is 
used to sort and combine the amino acids in a polypeptide chain. In eukaryotic 
cells, protein synthesis occurs in the cytoplasm, where there are three types of 
RNA molecules with different functions, but that cooperate together: 1) messenger 
RNA (mRNA) that carries the genetic information copied from the DNA in the 
form of three-base code “words”, each of which specifies a particular amino acid. 
2) Transfer RNA (tRNA) which is the key to deciphering the code word in 
mRNA. Each type of amino acid has its own type of tRNA, which binds and 
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carries it to the growing end of a polypeptide chain if the next code word on 
mRNA calls for it. The correct tRNA with its attached amino acid is selected at 
each step because each specific tRNA molecule contains a three-base sequence 
that can base-pair with its complementary code word in the mRNA. 3) Ribosomal 
RNA (rRNA) which is associated with a set of proteins to form ribosomes. These 
complex structures, which physically move along an mRNA molecule, catalyze 
the assembly of amino acid into protein chains. They also bind tRNAs and various 
accessory molecules necessary for protein synthesis. Ribosomes are composed of 
a large and small subunit, each of which contains its own rRNA molecule or 
molecules. 
A ribosome is composed of several different ribosomal RNA (rRNA) 
molecules and more that 50 proteins, organized into a large subunit (60S) and a 
small subunit (40S). The proteins in the two subunits differ, as do the molecules of 
rRNA. The small ribosomal subunit contains a single rRNA molecule, referred to 
as small rRNA (18S); the large subunit contains a molecule of large rRNA (28S) 
and one molecule each of two much small rRNAs. These rRNAs interact with 
mRNA and tRNAs in each phase of the translation, and the proteins contained in 
the ribosome bring them together to carry out the biochemical events leading to 
formation of proteins on ribosomes. 
The complex process of translating mRNA into protein can be divided into 
three stages: initiation, elongation and termination.  
The AUG codon for methionine functions as the start codon in the vast 
majority of mRNA. A critical aspect of initiation is to begin protein synthesis at 
the start codon, thereby setting the stage for the correct in-frame translation of the 
entire mRNA. Both prokaryotes and eukaryotes contain two different methionine 
tRNAs: tRNAiMet can initiate protein synthesis and tRNAMet can incorporate 
methionine only into a growing protein chain. The same aminoacyl-tRNA 
synthetase (MetRS) charges both tRNAs with methionine, but only tRNAiMet can 
bind at the appropriate site on the small ribosomal subunit to begin synthesis of a 
protein chain.  
Initiation of protein synthesis in eukaryotic cells begins with formation of a 
preinitiation complex prior to mRNA binding. Two eukaryotic factors, eIF3 and 
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eIF6, serve to keep the ribosomal subunits apart after they have previously 
finished synthesizing a protein chain so that they can participate again in starting a 
new chain (figure 16). To assemble a eukaryotic preinitiation complex, an active 
“ternary complex” of eIF2 bound to a GFP molecule and Met-tRNAiMet associates 
with a small ribosomal subunit complexed with two other factors, eIF3 and eIF1A, 
which stabilize binding of the ternary complex (figure 16-1). 
Most eukaryotic mRNAs have a single start site near the 5’ capped end of the 
mRNA. Interaction of the small ribosomal subunit with the methylated 5’-cap 
structure present in all eukaryotic mRNAs requires a set of proteins collectively 
called eIF4 (figure 16-2). After the methylated cap structure is recognized by 
eIF4F, any secondary structure at the 5’ end is removed by an associated helicase 
activity. The bound initiation complex, which contains the eIF3 group of proteins, 
then probably slides along the mRNA, most often stopping at the first AUG. 
However, selection of the initiating AUG is facilitated by specific surrounding 
sequences called Kozak sequences. At this point, the hydrolysis of GTP in eIF2-
GTP provides the energy for the releasing of all factors of the initiation complex 
(figure 16-3). Finally, the factor eIF5 assists union of the 40S complex with the 
60S subunit (figure 16-4). 
The correctly positioned eukaryotic 80S ribosome – Met-tRNAiMet complex is 
now ready to begin the task of stepwise addition of amino acids by the in-frame 
translation of the mRNA. As is the case of initiation, a set of special proteins, 
termed elongation factors (EFs), are required to carry out the process. The key 
steps in elongation are entry of each succeeding aminoacyl-tRNA, formation of a 
peptide bond, and the movement, or translation, of the ribosome with respect to 
the mRNA.  
The initiating Met-tRNAiMet is bound at the P site and base-paired with the 
AUG start codon, while the second aminoayl-tRNA is brought into the ribosome 
as a ternary complex in association with an EF1 α-GTP and becomes bound to the 
A site on the ribosome (figure 16-5). If the anticodon of the incoming aminoacyl-
tRNA corretly matches the second codon of the mRNA, a tight binding ensues at 
the A site. If the second codon does not match the incoming aminoacyl-tRNA, it 
diffuses away. The choice of the correct aminoacyl-tRNA and its tight binding at 
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Figure 16 – Protein synthesis. At the end of the translation 40S and 60S subunits are separated and linked to the initiation
factors eIF3 and eIF6. (1-2) Sequential addition of eIF2-GTP factor and eIF4 complex to the 40S-eIF3 complex, to form the 
initiation complex. 3) Flow of the initiation complex on the mRNA and positioning of this, through the binding of the Met-
tRNAi to the start codon. 4) Formation of the ribosome 80S through association of the major and minor subunits, due to the 
movement of eIF6 by eIF5-GTP. 5) A complex carrying the second amino acid (aa2) binds to the A site of ribosome, 
containing Met-tRNAi in the P site. 6) Conformational change of ribosome, inducing hydrolysis of elongation factor. 7) The 
28S rRNA catalyzes the formation of the peptide bond between Meti and aa2. 8) GTP-hydrolisis of the EF2 induces a 
subsequent conformational change of ribosome, which involves its translocation of a codon along the mRNA and 
displacement of the deacylated Met-tRNAi to the E site and the tRNA bound to the peptide to the P site. 9) The release factor
eRF1 binds to the A site and recognizes termination codon and works in conjunction with the factor eRF3-GTP in the cutting
of the protein chain from the peptidil-tRNA [Lodish, 2000].
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the A site requires energy that is supplied by hydrolysis of the EF1 α-GTP 
complex (figure 16-6). 
With the initiating Met-tRNAiMet at the P site and the second aminoacyl-tRNA 
tightly bound at the A site, the α amino group of the second amino acid reacts with 
the activated methionine on the initiator tRNA, forming a peptide bond. This 
critical peptidyltransferase reaction actually effects the transfer of the growing 
peptide chain on the peptidyl-tRNA at the P site to the activated amino acid on the 
incoming aminoacyl-tRNA (figure 16-7).  
During the process of peptide synthesis and tRNA site changes, the ribosome is 
moved along the mRNA a distance equal to one codon with the addition of each 
amino acid. This translocation step is catalyzed by EF2-GTP, which is hydrolyzed 
to provide the required energy. After peptide linkage tRNAiMet, now without its 
activated methionine, is moved to an exit (E) site on the ribosome and is soon 
discharged (figure 16-8). Concurrently, another ternary complex, carrying the next 
amino acid to be added, enters the ribosome, and the cycle continues. 
The final phase of protein synthesis, like initiation and elongation, requires 
highly specific molecular signals that decide the fate of the mRNA-ribosome-
tRNA-peptidyl complex. Two types of specific termination (release) factors are 
involved in this process. Eukaryotic eRF1, whose shape is though to be similar to 
that of tRNAs, apparently acts by recognizing the stop codons. Like some of the 
initiation factors and the elongation factors, the release factor eRF3 is a GTP-
binding protein and acts in concert with the codon-recognizing factor to promote 
cleavage of the peptidyl-tRNA, thus releasing the completed protein chain (figure 
16-9) [Lodish, 2000]. 
 
Translational read-through 
 
Translational read-through is a strategy with the purpose to suppress the effects 
of a premature nonsense codon by modifying gene expression. This may be 
achieved by two different mechanisms. First, by decreasing the accuracy of 
translation elongation; second, by reducing the efficacy of the translation 
termination machinery. In the past few decades it has been realized that 
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aminoglycoside antibiotics can decrease the fidelity of the eukaryotic elongation 
machinery. Consequently, this drug group may hold a valuable potential in the 
pharmacogenetic therapy of nonsense mutation related genetic disorders. 
Aminoglycosides inhibit prokaryotic protein synthesis at appropriate 
(“therapeutic”) concentrations. However, when applied at microbiologically sub-
lethal levels some may induce incorporation of the wrong amino acid (mis-
incorporation) at a sense codon or the insertion of an amino acid at a stop codon 
(leading to translational read-through) [Kellermayer, 2006]. Similar effects, 
namely errors in the translation of polyU mRNAs, were demonstrated by Wilhelm 
et al [1978 a, b] in eukaryotes and in human cells but at concentrations 10 – 15 
times higher than the typical therapeutical antibacterial concentrations. The 
usefulness of aminoglycosides as antibacterial agents lies in the ability to bind 
with high affinity adenine 1408 present on the minor rRNA in prokaryotes and 
with low affinity the guanine in the same position in eukaryotes. Precisely for this 
reason, to have an effect on eukaryotic cells, the needed concentration of 
aminoglycoside is greater [Recht et al, 1999]. 
 
Mechanism of action of aminoglycosides 
 
During protein synthesis the ribosome catalyses the sequential addition of 
amino acids to a growing polypeptide chain, using mRNA as a template and 
aminoacylated tRNAs (aa-tRNAs) as substrates. Correct base pairing between the 
three bases of the codon on mRNA and those of the anticodon of the cognate aa-
tRNA dictates the sequence of the polypeptide chain. Discrimination against 
noncognate tRNA, which generally has two or three mismatches in the base 
pairing, can be accounted for by the difference in the free energy of base pairing to 
the codon compared with cognate tRNA. For near-cognate tRNA, which usually 
involves a single mismatch, the free-energy difference in base pairing compared 
with cognate tRNA would predict an error rate that is one to two orders of 
magnitude higher than the actual error rate of protein synthesis, and it has long 
been recognised that the ribosome must improve the accuracy of protein synthesis 
by discriminating against near-cognate tRNAs. This discrimination involves the 
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30S subunit, which binds the mRNA and the anticodon stem-loop (ASL) of tRNA 
[Ogle et al, 2001]. 
At the beginning of the elongation cycle, which involves the addiction of a new 
amino acid to a growing polypeptide chain, the aa-tRNA is presented to the 
ribosome as a ternary complex with elongation factor 1A (EF1A) and guanosine 
triphosphate (GTP). The selection of cognate tRNA is believed to occur in two 
stages, an initial recognition step and a proofreading step, that are separated by the 
irreversible hydrolysis of GTP by EF1A. In this scheme, the discrimination energy 
inherent in codon-anticodon base pairing is exploited twice to achieve the 
necessary accuracy. Experiments suggest that the binding of cognate rather than 
near-cognate tRNA results in higher rates of both GTP hydrolysis by EF1A and 
accommodation, a process in which the acceptor arm of the aa-tRNA swings into 
the peptidyl transferase site after its release from EF1A. In both steps, the higher 
rate is proposed to be the result of structural changes in the ribosome induced by 
cognate tRNA. In the context of proofreading mechanisms alone, it is unclear 
whether additional structural discrimination by the ribosome, over that inherent in 
the energetics of codon-anticodon base pairing, is actually required in decoding. 
The prospect of a direct involvement of the ribosome in the recognition of the 
codon-anticod duplex was revived when it was shown the error-inducing antibiotic 
paromomycin changes the conformation of a 16S rRNA fragment of the decoding 
centre, in prokaryotes (figure 17a); the affected residues were stringly implicated 
in tRNA binding. Furthermore, kinetic experiments have shown that both GTP 
hydrolysis and accommodation (peptide bond formation) are accelerated for 
cognate relative to near-cognate ternary complex. This implies that the energy 
derived from the binding of a cognate aa-tRNA anticodon induces conformational 
changes in the ribosome, and is used to drive the irreversible chemical steps on the 
tRNA selection pathway [Ogle et al, 2001; Ogle et al, 2003].  
The binding of mRNA and cognate tRNA in the A site induces A1492 and 
A1493, two universally conserved bases, to flip out of the internal loop of helix 
44. This binding also causes the conserved base G530 to switch from the syn 
conformation present in the native structure to an anti conformation. In their new 
conformations, A1492 and A1493 interact, respectively, with the first and second 
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base pairs of the codon-anticodon helix, whereas G530 interacts with both the 
second position of the anticodon and the third position of the codon. The result of 
these induced changes is that the first two base pairs of the codon-anticodon helix 
are closely monitored by the ribosome in a way that would be able to discriminate 
between Watson-Crick base pairing and mismatches, whereas the environment of 
the third, or “wobble”, position appears to be suited for accommodating other 
base-pairing geometries [Ogle et al, 2001]. 
When the ribosomal base A1492 interacts with a mismatch between the first 
position of the codon and the anticodon of near-cognate tRNA (figure 17b), the 
wobble geometry displaces the base of the codon into the minor groove so that it 
can no longer form hydrogen bonds with A1492, but at the same time there is no 
room for a water molecule to solvate the polar groups. This amounts to a large 
desolvation penalty, which can reduce the affinity of near-cognate tRNA 
anticodon ASL fragments to the ribosome by more than three orders of magnitude. 
The principles and extent of discrimination against mismatch at the second 
position are similar [Ogle et al, 2003]. 
The changes induced in the 30S subunit by cognate tRNA are energetically 
favourable because various compensating interactions can be made by the 
ribosome with the codon-anticodon helix but only when the first two base pair are 
canonical Watson-Crick base pairs. In the case of near-cognate tRNA, fewer of 
these interactions would be possible, so the induced changes would normally be 
less favourable. By paying part of the energetic cost of these induced changes, 
especially in displacing A1492 and A1493 from their internal loop in helix 44, 
amimoglycoside facilitates the binding of near-cognate tRNA, along with the full 
changes induced as a result. This result is consistent with the finding that 
paromomycin accelerates precisely those steps (GTP hydrolysis and 
accommodation) for near-cognate tRNA that are normally slower as compared 
with cognate tRNA and agrees with earlier proposals that paromomycin works by 
inducing structural changes in the decoding site, rather than by making direct 
interactions with mRNA or tRNA [Ogle et al, 2001]. 
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Aminoglycoside antibiotics approach the clinic 
 
Aminoglycosides have been shown to suppress premature translation 
termination at nonsense codons with an efficacy varying from 1% to 25% in 
human cell lines, largely depending on the context of the stop mutations. 
Consequently, an increased amount of full size, functional protein may be 
produced as a result of aminoglycoside therapy, even if only in low percentage. 
This effect may be significant, however, especially in recessive disorders resulting 
from nonsense mutations, where protein expression approaches zero [Kellermayer, 
2006]. 
In 1985, Burke and Mogg were the first to demonstrate that aminoglycosides 
geneticin (G418) and paromomycin could partially restore the synthesis of a 
protein codifying by a mutated gene, in an animal cell culture. 
Subsequently, various experiments on the suppression of disease-causing 
premature stop codon mutations in cystic fibrosis transmembrane conductance 
regulator (CFTR) were carried out. Howard et al [1996] observed a dose-
dependent increase in the expression of full-length CFTR from the R553X mRNA, 
produced by HeLa cells transfected with the mutated cDNA, as a function of G418 
concentration, indicating that G418 stimulates read-through of the R553X 
mutation. Quantification showed that the amount of the full-length CFTR 
produced was as much as 25% of the level of protein expression obtained from the 
wild-type CFTR cDNA. Even more full-length CFTR (35% of wild-type) was 
observed in the cells transfected with the CFTR G542X cDNA. The same group 
found that IB3-1 cells, a bronchial epithelial cell line carrying the ∆F508 mutation 
on one chromosome and the W1282X premature stop mutation on the other, 
regained cAMP-activated chloride conductance following growth for 18 hours in 
the presence of either G418 or gentamicin [Bedwell et al, 1997]. To address 
whether aminoglycosides can suppress a CFTR premature stop mutation in an 
animal model, they constructed a mouse model with a null mutation in 
endogenous CFTR locus (Cftr-/-) that also expressed a human CFTR-G452X 
cDNA under control of the intestinal fatty acid binding protein promoter. They 
then investigated whether the daily administration of the aminoglycoside 
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antibiotics gentamicin or tobramycin could restore the expression of a detectable 
level of CFTR protein. Immunofluorescence staining of intestinal tissues from 
Cftr–/– hCFTR-G542X mice revealed that gentamicin treatment resulted in the 
appearance of hCFTR protein at the apical surface of the glands of treated mice. 
Weaker staining was also observed in the intestinal glands following tobramycin 
treatment [Du et al, 2002]. 
An important concern for the clinical use of aminoglycosides is the side effects 
associated with their use, which include kidney damage and hearing loss. Because 
of their potential toxicity, administration protocols have been developed that 
maintain aminoglycoside serum concentrations within a clinically acceptable 
range of recommended peak and trough levels. In the previous study, Du et al 
showed that gentamicin suppressed the hCFTR-G542X nonsense mutation in vivo, 
although peak serum concentrations used were well above the levels allowed 
during the recommended clinical use of these compounds. Thus, it was not clear 
whether an effective level of suppression could be accomplished at concentrations 
within a safe clinical range. For this reason, they examined whether gentamicin 
and amikacin could suppress the G542X mutation when administered at doses 
within the recommended therapeutic range of serum peak an trough levels. They 
obtained evidence that both compounds could suppress the hCFTR-G542X 
mutation in the Cftr-/- mouse model and partially restore functional CFTR 
expression when administrated at doses that produced serum levels in the 
recommended range. However, their results indicate that amikacin suppressed the 
hCFTR-G542X mutation in vivo much more effectively than gentamicin under 
these conditions, suggesting that it may represent a better choice for the 
suppression of the hCFTR-G542X stop mutation [Du et al, 2006]. 
Moreover, Wilschanski et al [2003] performed a topic treatment, by the 
application of gentamicin to the nasal epithelium of patients with cystic fibrosis. 
This restored CFTR function in about 90% of patients who had stop mutations in 
CFTR. After gentamicin treatment, the electrophysiological abnormalities caused 
by the CFTR defect resolved in 21 percent of the patients and chloride or sodium 
transport was restored in 68 percent. Gentamicin seems to be more effective in 
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patients who are homozygous for stop mutations than in those who are 
heterozygous. 
Positive results also came from aminoglycoside treatment of Duchenne’s 
muscular dystrophy (DMD). The group of Barton-Davis [1999] tested the in vivo 
effects of gentamicin on the mdx mouse, the animal model for this disease which 
has a stop codon in the dystrophin gene. The muscle cells taken from treated mdx 
mice showed a restoration of dystrophic protein with an increase of 10% - 20%. 
Howard et al [2004] tested gentamicin, amikacin, tobramycin and paromomycin 
for the ability to induce stop codon read-through of eight premature termination 
codons, shown to be causative for Duchenne’s or Becker’s muscular dystrophy. 
They showed variable aminoglycoside suppression with induced read-through 
levels between approximately 1 and 10% depending on the sequence context and 
aminoglycoside utilised. Despite these encouraging results, two clinical trials of 
gentamicin treatment in DMD have observed no changes in muscle strength or 
increased dystrophin expression in post-treatment muscle biopsies. These 
conflicting studies must be interpreted cautiously, because our understanding of 
the molecular mechanisms associated with gentamicin treatment is incomplete. 
For example, the efficiency of termination and aminoglycoside suppression are 
determined by the stop codon and the surrounding sequence context, but the rules 
that govern these context effects are poorly understood. In addition, gentamicin 
consists of three major components, gentamicin C1, C2, and C1a. Variations in the 
amount of each isoform do not substantially influence antibacterial activity but 
may result in differing levels of stop codon read-through. 
Given the initial positive results, investigators have tried to use these 
antibiotics on other types of genetic disorders caused by nonsense mutations. Lai 
et al. [2004] proposed a therapeutic approach for ataxia-teleangiectasia, an 
autosomal recessive neuro-degenerative disorder with onset in early childhood, 
treating 13 lymphoblastoid cell lines with primary  premature termination codon 
mutations, with different types of aminoglycosides (G418, gentamicin, tobramycin 
and paromomycin). They obtained a restoration of the ATM gene using G418 and 
gentamicin. 
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Pinotti et al [2006], through functional assays and a fluorescence-based 
approach, investigated the spontaneous and aminoglycoside-mediated read-
through of nonsense mutations in FVII. Results indicated that treatment with the 
aminoglycosides G418 or gentamicin induces a significant increase in 
extracellular FVII protein levels. However, the specific activity of FVII variants 
resulted in being remarkably reduced as compared with wild-type FVII, thus 
indicating the synthesis of dysfunctional FVII molecules. 
Finally, Keeling et al [2001] tested gentamicin activity on the restoration of the 
level of protein expression in Hurley disease. They found that gentamicin 
treatment was capable of restoring 2.5 – 3% of normal α-L-iduronidase activity in 
cultured Hurley fibroblasts.  
A major limitation of the read-through technique is that the aminoglycoside 
action is not gene-specific and can act on correct termination codons, that are not 
derived from nonsense mutations. The proteins generated would, therefore, have 
altered functions and, if not having a proper quaternary structure, they can produce 
formation of toxic aggregates. These proteins may also interact with protein 
complexes in important cellular pathways damaging functions of the cell 
[Kaufman, 1999]. 
 
Context-dependent suppression of termination codons 
 
Translation termination is normally a highly efficient process. Although the 
mis-incorporation of an amino acid at a stop codon (a process termed suppression) 
normally occurs at a frequency of only 10-4 in intact cells, the overall efficiency of 
this process can be influenced by a number of variables. Not only do different stop 
codons appear to facilitate the termination process with different efficiencies, but 
the efficiency of translation termination can also be influenced by the local 
sequence context surrounding the stop codon. A statistical analysis of the context 
surrounding the stop codons at the end of genes in several organisms revealed a 
bias toward certain nucleotides on either side of the termination codon. In all 
species examined, the strongest bias was found at the base immediately following 
the stop codon. This led to the proposal that the actual translation termination 
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signal may consist of a tetranucleotide sequence. The importance of nucleotides 
immediately upstream and downstream of the stop codon in determining the 
efficiency of translation termination is clearly established in prokaryotes. Studies 
of the context influence on the efficiency of translation termination in yeast cells 
indicated that upstream and downstream sequences act together to determine the 
overall efficiency of translation termination. In particular, the fourth base was 
found to be an important determinant for the efficiency of termination in yeast, but 
this effect varied as a function of the stop codon that was present. The importance 
of the local sequence context in determining the efficiency of translation 
termination in higher eukaryotes is less well understood [Manuvakhova et al, 
2000].   
Manuvakhova et al [2000] wanted to determine whether the sequence context 
can also influence the ability of aminoglycosides to suppress stop codons in 
mammals. To do this, they constructed a reporter system that allowed them to 
accurately monitor the efficiency of translation termination in different sequence 
contexts using a rabbit reticulocyte translation system.  
One of the most surprising findings of their study was the complex effects 
observed in the relative level of read-through when only the fourth base of the 
tetranucleotide termination signal was changed. In assays with the UGAN series of 
constructs, they found that C in position 4 always led to the most read-through. 
This trend was observed in the basal read-through of the in vitro translation 
system, and in read-through induced by members of the 4,6 or 4,5 disubstituted 
classes of aminoglycosides. In most cases, read-through was lowest when U was 
present in the fourth position of the UGAN constructs. The only exception to this 
trend was with lividomycin, where A and G in position 4 allowed the lowest level 
of readthrough. When assays were done with the UAGN constructs, they found 
that the 4,6 disubstituted class of aminoglycosides was again similar to the 
uninduced level of read-through, with U mediating the most read-through 
followed by C. Nucleotides A or G induced the least read-through with these 
compounds. However, this trend was not maintained when they examined the 
level of read-through induced by the 4,5 disubstituted classes of aminoglycosides 
in the UAGN constructs. Finally, a distinct trend in the rank order of suppression 
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was mediated by almost every aminoglycoside in the UAAN constructs. These 
results again indicate that different aminoglycosides influence the decoding site 
(and consequently, the proofreading step that discriminates between cognate and 
near-cognate aminoacyl-tRNAs within the A site) in subtly different but important 
ways. They conclude from these results that a simple pattern of suppression that 
can be attributed solely to the fourth position of the tetranucleotide signal does not 
exist.  
Their results also demonstrate that the sequence context beyond the 
tetranucleotide termination signal can influence the level of read-through induced 
by several aminoglycosides.  
Finally, it is important to note that other translation factors present in the 
complete translation system may also influence the overall efficiency of 
translation termination. For example, one or more components of the surveillance 
complex (which includes Upf1p, Upf2p, and Upf3p) may mediate important 
effects on termination, because the loss of any of these proteins results in a 
nonsense suppressor phenotype [Manuvakhova et al, 2000]. 
 
Aminoglycosides and analogous 
 
As a class of antibiotics, aminoglycosides have a backbone structure consisting 
of an aminocyclitol ring saturated with amine and hydroxyl substitutions. In the 
majority of clinically useful aminoglycosides, this aminocyclitol moiety is 
streptamine or 2-deoxystreptamine. Streptomycin, possessing a streptidine 
molecule, is the only exception. The aminocyclitol nucleus is connected through 
glycosidic linkages to various amino sugars (aminoglycosides). The 
aminoglycosides can be conveniently divided into three structural types based on 
the position of their glycosidic linkages. These structural types include the 4,6-
disubstituted 2-deoxystreptamines, containing most of the clinically useful 
aminoglycosides such as gentamicin, tobramycin, amikacin, kanamycin and 
netilmicin, the 4,5-disubstituted 2-deoxystreptamines (neomycin and 
paromomycin), and others (streptomycin and spectinomycin) (figure 18). 
Spectinomycin, although often considered an aminoglycoside, does not contain an 
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Neomycin Paromomycin
Gentamicin Tobramycin Amikacin
Streptomycin Spectinomycin
a) 4,6-Disubstituted 2-deoxystreptamines
b) 4,5-Disubstituted 2-deoxystreptamines
c) Others
Figure 18 – Representative structures of clinically useful aminoglycosides [Jana and Deb, 2006].
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amino sugar. Thus, several investigators have suggested that the term 
aminocyclitol be used to describe this entire group of agents rather than the less 
precise term aminoglycoside. The aminoglycoside structure is important in 
understanding their chemical properties. These are basic, strongly polar 
compounds that are positively charged (cationic). They are highly soluble in 
water, relatively insoluble in lipids, and have enhanced antimicrobial activity in 
alkaline rather than acidic environments. As a result, aminoglycosides are 
minimally absorbed from the gut and penetrate the blood brain barrier poorly. The 
cationic nature of the aminoglycosides contributes to their antimicrobial activity. 
Because of their positive charge, they are able to bind negatively charged 
lipopolysaccharide of the bacterial cell wall and a variety of intracellular and cell 
membrane anionic molecules such as DNA, RNA, and phospholipids. 
Unfortunately, their positive charge at physiological pH also contributes to their 
toxicities, e.g., nephrotoxicity, ototoxicity, and neuromuscular blockade. 
Aminoglycosides are metabolically stable compounds that are excreted unchanged 
in the urine. 
Different classes of aminoglycoside antibiotics bind to different sites on the 
rRNA, depending on the structural complementarity between the two. For 
example, neomycin, paromomycin, gentamicin and kanamycin are believed to 
bind to the A site on the 16S rRNA in E. coli in a similar fashion and were shown 
to protect bases A1408 and G1494 in chemical footprinting experiments. Four 
bases, A1408, A1492, A1493, and G1494, in the rRNA A site interact with tRNA, 
although with different affinities. The binding of the aminoglycosides to the A site 
in the decoding region (i.e., the site of codon and anticodon recognition) interferes 
with the accurate recognition of cognate tRNA by rRNA during translation. These 
interactions are also thought to interfere with the translocation of tRNA from the 
A site to the peptidyl– tRNA site (P site) [Jana and Deb, 2006]. 
Fourmy et al. [1998] provided structural evidence on the mode of interactions 
of paromomycin, a representative aminoglycoside of the neomycin class, with a 
27-nucleotide RNA template that was designed to mimic the A site region of the 
16S rRNA in E. coli. Specific interactions were observed between aminoglycoside 
chemical groups important for antibiotic activity and conserved nucleotides in the 
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RNA. Common chemical groups among A site binding aminoglycosides on rings I 
and II of paromomycin make sequence specific contacts with the A site RNA. 
Rings III and IV contact RNA non-specifically by electrostatic interactions with 
the phosphodiester backbone. The structure suggests that rings I and II are 
essential for specific binding of aminoglycosides to rRNA and that the 
contribution of rings III and IV to the specificity of binding is minor. This 
prediction is supported by experimental data: neamine, which lacks rings III and 
IV, binds to 16 S rRNA and causes miscoding. This suggests that the conserved 
rings, I and II, are the minimum motif for specific binding of aminoglycosides to 
the A site of the ribosome. 
The 4,6-disubstituted geneticin (G418), a gentamycin-related aminoglycoside, 
is used in medicine as an anti-parasitic agent, although with some limitations due 
to its toxicity to human ear and kidney cells. In molecular biology, geneticin is 
routinely employed as a selection marker in eukaryotic cells transfected with a 
gene coding for an enzyme that inactivates the aminoglycoside. It contains three 
rings that are functionalised by hydroxyl, ammonium amd methyl groups. The two 
sugar rings constituting the neamine part common to most of the aminoglycosides 
bind to the A site. The essential hydrogen bonds involving ring I (to A1408) and 
ring II (to the phosphate oxygen atoms of the bulged adenine bases 1492 and 1493 
and to G1494) are conserved and additional contacts are observed from ring III 
(phosphate oxygen atoms of G1405 and U1406) [Vicens and Westhof, 2003].  
Finally, it is important to point out which are the advantages and disadvantages 
of aminoglicosydes. Advantages consists in: rapid bacterial action, relatively low 
cost, chemical stability, no allergic reaction and synergistic action with other 
antibiotic. On the contrary, disadvantages consist in: inactivity against anaerobes, 
narrow therapeutic index, toxicities (nephrotoxicity, ototoxicity) and lack of oral 
absorption [Jana and Deb, 2006]. 
Given the significant disadvantages of the aminoglycosides, several research 
groups started projects aimed at developing molecules able to promote read-
through and tested the molecules on in vitro and in vivo model systems. For 
instance, in a recent paper by Welch et al. [2007], two high-throughput screens 
(comprising 800,000 low molecular weight compounds) were performed to 
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identify compounds that promoted UGA nonsense suppression. Chemical 
scaffolds were identified and optimized through extensive medicinal chemistry 
efforts. These analyses identified PTC124 (3-[5-(2-fluorophenyl)-
[1,2,4]oxadiazol-3-yl]-benzoic acid; C15H9FN2O3) as a candidate for further 
development.  
PTC124 showed to promote the suppression of premature termination codons 
in primary muscle cell cultures from DMD patients, in mdx mice and in a CF 
mouse model that expressed a human CFTR-G542X transgene in a Cftr-/- 
background, leading to a significant restoration of dystrophin and CFTR 
expression and function [Welch et al, 2007; Du et al, 2007].  
Moreover, PTC124 showed to be able to promote read-through of premature 
termination without affecting normal termination, even at drug exposure levels 
substantially greater than the values achieving maximal activity [Welch et al, 
2007].  
This selectivity of PTC124, its well characterized activity profile, oral 
bioavailability and pharmacological properties indicate that this drug may have 
broad clinical potential for the treatment of a large group of genetic disorders with 
limited or no therapeutic options. 
 
Mithramycin 
 
Mithramycin is an aureolic acid-type polyketide described for the first time in 
1950s and produced by several actinomycetes, like Streptomyces argillaceus, 
Streptomyces plicatus, Streptomyces tanashiensis and Streptomyces atroolivaceus.  
Initially, the members of the aurelic acid family were isolated due to their 
antibiotic activity against Gram-positive bacteria. However, they are not active 
against Gram-negative bacteria due to permeability problems. Their main 
pharmacological interest resides in their antitumor activity. The members of this 
family interact with the DNA helix minor groove in regions with high GC content 
and in a nonintercalative way. This binding is carried out by complexes of dimers 
together with a Mg2+ ion. During these interactions, several H-bonds are created 
among the aglycon hydroxyl groups and the guanine amino protons.  
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The interaction with the double helix causes a DNA-dependent inhibition on 
RNA synthesis, which gives this family of compounds a strong antitumor activity 
against a variety of cancer cell lines. Based on this antitumor activity, mithramycin 
has found clinical application in the treatment of Paget’s disease and testicular 
carcinoma. In addition, its hypocalcemic effects has been used to manage 
hypercalcemia in patients with malignancy-associated bone lesions [Remsing et al, 
2003; Lombó et al, 2006].  
The specificity for GC-rich regions along the DNA makes these compounds 
good inhibitors of specific promoter regions, preventing the binding of regulatory 
proteins. This effect has been described for the c-myc, c-Ha-ras, c-myb and MDR1 
genes. Mithramycin binds at the C-fos-depending Sp1 regulatory regions, and 
therefore, it prevents transcription due to this transcriptional factor, generating a 
global inhibition mechanism [Lombó et al, 2006]. 
In 1999, Bianchi et al reported that mithramycin (MTH) is a potent inducer of 
erythroid differentiation in K562 cells. Differentiation was found to be associated 
with increase in the synthesis of γ-globin mRNA and production of mostly Hb 
Portland. In addition, the same group evaluated the effects of MTH on HbF 
production in healthy human and thalassemic-cultured erythroid precursor cells. In 
several independent experiments, using peripheral blood from different healthy 
donors, they reproducibly found an increase in HbF production. This increase was 
found to be consistently higher than that induced by hydroxyurea (HU), a potent 
inducer of HbF both in vitro and in vivo. These data were fully in agreement with 
quantitative RT-PCR analysis, showing a preferential increase of γ-globin mRNA 
accumulation in MTH-treated erythroid precursors in comparison to α-globin and 
β-globin mRNA. In addition, the data demonstrate that MTH is a powerful inducer 
of HbF production in erythroid progenitors from β-thalassemia patients. Unlike 
HU, the effect of MTH was not associated with inhibition of cell growth [Fibach 
et al, 2003]. 
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AIM OF THE THESIS 
 
 
The β-thalassemia is an autosomal recessive disease characterized by a reduced 
or absent synthesis of β-globin chains, caused by the presence of mutations within 
or near the β-globin gene. Among these is the C → T substitution at the first base 
of codon 39 in the second exon of the gene. Such mutation, known as β039, 
belongs to the nonsense mutations, which lead to the formation of stop codons, 
causing the premature termination of translation. The β-thalassemia caused by the 
presence in homozygosity of this mutation shows a very serious phenotype, 
because the synthesis of β-globin chains is totally absent. 
Actually, there are two approaches to directly overcome diseases caused by 
nonsense mutations: gene therapy, meaning introduction of an exogenous gene 
into diseased cells, and translational read-through induced by aminoglycosides, 
which decrease the accuracy of translational elongation and reduce the efficacy of 
the translation termination machinery. 
Our purpose was to study and verify the effects and clinical utility of such 
approaches.  
In this respect, we intended to develop third generation lentiviral vectors 
containing the βwt- or β039-globin gene, the first useable in gene therapy and both 
to produce cellular models, suitable to study and develop new therapeutic 
strategies targeted to the correction of this mutation, in particular aminoglycosides 
activity. Therefore, we aimed to produce such cellular models using K562 human 
erythroid cell line and utilize them to verify the translational correction activity on 
β
039 nonsense mutation of several aminoglycosides. Whether identified active 
compounds, we proposed to use them to correct the mutation in erythroid 
precursors cells isolated from β039-thalassemia patients, whose in vitro growth 
represents more closely than cell lines the in vivo situation. 
Finally, we intended to use the β039 erythroid progenitors to test out the 
possible utilize of the lentiviral vector producing βwt-globin mRNA for gene 
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therapy of β0-thalassemias and the combined effects of gene therapy and fetal 
haemoglobin induction by treatment with mithramycin, a potent HbF inducer. 
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MATERIALS AND METHODS 
 
 
Synthetic oligonucleotides 
 
The oligonucleotides used as primers in the chain polimerization and 
sequencing reactions were synthesized by Sigma-Genosys (Cambridge, UK), 
while those used for the Real Time quantitative PCR were purchased from 
Applied Biosystems (Applera Italia, Monza, Italy). All the oligonucleotides were 
designed using the software Primer ExpressTM, version 2.2 (Perkin-Elmer Applied 
Biosystems) and the sequences are reported on table 1 and 2. 
 
Restriction enzymes 
 
The restriction endonucleases used in the cloning experiments were 
commercial: table 3 shows the sequence recognised, concentration, buffer, 
incubation temperature and company from which the enzymes were bought. 
 
Plasmids and vectors 
 
Plasmids, lentiviral and helper vectors used in the cloning experiments were 
kindly provided by Prof. Stefano Rivella (Weill Medical College of Cornell 
University, New York). All the maps were created using the following softwares: 
BioEdit version 7.0.0 (Tom Hall Copyright © 1997-2004) and Plasmapper version 
2.0. 
Instead, for the restriction analysis we used pDRAW32 1.0 (Revision 1.1.86, by 
Kjeld Olesen, Acaclone software) and RestrictionMapper 
(www.restrictionmapper.org). 
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Aminoglycosides 
 
The aminoglycosides used for the treatment of K562 cell clones and erythroid 
precursors were bought from GIBCO (Invitrogen-Life Technologies, Carlsbad, 
CA, USA) (G418) and Sigma (St Louis, MO, USA) (gentamicin, streptomycin, 
neomycin, tobramycin, paromomycin, kanamycin, amikacin). All of them were 
resuspended in sterile water, sterilized by filtration with acetate cellulose filters 
having pore diameter of 0.22 µm, divided in aliquots and stored at – 20°C. 
 
Cloning 
 
Enzymatic digestion 
 
For each digestion, 15 µg of DNA were incubated with 5 U/µg restriction 
enzyme and 1X buffer, chosen depending on the endonuclease used. The final 
reaction volume was at least ten times higher than the enzyme volume. The 
incubation was performed at the optimum temperature for the restriction enzyme 
(usually 37°C), for about 16 hours or less, depending on the requested result. The 
digestion products were visualised through an electrophoretic analysis on 0.8% 
agarose gel, using one of the following molecular weight markers: 1kb DNA 
Ladder (10,000, 8,000, 6,000, 5,000, 4,000, 3,500, 3,000, 2,500, 2,000, 1,500, 
1,000, 750, 500, 250 bp) (MBI Fermentas, Maryland, USA) or pUC Mix Marker 8 
(1,116, 883, 692, 501, 489, 404, 331, 242, 190, 147, 111, 110, 67 bp) (MBI 
Fermentas). The enzyme was inactivated by incubation at 65°C for 20 minutes. 
 
Electrophoresis on agarose gel 
 
To prepare the agarose gel for the electrophoretic analysis, the required 
amount, depending on the gel percentage, of the agarose powder was dissolved in 
100 ml of 1X TAE buffer (0.04 M Tris-Acetato, 0.001 M EDTA pH 8), boiling 
until the agarose melt completely. The solution were cooled and 0.5 µg/ml 
ethidium bromide was added. The gel was done solidify for about 30 minutes in a 
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clean casting plate with an appropriate comb and then immersed into 1X TAE 
buffer. 1 µl of loading buffer (0.25% Orange G, 50% glycerol in TE) was added to 
each sample before being loaded. On both the sides of the gel a molecular weight 
marker was added. 1 µl of 1kb DNA Ladder (10,000, 8,000, 6,000, 5,000, 4,000, 
3,500, 3,000, 2,500, 2,000, 1,500, 1,000, 750, 500, 250 bp) (MBI Fermentas) or 
pUC Mix Marker 8 (1,116, 883, 692, 501, 489, 404, 331, 242, 190, 147, 111, 110, 
67 bp) (MBI Fermentas) was up to the loading volume with water. The 
electrophoresis was performed at 80 Volt. The DNA was visualised using UV rays 
and then photographed with a Polaroid camera. 
 
Purification of vectors and inserts by QIAquick® Gel Extraction Kit 
 
After the digestion reaction, the DNA fragments, corresponding to vector and 
insert, were extracted from the agarose gel and purified with the Qiaquick Gell 
Extraction Kit (QIAGEN, Milan, Italy).  
This technique is based on the use of a column containing a silica-gel 
membrane with selective binding properties. Special buffers are optimized for 
efficient recovery of DNA and removal of contaminants.  
After electrophoretic separation, the DNA fragment was excised from the 
agarose gel. The gel slice was weighted and 3 volumes of Buffer QG to 1 volume 
of gel was added. An incubation was performed at 50°C for 10 minutes, mixing 
every 2 – 3 minutes to help to dissolve the gel. After the gel slice was dissolved 
completely, 1 gel volume of isopropanol was added to the sample, which was 
applied to the QIAQuick column, which was centrifuged for 1 minute at the 
maximum speed. The eluate was discarded and 0.5 ml of Buffer QG was added to 
the column, to eliminate all the agarose traces. The column was centrifuged once 
again and then washed using 0.75 ml of Buffer PE, incubating at room temperature 
for 5 minute and centrifuging at 13,000 rpm for 1 minute. Another centrifugation 
allowed the elimination of all washing solution. To elute DNA, 50 µl of Buffer EB 
(10 mM Tris-HCl pH 8.5) were added to the center of the QIAQuick membrane 
and an incubation was performed at room temperature for a range of time, from 1 
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to 15 minutes, depending on the fragments size. The column was finally 
centrifuged at the maximum speed for 1 minute and the DNA was collected. 
 
Spectrophotometric quantification 
 
The spectrophotometric quantification was performed by using a single ray UV 
spectrophotometer SmartSpecTM Plus (BIORAD, Hercules, California, USA). 
Each quantification required from 0.5 to 1 µl of genomic DNA, in order to 
determine an optical density at 260 nm (OD260 nm) of 0.1 to 1.0: after deducting the 
value of optical density of the blank, the concentration of the extracted DNA was 
calculated considering that 1 OD260 nm corresponds to the concentration of 50 
ng/µl. For each sample was also measured the optical density at 280 nm to 
determine the possible contamination of protein molecules, taking into account 
that the ratio OD260nm/OD280nm of the pure DNA is between 1.8 and 2.0. 
 
Ligation 
 
The ligation reaction was carried out among the fragments of DNA 
corresponding to the vector and insert, previously purified and quantified. We 
used from 50 ng to 130 ng of vector and a quantity of insert so as to have a 
molecular ratio vector:insert, usually equal to 1:4 – 1:8.  
The reaction was set up in a final volume of 10 µl: first, vector, insert and 
ultrapure water were incubated at 65°C for 5 minutes to stretch DNA molecules 
which have to be ligated; then, it was added a solution containing 1 µl of 10X 
Ligation Buffer (400 nM Tris-HCl pH 7.8, 100 mM MgCl2, 100 mM DTT, 5 mM 
ATP) and 5 U of T4 DNA Ligase (MBI Fermentas). The reaction was finally 
incubated at 22°C for 1 hour and at 16°C for 1 night. 
The enzyme was inactivated through incubation at 65°C for 10 minutes and the 
reaction was stored at -80°C.  
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Preparation of ultra-competent bacteria 
 
The bacteria of the E. coli strains JM109, XL1-Blue and TOP10 were made 
ultra-competent through the rubidium chloride method: the bacteria were 
inoculated into 2 ml of LB Medium (Luria Bertani Medium: 10 g/l bacto-tryptone, 
5 g/l yeast extract, 10 g/l NaCl) and kept at 37°C with vigorous shaking for 1 
night. The day after, they were diluted 100 times with Psi broth (5g/l yeast extract, 
20 g bacto-tryptone, 5 g/l MgSO4 pH 7.6), allowed to proliferate to an optical 
density, measured at 550 nm, corresponding to 0.48 OD550nm and incubated on ice 
for 15 minutes. The bacteria were collected by centrifugation at 5,000 rpm for 5 
minutes at 4°C, resuspended with 80 ml (0.4 volumes compared to the initial 
culture) of TfbI (30 mM CH3COOK, 100 mM RbCl, 10 mM CaCl2, 50 mM 
MnCl2, 15% v/v glycerol, pH 5.8) and incubated on ice for 15 minutes. They were 
then re-collected, resuspended in 8 ml (0.04 volumes compared to the initial 
culture) of TfbII (10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15% v/v glycerol, 
pH 6.5), divided in aliquots of 500 µl, incubated on ice for 15 minutes, frozen 
immediately in liquid nitrogen and stored at -80°C. 
 
Trasformation 
 
The ultra-competent bacteria were thawed slowly on ice, then an aliquot of 120 
µl was placed in a tube of polypropylene, pre-cooled on ice, and 50% of the 
plasmid obtained by the ligation reaction was added, stirring gently. After an 
incubation on ice for 4 hours, the reaction was subjected to thermal shock to allow 
the penetration of the plasmids inside the cells: first, it was incubated at 42°C for 
45 seconds and immediately on ice for 2 minutes. Then, after adding 1 ml of LB 
Medium, pre-equilibrated at room temperature, there was a 1 hour incubation at 
37°C with slow shaking, in order to develop the antibiotic resistance. The bacteria 
were, finally, plated on Petri dishes containing semi-solid medium (LB Medium 
added to 15 g/l bacto-agar), in the presence of antibiotic (100 µg/ml ampicillin), 
and incubated at 37°C for 1 night. The recombinant bacteria give rise to white 
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colonies, while those that have not incorporated the plasmid can not survive 
because they lack the resistance to the ampicillin. 
 
Rapid method for analysing the size of the plasmid (Rapid Disruption) 
 
The technique allows the qualitative analysis of the size of a recombinant 
plasmid, starting from the bacterial clone, through electrophoretic analysis.  
In the presence of single bacterial colonies of about 1 mm in diameter, using a 
sterile stick a small portion of each colony was transferred to a new Petri dish 
added with the antibiotic (Master Plate): the dish was kept in incubator at 37°C for 
1 night and then stored at 4°C. About 1 quarter of each colony to be analysed was 
taken from the Master Plate and transferred into vials containing 12.5 µl of a 10 
mm EDTA pH 8 solution; after adding 12.5 µl of lysis solution (0.2 N NaOH, 
0.5% SDS, 20% sucrose), an incubation was carried out at 70°C for 5 minutes. To 
the lysate were added 0.375 µl of KCl and 0.75 of bromophenol blue 0.4%, it was 
then incubated on ice for 5 minutes and centrifuged at 12,000 rpm for 3 minutes at 
4°C to remove bacteria debris. To analyse the size of the plasmid contained in the 
supernatant, an aliquot of this was subjected to electrophoretic migration in 0.8% 
agarose gel. The bacterial colony containing the correct plasmid was finally 
recovered from the Master Plate. 
 
Heat lysis of bacteric clones 
 
In order to rapidly obtain a plasmid template to be amplified by PCR, the 
bacteric clone was washed twice, then resuspended in 20 µl of ultrapure water, 
lysed at 96°C for 6 minutes and immediately chilled on ice. After centrifugation at 
maximum speed for 20 minutes at 4°C, the incorporated plasmid was collected in 
the supernatant.  
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Polymerization chain reaction (PCR) 
 
The polymerization chain reaction amplifies a specific sequence of DNA, 
allowing to use the sample for several types of analysis, including sequencing. 
In the case of the amplification of a plasmid DNA incorporated into a bacterial 
clone, the template can be made up of 2 µl of the supernatant obtained by the heat 
lysis of the colony of interest. 
Each reaction was carried out in a final volume of 100 µl, in the presence of 1X 
buffer (10 mM Tris-HCl pH 8.8, 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-
100), 33 µM dNTPs, 0.25 µM forward and reverse primers and ultra-pure water.  
Every reaction was subjected to a denaturation of 5 minutes at the temperature 
of 96°C, then 2 U of DyNAzymeTM II DNA Polymerase (Finnzymes, Espoo, 
Finland) was added; 30 – 40 cycle of amplification were performed, each of which 
was characterized by: 30 seconds at 95°C to denature the DNA molecules; 20 
seconds at a temperature of 1 or 2 degree below the melting temperature (Tm) of 
primers, to facilitate the annealing to the filaments of DNA; a final phase of 
elongation of the DNA chains at 72°C for a time variable depending on the size of 
the amplificate, considering that polymerase can include about 1,000 bp/minute. 
The reactions were finally maintained at a temperature of 72°C for additional 10 
minutes to complete the process of elongation.  
The obtained PCR products were analysed by electrophoresis on agarose gel at 
a different percentage depending on the length of the amplificate. Those to be 
allocated to sequencing were also purified from the primers and free nucleotides 
using filtrating membrane Microcon® (Millipore Corporation, Billerica, MA, 
USA). 
 
Plasmid purification 
 
Once identified, the bacterial clone containing the plasmid of interest was 
subjected to purification by two different techniques: FlexiPrep Kit (Pharmacia 
Biotech, GE Healthcare Europe, Milan, Italy), which uses the resin SephaglasTM 
FP for the isolation of the plasmid DNA and the removal of contaminants through 
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different steps of centrifugation, used to purify small quantity of plasmid, and 
three different QIAGEN kits, which differ in the amount of plasmid that can 
purify: QIAGEN Plasmid Purification Mini Kit, QIAGEN Plasmid Purification 
Midi Kit, QIAGEN EndoFree® Plasmid Purification Maxi Kit. Each of these kits 
requires the use of a column containing an ion exchange resin. 
 
MINIprep con FlexiPrep Kit 
 
A recombinant bacterial colony was inoculated into 6 ml of LB Medium 
containing the appropriated antibiotic and incubated for approximately 16 hour 
with vigorous shaking. The plasmid purification was performed with 5 ml of 
bacterial cells. The bacteria were first collected by centrifugation at 14,000 rpm 
for 30 seconds, washed with 1 ml of STE (10 mM Tris-HCl pH 8, 100 mM NaCl, 
1 mM EDTA) and finally resuspended with 400 µl of Solution I (100 mM Tris-
HCl pH 7.5, 10 mM EDTA, 400 µg/ml RNase I). There were then added 400 µl of 
Solution II (1 M NaOH, 5.3% w/v SDS), which, after mixing by inverting the tube 
6 times, allowed the lysis of bacteria; the solution was finally neutralized by the 
addition of 400 µl of Solution III (3 M potassium, 5 M acetate) and the subsequent 
mixing by inverting consecutively for 6 times. A centrifugation at 12,000 rpm 
permitted the separation of chromosomal DNA, proteins and cellular debris from 
the plasmid DNA, contained in the supernatant: to this last were, then, added 0.7 
volumes of isopropanol and an incubation at room temperature for 10 minute was 
performed to allow the precipitation of plasmid. After a centrifugation at 12,000 
rpm for 10 minutes at 4°C, the plasmid collected was treated with 300 µl of 
Sephaglass microresin (Sephaglas FP in 7 M guanidine-HCl, 50 mM Tris-HCl pH 
7.5, 10 mM CDTA solution), mixed for 1 minute to dissolve the pellet, centrifuged 
at 14,000 rpm for 15 seconds, washed first with 400 µl of Wash Buffer (20 mM 
Tris-HCl pH 7.5, 2 mM CDTA, 200 mM NaCl, 60% v/v ethanol), then with 600 µl 
of 70% ethanol and, finally, allowed to air dry for 10 minutes. The elution of the 
plasmid DNA from the resin was performed in TE pH8 (Tris-EDTA: 10 mM Tris-
HCl pH 8, 1 mM EDTA pH 8), incubating at room temperature for 5 minutes and, 
then, centrifuging at 12,000 rpm for 1 minute to obtain a clear supernatant.  
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Finally, the plasmid was analysed through electrophoresis in 0.8% agarose gel, 
quantified and stored at -80°C. 
 
MINIprep with QIAGEN Plasmid Purification Mini Kit 
 
A recombinant bacterial colony was inoculated into 20 ml of LB Medium 
containing the appropriated antibiotic and incubated for approximately 16 hour 
with vigorous shaking. 
The plasmid purification was performed using the QIAGEN Plasmid 
Purification Mini Kit and all the bacterial suspension. The bacteria were first 
collected by centrifugation at 3,500 rpm for 30 minutes at 4°C, washed with 1 ml 
of STE and re-centrifuged at 8,000 rpm for 15 minutes at 4°C; the bacterial 
precipitate was, then, resuspended in 300 µl of Buffer P1 (50 mM Tris-HCl pH 8, 
10 mM EDTA, 100 µg/ml RNase A). There were subsequently added 300 µl of the 
lysis Buffer P2 (200 mM NaOH, 1% w/v SDS) and, after mixing by inverting the 
tube 4 times, an incubation at room temperature for 5 minutes was performed; 
finally, 300 µl of Buffer P3 (3 M potassium acetate pH 5.5) pre-chilled at 4°C 
were added to neutralize the lysis: the solution was mixed 4 times by inverting the 
tube and incubated on ice for 15 minutes. The plasmid DNA was separated from 
chromosomal DNA, proteins and cellular debris through centrifugation at 12,000 
rpm for 30 minutes at 4°C: the supernatant containing the plasmid DNA was re-
centrifuged at 12,000 rpm for 15 minutes at 4°C, then the plasmid was purified 
using a chromatographic column QIAGEN Tip-20, on ion exchange resin. Three 
different buffers were loaded on the column: 1 ml of Buffer QBT (750 mM NaCl, 
50 mM MOPS pH 7.0, 15% v/v isopropanol, 0.15% v/v Triton X-100) to 
equilibrate, 4 ml of Buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 15% v/v 
isopropanol) for the 2 subsequent washing and 800 µl of Buffer QF (1.25 M NaCl, 
50 mM Tris-HCl pH 8.5, 15% v/v isopropanol) to elute. The plasmid DNA was 
precipitated from the elution buffer adding 0.7 volumes of room-temperature 
isopropanol, mixing vigorously and centrifuging at 12,000 rpm for 30 minutes at 
4°C; after removing the supernatant, the precipitate was washed with 1 ml of 
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room-temperature 70% ethanol, centrifuged at 12,000 rpm for 10 minutes at 4°C, 
resuspended with 40 µl of TE pH 8 and incubated at 65°C for 5 minutes. 
Finally, the plasmid was analysed through electrophoresis in 0.8% agarose gel, 
quantified and stored at -80°C. 
 
MIDIPrep with QIAGEN Plasmid Purification Midi Kit 
 
A recombinant bacterial colony was inoculated into 200 ml of LB Medium 
containing the appropriated antibiotic and incubated for approximately 16 hour 
with vigorous shaking. 
The plasmid purification was performed using the QIAGEN Plasmid 
Purification Midi Kit and 100 ml of the bacterial suspension. The bacteria were 
first collected by centrifugation at 10,000 rpm for 10 minutes at 4°C, washed with 
32 ml of STE and re-centrifuged at 10,000 rpm for 15 minutes at 4°C; the bacterial 
precipitate was, then, resuspended in 4 ml of Buffer P1 (50 mM Tris-HCl pH 8, 10 
mM EDTA, 100 µg/ml RNase A). There were subsequently added 4 ml of the 
lysis Buffer P2 (200 mM NaOH, 1% w/v SDS) and, after mixing by inverting the 
tube 4 times, an incubation at room temperature for 5 minutes was performed; 
finally, 4 ml of Buffer P3 (3 M potassium acetate pH 5.5) pre-chilled at 4°C were 
added to neutralize the lysis: the solution was mixed 4 times by inverting the tube 
and incubated on ice for 15 minutes. The plasmid DNA was separated from 
chromosomal DNA, proteins and cellular debris through centrifugation at 12,000 
rpm for 30 minutes at 4°C: the supernatant containing the plasmid DNA was re-
centrifuged at 12,000 rpm for 15 minutes at 4°C, then the plasmid was purified 
using a chromatographic column QIAGEN Tip-100, on ion exchange resin. Three 
different buffers were loaded on the column: 4 ml of Buffer QBT (750 mM NaCl, 
50 mM MOPS pH 7.0, 15% v/v isopropanol, 0.15% v/v Triton X-100) to 
equilibrate the column, 20 ml of Buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 
15% v/v isopropanol) for the 2 subsequent washing and 5 ml of Buffer QF (1.25 M 
NaCl, 50 mM Tris-HCl pH 8.5, 15% v/v isopropanol) to elute. The plasmid DNA 
was precipitated from the elution buffer adding 0.7 volumes of room temperature 
isopropanol, mixing vigorously and centrifuging at 12,000 rpm for 30 minutes at 
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4°C; after removing the supernatant, the precipitate was washed with 3 ml of 
room-temperature 70% ethanol, centrifuged at 12,000 rpm for 10 minutes at 4°C, 
resuspended with 200 µl of TE pH 8 and incubated at 65°C for 5 minutes. 
Finally, the plasmid was analysed through electrophoresis in 0.8% agarose gel, 
quantified and stored at -80°C. 
 
MAXIPrep with QIAGEN EndoFree® Plasmid Purification Maxi Kit 
 
A recombinant bacterial colony was inoculated into 250 ml of LB Medium 
containing the appropriated antibiotic and incubated for approximately 16 hour 
with vigorous shaking. 
The plasmid purification was performed using the QIAGEN EndoFree® 
Plasmid Purification Midi Kit and all the bacterial suspension. The bacteria were 
first collected by centrifugation at 10,000 rpm for 10 minutes at 4°C, washed with 
32 ml of STE and re-centrifuged at 10,000 rpm for 15 minutes at 4°C; the bacterial 
precipitate was, then, resuspended in 10 ml of Buffer P1 (50 mM Tris-HCl pH 8, 
10 mM EDTA, 100 µg/ml RNase A). There were subsequently added 10 ml of the 
lysis Buffer P2 (200 mM NaOH, 1% w/v SDS) and, after mixing by inverting the 
tube 4 times, an incubation at room temperature for 5 minutes was performed; 
finally, 10 ml of Buffer P3 (3 M potassium acetate pH 5.5) pre-chilled at 4°C were 
added to neutralize the lysis: the solution was mixed 4 times by inverting the tube 
and incubated on ice for 15 minutes. The plasmid DNA was separated from 
chromosomal DNA, proteins, cellular debris and SDS pouring the lysate into the 
barrel of a QIAfilter MAXI Cartridge, incubating at room temperature for 10 
minutes, inserting the plunger into the QIAfilter MAXI Cartridge and filtering the 
cell lysate. 2.5 ml of Buffer ER were then added to the filtered lysate, mixed by 
inverting approximately 10 times and incubated on ice for 30 minutes. After, a 
chromatographic column QIAGEN Tip-500, on ion exchange resin, was 
equilibrated with 10 ml of Buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 
15% v/v isopropanol, 0.15% v/v Triton X-100) and the filtered lysate was applied 
to the resin, which was washed twice with 30 ml of Buffer QC (1.0 M NaCl, 50 
mM MOPS pH 7.0, 15% v/v isopropanol). The plasmid DNA was then eluted with 
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15 ml of Buffer QN (1.6 M NaCl, 50 mM MOPS pH 7.0, 15% v/v isopropanol) 
and precipitated from the elution buffer adding 0.7 volumes of room-temperature 
isopropanol, mixing vigorously and centrifuging at 12,000 rpm for 30 minutes at 
4°C; after removing the supernatant, the precipitate was washed with 5 ml of 
endotoxin-free room-temperature 70% ethanol, centrifuged at 12,000 rpm for 10 
minutes at 4°C, air-dried for 5 – 10 minutes and resuspended with 200 µl of 
endotoxin-free TE pH 8. 
Finally, the plasmid was analysed through electrophoresis in 0.8% agarose gel, 
quantified and stored at -80°C. 
 
Microcon® YM-100 
 
The polymerization chain reaction products of over 100 bp, to be used for 
sequencing, were purified using Microcon® YM-100 (Millipore Corporation), a 
filtrating membrane with molecular weight limit. On each filter was loaded all the 
PCR reaction and a centrifuge at 2,400 rpm for 15 minutes was performed. The 
filter was, then, washed with 300 µl of ultra-pure water and centrifuged at 2,400 
rpm for 15 minutes. To elute the DNA, 25 µl of ultra-pure water were loaded on 
the membrane, which was then left in constant agitation at 140 rpm for 15 
minutes. The filter was then placed upside down in a new vial and subsequently 
centrifuged at 2,400 rpm for 5 minutes. The eluate was finally stored at -80°C. 
 
DNA sequencing 
 
Each reaction was set up in a final volume of 20 µl,  using 10 – 100 ng of PCR 
products, 3.2 pmoles of primers at the concentration of 50 ng/µl and sterile water 
up to the volume of 12 µl; were then added 8 µl of Terminator Ready Reaction 
Mix of ABI PRISM® Big DyeTM Terminator Cycle Sequencing Ready Reaction Kit, 
v 2.0 (Perkin-Elmer, Applied Biosystems), containing the dideoxyribonucleotides 
labelled with four different fluorochromes, the enzyme AmpliTaq® DNA 
Polymerase and salts (MgCl2, Tris-HCl pH 9.0). Each samples was subjected to 45 
thermal cycles: 10 seconds at 96°C, for the denaturation of the DNA, 5 seconds at 
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a temperature slightly lower than the melting temperature (Tm) of primer, for the 
annealing, 3 minutes at a temperature equal to that of annealing, for the 
elongation.  
The unincorporated dideoxyribonucleotides were eliminate from the obtained 
products through the use of a 96-well plate MultiscreenTM (Millipore Corporation) 
loaded with resin Sephadex G-50 Superfine. The reactions were freeze-dried and 
resuspended in 2.5 µl of loading buffer (83% formamide deionized, 4 mM EDTA 
pH 8, 8.3 mg/ml dextran blue), collected by centrifugation, denatured at 96°C for 
3 minutes and chilled on ice.  
After loading on a sequencing gel (6 M urea, 4% acrylamide PAGE-PLUS™ 
Concentrate, TBE 1X, 0.06% ammonium persulfate, 0.07% TEMED), the samples 
were, finally, subjected to electrophoresis, through ABI PRISMTM377 DNA 
Sequencer (Perkin-Elmer, Applied Biosystems), using TBE 1X (Tris-borate: 89 
mM Tris, 89 mM boric acid, 2 mM Na2EDTA.2H2O) as running buffer.  
For the sequence analysis was used the software Sequencing Analysis 3.3 
(Perkin-Elmer, Applied Biosystems). 
 
Purification with SephadexTM G-50 Superfine 
 
The products of PCR reactions to be used for sequencing were subjected to 
purification using a 96-well plate MultiscreenTM (Millipore Corporation) 
containing the resin SephadexTM G-50 Superfine (Amersham Biosciences, GE 
Healthcare). After hydration, two hours long, of the resin contained into the wells 
to be used, the plate was centrifuged at 2,705 rpm for 6 minutes at room 
temperature, to remove the water used for the hydration. The sequence reactions 
were then loaded at the centre of the resin of the hydrated wells and the plate was 
again centrifuged at 2,705 rpm for 6 minutes at room temperature. 
 
Cell cultures  
 
The human leukemia K562 cells [Lozzio and Lozzio, 1975] were cultured in 
Roswell Park Memorial Institute 1640 medium (RPMI-1640, SIGMA) 
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supplemented with 10% fetal bovine serum (FBS, Biowest, Nuaillé, France), 2 
mM L-Glutamine (CAMBREX – Biowhittaker Europe, Milan, Italy), 100 
units/mL penicillin and 100 mg/mL streptomycin (Pen-Strep, CAMBREX – 
Biowhittaker).  
The 293T cell line, human embryonic cells of kidney transformed with the T 
antigen of the SV40 virus, and HeLa cell line, tumor cells of the human cervix, 
were respectively cultured in Dulbecco’s Modified Eagle Medium (D-MEM, 
CAMBREX) and Minimum Essential Medium Eagle (E-MEM, CAMBREX) 
supplemented with 10% fetal bovine serum (FBS) (Biowest), 2 mM L-Glutamine 
(CAMBREX – Biowhittaker), 100 units/mL penicillin and 100 mg/mL 
streptomycin (CAMBREX – Biowhittaker). These two cell lines, which grow in 
adhesion, need before splitting to be washed with DPBS (Dulbecco’s Phosphate 
Buffered Saline, CAMBREX) and detached from the support through treatment 
with trypsin (trypsin 0.05%, EDTA 0.02%) (EuroClone, Siziano, Italy). During the 
experiment of transfection or transduction was used Iscove’s Modified Dulbecco’s 
Medium (I-MDM, CAMBREX) supplemented with 10% fetal bovine serum (FBS, 
Biowest), 2 mM L-Glutamine (CAMBREX – Biowhittaker), 100 units/mL 
penicillin and 100 mg/mL streptomycin (CAMBREX – Biowhittaker). 
All the cells were cultured at 37°C in humidified atmosphere of 5% CO2/air. 
 
Virus Production 
 
Viral stocks were generated by transfection of pCCL.βwt.PGW or 
pCCL.β039.PGW and the helper vectors pMD2.VSVG (coding the envelope protein 
VSV-G), pMDLpg.RRE  (coding the proteins GAG and POL) and pRSV.REV 
(coding the protein REV) into 293T cells [Dull et al, 1998]. The 293T cells (5 x 
106) were plated in 10-cm diameter cell culture dishes 24 hours before transfection 
in Dulbecco’s Modified Eagle Medium (D-MEM, CAMBREX – Biowhittaker) 
with 10% Fetal Bovine Serum (FBS, Biowest), 2 mM L-Glutamine (CAMBREX – 
Biowhittaker), 100 U/mL penicillin and 100 µg/ml streptomycin (Pen-Strep, 
CAMBREX – Biowhittaker) in humified atmosphere of 5% CO2/air.  The culture 
medium was changed with Iscove’s Modified Dulbecco’s Medium (I-MDM) 
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(CAMBREX – Biowhittaker) 2 hours before transfection. A total of 25.5 µg DNA 
was used for transfection of one dish: 3 µg of the envelope plasmid pMD2.VSVG, 
5 µg and 2.5 µg of the two packaging plasmid, pMDLpg.RRE and pRSV.REV 
respectively, 15 µg of the lentiviral vector. A 0.1 times TE (10 mM Tris, pH 8.0, 
plus 1 mM EDTA) and H2O solution (2 times to 1 respectively) was added to the 
plasmid up to a final volume of 450 µl. The precipitate was, subsequently, formed 
by adding 50 µl of 2.5 mM CaCl2 solution, mixing well and adding dropwise 500 
µl of 2 times HEPES-buffered saline (281 mM NaCl, 100 mM HEPES, 1.5 mM 
Na2HPO2, pH 7.12) while vortexing, so as to allow the formation of small-size 
precipitates of calcium phosphate. The solution was immediately added dropwise 
to the cells. The medium was replaced after 16 hours, so as to remove the residual 
CaPO4 salts. The viral supernatant was collected after another 24 hours, replaced, 
and again collected after 24 hours. Each time, the supernatant was filtered through 
0.2-µm pore size cellulose acetate filters, divided in aliquots and stored at -80°C. 
 
Virus titration 
 
The viral titre of the lentiviral particles produced was determined by infection 
of HeLa cells. The HeLa cells (5 x 104) were plated in three wells of a 6-well plate 
(9.5 cm2 each well) 24 hours before transduction in 1 ml of E-MEM supplemented 
with 10% Fetal Bovine Serum (FBS, Biowest), 2 mM L-Glutamine (CAMBREX – 
Biowhittaker), 100 U/mL penicillin and 100 µg/ml streptomycin (Pen-Strep, 
CAMBREX – Biowhittaker) in humified atmosphere of 5% CO2/air. The aliquot 
of the viral solution was thawed at room temperature, while in the wells were 
removed the following volumes of medium: 500 µl from the first well and 100 µl 
from the second and the third. 500 µl of viral solution were then taken and added 
to the first well. After mixing well, 100 µl of medium were transferred from the 
first to the second well, so as to obtain a 1:10 dilution of the viral solution 
(corresponding to 50 µl). The same operation was carried out from the second to 
the third well, so as to achieve a further 1:10 dilution. To facilitate the 
transduction, 10 µl of 100X polybrene (800 µg/µl, Chemicon International, 
Millipore Corporation) were added to each well. The cells were then cultured at 
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37°C  in humidified atmosphere of 5% CO2/air for 16 hours, after which the 
medium was changed to eliminate the residual viral particles.  
To determined the viral titre, the cells were subjected to FACScan analysis, to 
detect the percentage of GFP (Green Fluorescent Protein) – positive cells, and to 
quantitative real time PCR, to detect the copy-number of viral genome inserted 
into the cellular genome [Sastry et al, 2002]. 
 
Preparation of cells for FACS analysis 
 
Hela cells were washed with DPBS (Dulbecco's Phosphate Buffered Saline), 
detached using 1 ml of trypsin, which was blocked adding 2 ml of FBS (Fetal 
Bovine Serum, Biowest), and centrifuged at 1,200 rpm for 5 minutes at 4°C. Half 
of the collected cells was transferred to a tube for cytometry, adding 2 ml of DPBS 
to run a wash. After centrifugation at 1,500 rpm for 5 minutes at 4°C, the 
supernatant was removed and the cellular pellet was resuspended with 500 µl of 
DPBS. Samples were kept on ice until the analysis of the fluorescence that was 
made with FACScan (flow-activated cell sorting, Becton-Dickinson, San Jose, 
CA) using the Cell Quest Pro software (Becton Dickinson). 
 
FACS analysis 
 
The FACS analysis of the Hela cells led to the setting of some parameters of 
the instrument. Channels to be used for data collection and their parameters were 
then set up: FSC (Forward Light Scatter) and SSC (Sideward Light Scatter), 
which collect data from the physical and morphological characteristics of the cells 
through phenomena of diffraction, reflection and refraction of light, and FL1 (FL-
1 Height), which receives data on green fluorescence emitted by the GFP 
expressed by the lentiviral genome. It was then set the maximum number of cells 
to be counted by the instrument, 20,000 cells. Finally, using the untransduced 
HeLa cells, lacking fluorescence, we set the parameters of diagrams obtained from 
the analysis, cytogram and histogram. First, we made a Gate, namely we selected 
within the heterogeneous population a homogeneous subpopulation, requiring to 
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the instrument the analysis only of that subpopulation. In the second, instead, we 
imposed that the peak formed by cells were placed entirely on the left of the value 
of fluorescence of 101, used as a threshold value. 
 
Genomic DNA extraction 
 
The cells were centrifuged at 2,000 rpm for 5 minutes at 4°C, then the pellet 
was washed with DPBS and, after a second centrifugation, resuspended in 400 µl 
of solution A (10 mM Tris-HCl pH 8.00, 400 mM NaCl, 2 mM EDTA). There 
were then added 20 µl of 10% SDS (sodium dodecyl phosphate) and 20 µl of 
proteinase K solution (10 mg / ml proteinase K, 2 mM CaCl2, 50 mM Tris, H2O, 
glycerol). After 2 hours of incubation at 56°C, 1 volume of phenol-chloroform-
isoamyl alcohol (25:24:1), calculated in relation to the initial volume, was added 
and the tube was inverted consecutively for 5 minutes and centrifuged at 12,000 
rpm. Once collected the aqueous phase, extraction with phenol was repeated for 
better purifying the DNA. To the aqueous phase, obtained by the second 
extraction, was then added an equal volume of chloroform-isoamyl alcohol (24:1), 
the tube was again inverted consecutively for 5 minutes, and finally centrifuged at 
12,000 rpm for 5 minutes. Once collected the aqueous phase, its volume was 
measured and 2.5 volumes of cold 96% ethanol were added. After centrifugation 
at 12,000 rpm for 5 minutes at 4°C, the pellet was resuspended in 50 µl of TE 1X 
(pH 8.00, filtered). To facilitate the re-suspension of genomic DNA, all samples 
were kept at 56°C for about 2 hours and then stored at 4°C. 
 
Quantitative real time PCR assay 
 
Quantitative PCR reactions were performed using 100 ng or 200 ng of genomic 
DNA and a specific probe for the β-globin gene. As reference genes, there were 
used Aγ-globin gene in the case of HeLa cells and K562 clones, and UBC gene or 
C21orf104 sequence in the case of erythroid precursor cells. The reaction mix, 
having a final reaction volume of 25 µl, contained: the pair of primers forward 
PFβ and reverse PRβ for β-globin gene, the probe Pβ, labelled in 5' with the 
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chromogenic molecule reporter FAM (6-carboxy -fluorescein) and in 3' with the 
quencher group TAMRA (6-carboxy-N, N, N', N'-tetramethyl-Rhodamine) (table 
2) and the TaqMan Universal PCR Master Mix 1X (APPLERA Italy, Applied 
Biosystems). That mix contains the triphosphate deoxyribonucleotides (dNTPs), 
where dUTP replaces dTTP; 1 mM MgCl2; the chromophore "Rox", which serves 
as a reference for the normalization of data by the instrument in order to cancel 
any volume errors made during the operation by the operator; the enzyme 
AmpliTaq Gold DNA polymerase; the enzyme AmpErase uracil-N glicosilase, 
which degrades sequences containing uracile in place of thymine, leaving intact 
the original filament of template. This enzyme acts in the first phase of the 
reaction (when the temperature is 50°C) removing all the contaminant molecule, 
which may be present in the plate or tips; at a temperature of 95°C it is irreversibly 
inactivated.  
On the same samples of HeLa and K562 cell clones, we carried out 
amplification reactions of the Aγ-globin gene, used as reference gene, with the 
specific forward PFγ and reverse PRγ primers and probe Pγ labelled in 5' with the 
chromogenic molecule reporter FAM (6-carboxy -fluorescein) and in 3' with the 
quencher group TAMRA (6-carboxy-N, N, N', N'-tetramethyl-Rhodamine) (table 
2). The γ-globin gene represents a good reference because of its location in the 
same chromosome, within the same gene cluster, of the β-globin gene. In the case 
of erythroid precursor cells, on the same samples analyzed with the β-globin 
probe, we carried out amplification reactions of the UBC and C21orf104 
sequences, used as reference genes, using the UBC and C21orf104 kits for allelic 
quantification (Applied Biosystems), so as to be able to choose the best reference 
gene for each experiment based on the slope of the standard curves.  
All reactions were arranged in duplicate on 96-well optical plastic plates 
Microamp Optical (APPLERA Italy, Applied Biosystems, Monza, Italy), and for 
each probe used a negative control was performed, represented by a reaction in the 
absence of genomic DNA; moreover, we carried out reactions for 5 points of the 
standard, DNA of not infected Hela cells, at scalar concentrations, to build two 
curves of calibration, one for the β-globin gene and one for the γ-globin gene. The 
amplification was then performed using the thermal cycler ABI Prism™ 7700 
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(APPLERA Italy, Applied Biosystems), using the program Sequence Detector v 
1.7 (APPLERA Italy, Applied Biosystems). Two first cycles (50°C for 2 minutes 
and 95 ° C for 10 minutes) were necessary to activate the 5' – 3' exonuclease 
function of the polymerase; the next 40 cycles consist of a phase of denaturation at 
95°C for 15 seconds and a phase at 60°C for 1 minute, in which take place both 
the annealing of primers and probe and the extension of the filament of DNA. 
 
The change in the fluorescence emitted by the quencher group during the 
amplification is minimal compared to that of the reporter group, which is why it is 
used as internal reference, in order to obtain automatic normalization of the 
reporter group. The system is based on the following mathematical relationship:  
∆Rn = (Rn+) - (Rn-)  
where (Rn+) is the ratio between the emission of quencher and that of reporter, 
calculated at each cycle of amplification, and (Rn-) represents the ratio between 
the two emissions before the start of the PCR reaction.  
Considering the different values of fluorescence ∆Rn at each cycle, it is 
possible to get a spectrogram, which shows the number of cycles on the x-axis and 
the calculated ∆Rn (Normalized Reporter) value on the y-axis. From the 
spectrogram it is possible to derive the value of the cycle threshold, called Ct, 
which represents the cycle at which you can record the first appreciable increase in 
the intensity of emitted fluorescence, not covered by the background signal. The 
value of threshold is chosen by the operator and corresponds to a specific ∆Rn 
value to which all the samples are compared and on the basis of which it is 
possible to derive their respective values of Ct. To minimize the experimental 
error, it is necessary to consider a reference gene into the system, i.e. the γ-globin 
gene. The fold of β-globin transgenes was expressed as 2-∆∆CT, where ∆∆CT 
represents the subtraction of the ∆CT obtained from untransduced cells from the 
∆CT derived from infected cells. ∆CT is the difference between the amplification 
cycle equivalent to a significant fluorescence level (CT) obtained by the 
amplification of β-globin gene and the corresponding amplification cycle of the 
reference gene. This equation can be applied to have a relative quantification of 
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our templates if the slopes of β-globin and reference genes amplifications are 
comparable. 
 
Production of stable transgenic cell lines 
 
K562 transduction 
 
Cells were infected with the thawed viral supernatant at various multiplicities 
of infection (MOIs: 0.5 – 2). The cells (1 x 105) were plated, two hours before the 
infection, in a 9.5-cm2 well with 50% RPMI (Sigma), 50% I-MDM (CAMBREX – 
Biowhittaker) supplemented with 10% FBS (Biowest), 2 mM glutamine 
(CAMBREX – Biowhittaker), 100 U/ml of penicillin and 100 µg/mL of 
streptomycin (Pen-Strep, CAMBREX – Biowhittaker). In order to facilitate the 
cell infection, 10 µl of the 800 µg/µl transduction agent polybrene (Chemicon 
International, Millipore Corporation) was added to the K562 cells plated, which 
were subsequently cultured in a 5% CO2 incubator. The medium was change after 
about 16 hours, so as to eliminate the remained viral particles. 
 
Cell cloning 
 
After having determined the cell concentration through an automatic cell 
counter (SEAC h5-m), subsequent dilutions were executed using RPMI (Sigma) 
supplemented with 20% FBS (Biowest), 2 mM glutamine (CAMBREX – 
Biowhittaker), 100 U/ml of penicillin and 100 µg/mL of streptomycin (Pen-Strep, 
CAMBREX – Biowhittaker), so as to obtain a final concentration of 4 cells/ml. 
The cell suspension was aliquoted in a 96-well plate, 100 µl of solution/well, in 
order to obtain individual clones. The plate was then placed at 37°C in humidified 
atmosphere of 5% CO2/air for about 2 hours and then carefully checked at the 
optical microscope, to identify which well had a single cell.  
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Isolation of transgenic clones 
 
After making the cells expand for about a week, from each isolated clone was 
obtained a single colony, whose components are all equal to the mother cell. To 
identify colonies in which all the cells were able to emit green fluorescence, due to 
the GFP, whose gene is located on the lentiviral vector, they were analyzed by a 
fluorescence microscope. Once grown, it was possible to transfer the cells from 
the 96-well plate to a 24-well plate, and so up to a flask. 
 
DNA extraction from blood 
 
The DNA extraction from blood was performed using the QIAGEN Blood & 
Cell Culture DNA Mini Kit (QIAGEN) and 1 ml of whole blood. First, it was 
necessary to determine the leukocyte concentration which should not be more than 
1 x 107 leukocyte per ml. However, no more than 5 x 106 should be used for the 
isolation. 1 volume of ice-cold Buffer C1 (1.28 M sucrose, 40 mM Tris-CL pH 
7.5, 20 mM MgCl2, 4% Triton X-100) and 3 volumes of ice-cold distilled water 
were then added to the blood, so as to lysate the blood red cells and the leukocyte 
membrane. After mixing by inverting the tube several times, until the suspension 
becomes translucent, an incubation on ice for 10 minutes was performed. The 
suspension was then centrifuged at 1.300 g for 15 minute at 4°C and, after 
discarding the supernatant, the pelleted nuclei were re-suspended using 0.25 ml of 
ice-cold Buffer C1 and 0.75 ml of ice-cold distilled. The suspension was again 
centrifuged at 1.300 g for 15 minute at 4°C. This wash step removes all residual 
cell debris and haemoglobin from the nuclear pellet. The wash was repeated when 
the pellet was not white. The pellet was completely re-suspended with 1 ml of 
Buffer G2 (800 mM guanidine HCl, 30 mM Tris-Cl pH 8.0, 30 mM EDTA ph 8.0, 
5% Tween-20, 0.5% Triton X-100) by vortexing for 10 – 30 seconds at maximum 
speed and 25 µl of QIAGEN Protease were added. The suspension was then 
incubated at 50°C for 60 minutes. After equilibrating a chromatographic column 
QIAGEN Genomic-tip 20/G, on ion exchange, with 2 ml of Buffer QBT (750 mM 
NaCl, 50 mM MOPS pH 7.0, 15% v/v isopropanol, 0.15% v/v Triton X-100), the 
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sample was vortexed at maximum speed and applied to the equilibrated QIAGEN 
Genomic-tip, which was then washed three times with 1 ml of Buffer QC (1.0 M 
NaCl, 50 mM MOPS pH 7.0, 15% v/v isopropanol). The DNA was eluted twice 
with 1 ml of Buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15% v/v 
isopropanol) and precipitated by adding 1.4 ml of room-temperature isopropanol, 
mixing and centrifuging at > 5,000 g for 20 minutes at 4°C. After carefully 
removing the supernatant, 1 ml of cold 70% ethanol was added and the sample 
vortexed briefly and centrifuged at > 5,000 g for 10 minutes at 4°C. The 
supernatant was then removed and the pellet was air-dried for 5 – 10 minutes and 
re-suspended with 30 – 50 µl of TE pH 8.0. Finally, the DNA was dissolved at 
55°C for 1 – 2 hours.  
 
Cultures of erythroid precursor cells isolated from the blood of healthy 
subjects and patients with β-thalassemia 
 
The in vitro culture of stem cells from peripheral blood is carried out in two 
phases in liquid medium, which include different steps. The starting point is the 
buffy-coat, the corpuscular part of the blood, resulting from a pocket of blood 
collected from a healthy donor after informed consent. The buffy-coats had a 
volume of 35 ml that were diluted 1:2 with 1x PBS (Phosphate Buffered Saline) at 
room temperature. The 1X PBS was prepared by dilution with distilled H2O from 
10X PBS, which consists of a solution of 2 M NaCl, 27 mM KCl, 0.1 M Na2PO4, 
18 mM KH2PO4, in distilled H2O, sterilized by filtration through 0.2-µm pore size 
cellulose acetate filters, and stored at 4°C. The diluted sample was divided into 40 
ml aliquots and subjected to a centrifugation for density gradient on Lympholyte-H 
(NycogradeTM polysucrose 400 and sodium diatrizoate, Celbio, Milan, Italy): this 
created a gradient of dextran and other substances to facilitate the separation of 
corpuscular parts of the blood. The centrifugation created four separated layers, 
that from top to bottom are: serum, a whitish ring containing lymphocytes, 
fibroblasts, macrophages and erythroid precursors, a cloudy part containing 
Lympholyte with not separated cells and a red fund formed by red blood cells. The 
whitish ring is taken off, subjected to several washes with 1X PBS and transferred 
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to the phase I medium, as follows: α-MEM medium (α-minimal essential medium, 
Sigma-Aldrich), prepared from a powder and diluted with water; a solution of 
PEN-STREP (50 U/litre penicillin and 50 mg/litre streptomycin, Sigma-Aldrich); 
10% FCS (Fetal Calf Serum, Gibco, BRL, Life Technologies); 10% conditioned 
medium (CM), obtained from cell cultures of bladder cancer (cells 5637), rich in 
haematopoietic growth factors except the erythropoietin (EPO) and separated from 
the cells themselves by filtration; 1 µg/ml cyclosporine A (Sigma-Aldrich), 
prepared from cyclosporine diluted in absolute ethanol and 1X PBS in 1:1 ratio. 
The culture was then incubated at 37°C in humidified atmosphere of 5% CO2/air. 
It is important to check every day the cell viability and the absence of 
contamination. 
After 5 – 7 days of culture in phase I medium, the not adherent cells were 
recovered, washed and resuspended with fresh medium of phase II, which 
includes: α-MEM; 30% FCS; 10% deionized bovine serum albumin (BSA, Sigma-
Aldrich) dissolved in α-MEM; 0.01 mM β-mercaptoethanol (β-ME, Sigma-
Aldrich) prepared from a 100 mM solution diluted with sterile H2O; 0.001 mM 
dexamethasone (Sigma-Aldrich), prepared from a 6.4 mM solution diluted in 
sterile methanol (this compound is able to stimulate the erythroid line); 2 mM L-
Glutamine (Sigma-Aldrich); 1 U/ml human erythropoietin (EPO) (Tebu-bio, 
Magenta, MI, Italy); 10 ng/ml Stem Cell Factor (SCF, PeproTech EC Ltd, 
London, England), dissolved in 10 mM acetic acid. Some of these components 
(BSA, β-ME, dexamethasone, L-Glutamine) were sterilized using 0.2-µm pore 
size filters and stored in darkness at -20°C. The EPO and SCF, being protein 
factors, must be stored at -80°C to prevent degradation. The incubation in this 
phase lasted from 4 to 6 days. It is important to check every day the cells viability, 
the absence of contamination, but especially the formation of groups or "clones" of 
cells in the supernatant. Only if there are such cell agglomerations of pro-
erythrocytes, it is possible to continue with treatments. Sometimes there may be 
few and/or small cell agglomerations after the usual 4 – 6 days of phase II, as it 
has a slower growth, in which case it is possible to extend the phase II for another 
4 – 5 days to get a sufficient proliferation of colonies and then continue with 
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treatment. After each stage it is necessary to count the cells using the Coulter 
Counter Z1 (Coulter Electronics Limited, Luton, Beds, England). 
The volume of blood that can be taken from β-thalassemia patients is much 
lower than that can be taken from normal individuals (for ethical reasons and 
depending on the fact that these are individuals with a haematological disease). In 
fact, these individuals already have low levels of haemoglobin because of their 
disease and a sample of blood can only worsen the state of anemia of these people. 
Thus, in general, we use the minimum amount of blood needed to prepare 20 ml of 
culture, this amount may be sufficient for the high frequency of erythroid 
precursors contained, a situation that is backed and driven by the lack of 
haemoglobin. This cell culture can produce a maximum of 108 cells.  
Usually, 20 ml of whole blood were collected and brought up to 35 ml with 1x 
PBS. The diluted sample was subjected to centrifugation for gradient density on 
Lympholyte-H. From this point forward, the method was the same as the culture 
of erythroid precursors derived from the blood of healthy subjects. 
 
Transduction of erythroid precursor cells 
 
After having determined the amount of virus to be used for the transduction of 
erythroid precursor cells with a MOI equal to 0.3, based on the viral titre, all the 
progenitors were put in a 1.5 ml tube with 1 – 1.5 ml of α-MEM (Sigma-Aldrich) 
without FCS but supplemented with EPO and 800 ng/µl polybrene so as to have 
final concentrations equal to 1 U/ml and 10 mg/ml, respectively.  
An aliquot of viral particles were then thawed at room temperature for 30 
minutes, mixing once in a while, and the volume decided for the infection was 
transferred in the tube containing the cells, along with 15 µl of polybrene 100X 
(800 µg/µl). The cells were then incubated at 37°C in humidified atmosphere of 
5% CO2/air for 6 hours, mixing well every 30 minutes. The infected erythroid 
progenitors were then plated at 106 cells/ml. The medium was change after about 
16 hours, so as to eliminate the remained viral particles. After 5 days of incubation 
the cells were collected and analysed. 
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Treatment with mithramycin 
 
Treatments with mithramycin (Sigma-Aldrich) were carried out by adding the 
appropriate drug concentrations to the transduced erythroid precursors, seeded at 
106 cells/ml, and incubating at 37°C in humidified atmosphere of 5% CO2/air for 5 
days.  
 
Inhibition curve 
 
To determine the concentrations of aminoglycosides to use in the treatment of 
clones and erythroid precursors, we performed the curve of toxicity of each 
aminoglycosides so as to derive the IC50, namely the concentration that causes an 
inhibition of cell growth equal to 50%. We plated 6 x 104 wt3 βwt-globin and m5 
β
039-globin K562 clones cells in 9.5-cm2 wells with 2 ml RPMI (Sigma) with 10% 
FBS (Biowest) and treated with increasing concentrations of aminoglycosides. 
After 72 hours, the cells in each well were counted using the Bürker chamber 
(Vetrotecnica, Padova, Italy). The data obtained were then reported in a graph 
with the number of cells on the y-axis and the concentrations of aminoglycosides 
on the x-axis. 
 
Treatment with aminoglycosides 
 
Treatments with aminoglycoside antibiotics were carried out by adding the 
appropriate drug concentrations to the K562 clones cells and to the erythroid 
precursors, seeded at 30,000 cells/ml and at 106 cells/ml respectively, and 
incubating at 37°C in humidified atmosphere of 5% CO2/air for 3 days.  
 
RNA extraction 
 
The total cellular RNA was extracted by TRIZOL® Reagent (Gibco - 
Invitrogen-Life Technologies). All reagents and materials used were RNase – free. 
The cells (5 – 10 x 106) were centrifuged at 1,200 rpm for 5 minutes at 4°C, then 
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the pellet obtained was washed with 1X DPBS, re-centrifuged and then 
resuspended with 1 ml TRIZOL® Reagent (Gibco - Invitrogen-Life Technologies). 
After incubating for 5 minutes at room temperature, 200 µl of chloroform were 
added, stirring well, and incubating on ice for 5 minutes. The samples were then 
centrifuged at 12,000 rpm for 10 minutes at 4°C. To the collected aqueous phase 
an equal volume of isopropanol was added. The samples were then placed at -
80°C for at least 1 hour. The RNA precipitate was centrifuged at 12,000 rpm for 
20 minutes at 4°C, washed with 500 µl of cold 70% ethanol, re-centrifuged, 
freeze-dried and resuspended in 20 µl of water RNase – free.  
The extracted RNA was analyzed by electrophoresis on 0.8% agarose gel, 
before the treatment with DNase I and the reaction of RT-PCR. 
 
Treatment with DNase I 
 
Treatment with DNase I was made starting from the total RNA extracted from 
the cells before reverse transcription, through the use of the RQ1 RNase – free 
DNase kit (Promega).  
The reaction was carried out in a final volume of 10 µl, in the presence of 2 µg 
RNA, 1 µl of RQ1 DNase 10X Reaction Buffer (400 mM Tris-HCl pH 8.0, 100 
mM MgSO4, 10 mM CaCl2) and 2 U of RQ1 RNase – free DNase; the reaction 
was, therefore, incubated at 37 ° C for 30 minutes.  
Finally, after putting the reaction on ice, the enzyme was inactivated by the 
addition of 1 µl of RQ1 DNase Stop Solution (20 mM EGTA pH 8.0) and 
incubated at 65°C for 10 minutes. 
 
Reverse transcription reaction 
 
The reaction of reverse transcription was made with the ImProm-IITM Reverse 
Transcription System kit (Promega). Half of RNA treated with DNase I, equivalent 
to 1 µg, was subjected to reverse transcription, using Oligo(dT)15 or random 
primers, 0.5 µg per reaction. The RNA and primers were incubated at 70°C for 5 
minutes and then immediately cooled to 4°C. We, then, added the reaction 
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solution, prepared considering a final volume of 20 µl and progressively adding 
the following reagents: 5X ImProm-IITM Reaction Buffer, 25 mM MgCl2, 10 mM 
dNTPs mix, 1U/µl of Recombinant RNasin Ribonuclease inhibitor and l µl of 
Improm-IITM Reverse Transcriptase. The reaction of reverse transcription was then 
performed: the sample was incubated for 5 minutes at 25°C, to allow the annealing 
of the reverse transcriptase to the RNA, for 60 minutes at 42°C, to allow the 
extension, and at 70°C for 15 minute to inactivate the enzyme. 
 
Non-quantitative real time PCR for the characterization of the β-globin 
transcript 
 
Through the use of the Custom TaqMan® SNP genotyping Assays kit (Applied 
Biosystems), it is possible to discriminate between two transcripts that differ in 
only one base, such as the βwt and the β039 transcripts.  
The kit consists of a MIX 40X containing two primers, PR and PF, and two 
TaqMan® MGB probes, the Pβ039 labelled with the chromophore FAM (6-
carboxy-fluorescein) and Pβwt labelled with the chromophore VIC (compound 
under secret patent) (table 2).  
The reactions, carried out in duplicate for each sample, were arranged with 50 
ng of cDNA, 0.625 µl of 40X Assay Mix and 12.5 µl of 1X TaqMan® Universal 
PCR Master Mix and brought to a final volume of 25 µl with ultrapure water. The 
reactions were placed in a plastic optical 96-well plate MicroAmp Optical 
(Applera Italia, Applied Biosystems) and were carried out using the ABI Prism 
Thermal cycler™ 7700 (Applera Italia, Applied Biosystems) and the program 
Sequence Detector v 1.7 (Applera Italia, Applied Biosystems). First, two cycles 
(50°C for 2 minutes and 95°C for 10 minutes) were made to activate the 
exonuclease 5' – 3' function of the polymerase; the next 40 cycles consisted of a 
step of denaturing at 95°C for 15 seconds and a step at 60°C for 1 minutes, in 
which both the annealing of primers and probe and the extension of the filament of 
DNA take place.  
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Intracellular labelling technique 
 
This method was carried out with the BD Cytofix/Cytoperm™ Kit (BD 
Biosciences Pharmingen), which allows the cell permeabilization and the antibody 
binding to the proteins inside the cell. Since the labelled K562 clones cells were 
used for the analysis of the fluorescence using both the FACS and the fluorescence 
microscope, 1.5 x 106 cells were centrifuged at 1,800 rpm for 3 minutes at 4°C. 
After removing the supernatant, the pellet was washed with 500 µl of cold 1X PBS 
(Phosphate-Buffered Saline), re-centrifuged and then resuspended in 500 µl of BD 
Cytofyx-Cytoperm solution and incubated for 20 minutes at 4°C. After 
centrifugation at 1,800 rpm for 3 minutes at 4°C, the pellet was washed with 500 
µl of cold 1X PBS (Phosphate-Buffered Saline), incubated for 3 minutes at room 
temperature and then centrifuged at 1,800 rpm for 3 minutes at 4°C. After making 
a further wash, the cells were resuspended with 300 µl of solution 1X PBS – 1% 
BSA (bovine serum albumin, Sigma) and left in incubation 1 hour at room 
temperature in darkness. After that, the sample was centrifuged at 1,800 rpm for 3 
minutes at 4°C and the pellet resuspended with 30 µl of the solution of the 
monoclonal antibody βglobin-PE (PE-Phycoerythrin, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) diluted 1:10 in 1X PBS-1% BSA and incubated overnight 
at 4°C in darkness. After incubation, the sample was centrifuged at 1,800 rpm for 
3 minutes at 4°C, washed with 500 µl of cold 1X PBS re-centrifuged and the pellet 
resuspended with 30 µl of cold 1X PBS.  
 
Immunohistochemistry assay 
 
Part of the labelled cells (1/3) was transferred on a section of a chamber slide 
(CultureSlide, FALCON, Becton Dickinson). Each section of this slide had been 
previously treated with 30 µl of Poly-L-Lysine diluted 1:10, dried and washed 
with ultrapure water. In the section with the cells, 200 µl of 4% formalin were 
added, incubating for 25 minutes at room temperature. The fixed cells were finally 
washed for three times with 100 µl of cold 1X PBS. Each wash was followed by 5 
minutes incubation. After dried, the slide was covered with a micro cover glass, 
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fixed with a few drops of glycerol and displayed by a fluorescence microscope 
(Olympus BX60, Olympus Italia, Segrate (MI), Italy). It was possible to take 
pictures of cells through the camera mounted on microscope (Nikon digital Sight 
DS-2mV, Nikon Instruments, Calenzano (FI), Italy), subjected to certain 
exposures of fluorescent light with the help of special optical filters. 
In the case of treatment of erythroid precursors, analysed only by FACS, we 
labelled 5 x 105 to 7.5 x 105 cells and then all the volumes of the reagents were 
halved. 
 
Flow cytometry (FACS) assay 
 
The 2/3 of the volume of each sample labelled using the Cytofix/CytopermTM 
kit were transferred to a tube for FACS analysis and there were added 500 µl of 
Stainning Buffer (DPBS, 1% FBS). The FACS analysis of these cells was 
performed by FACScan (flow-activated cell sorting, Becton-Dickinson) using the 
Cell Quest Pro software (Becton-Dickinson).  
The analysis of K562 cells by the flow cytometer, as previously done for the 
Hela cells in the calculation of the viral titre, requires setting some basic 
parameters to obtain significant data for the experiment. Channels that were 
chosen for data collection were: FSC (Forward Light Scatter) and SSC (Sideward 
Light Scatter), which collect data from the physical and morphological 
characteristics of cells, FL1 (FL-1 Height), which receives data on green 
fluorescence emitted by GFP, FL2 (FL-2 Height), which receives data on 
fluorescent red - orange emitted by antibody βglobin-PE against β globin. After 
setting the number of cells to count (10,000 – 30,000), using cells that do not 
express green and red fluorescent, we have worked on histograms of green (No. 
cells - GFP) and red (No. cells - βglobin-PE) fluorescent in a way that the peak, 
representing cells, was beyond the fluorescence threshold of 101. A Gate was done 
on the morphological cytogram trying to exclude all the died or dying cells, in 
order to assess the effect of the compounds only on living cells. In addition, to 
analyze cells emitting two different fluorescences at the same time, the green and 
red, it was necessary to perform an electronic compensation on FL1 and FL2 
 129 
channels. This compensation consists in the subtraction from each channel of the 
interference created by the too wide wavelength emitted by the fluorochrome, 
using only cells that express either green fluorescent or red fluorescence. 
In the case of erythroid precursors, it was not necessary to make compensation, 
because they emitted only the red fluorescence of the βglobin-PE antibody. 
Channels that were chosen in this case were: FSC (Forward Light Scatter), SSC 
(Sideward Light Scatter) and FL2 (FL-2 Height).   
 
Quantitative real time PCR of the β-globin transcript 
 
Depending on the type of treated cells, the quantitative PCR reactions were 
prepared using different primers and probes. The Custom TaqMan® SNP 
Genotyping assays (Applied Biosystems) kit was used in the case of K562 clones, 
as the two probes (Pβwt and Pβ039) are able to discriminate between βwt and 
β
039-globin transcripts. On the contrary, in the case of erythroid precursors were 
used pair of forward and reverse primers and probe for β-globin mRNA (PFβ-PRβ 
and Pβ), α-globin mRNA (PFα-PRα and Pα) and γ-globin mRNA (PFγ-PRγ and 
Pγ). All the probes were labelled in 5’ with the chromogenic molecule reporter 
FAM (6-carboxyfluorescein) and in 3’ with the quencher TAMRA (6-carboxy-
N,N,N’,N’-tetramethylrhodamine) (table 2). In the case of the erythroid 
progenitors it was possible to use a generic probe for β-globin mRNA sequence 
because these cells express only the mutated transcript and it was therefore not 
necessary to discriminate between the two transcripts. 
The reaction mix, with a final volume of 25 µl, contained, as well as primers 
and probes, the  1X TaqMan Universal PCR Master Mix (Applera Italia, Applied 
Biosystems). On the same samples, amplification reactions of a reference gene 
were carried out. As reference gene we used either GAPDH or r18S. The specific 
primers and probe, labelled in 5’ with the chromogenic molecule VIC and in 3’ 
with TAMRA, are contained in the GAPDH kit (Applera Italia) and r18S kit 
(Applera Italia), respectively.   
All quantitative PCR reactions were performed in duplicate using 20 – 50 ng of 
cDNA and for each probe used we made a negative control, represented by a 
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reaction in the absence of cDNA; moreover, we carried out reactions for 5 points 
of the standard, cDNA of not treated cells, at scalar concentrations, to build two 
curves of calibration, one for the β-globin gene and one for the reference gene. 
The amplification was carried out using the ABI Prism 7700 Sequence Detector, 
which consists of a thermal cycler, ABI Prism 7700, in which the reagents are 
placed in optical plastic 96-well plate MicroAmp Optical (Applera Italia), a 
computer and a software, the Sequence Detector Application Program version 1.7, 
which manages the instrumentation and analysis of data. Initially, two cycles 
(50°C for 2 minutes and 95°C for 10 minutes) were made to activate the 
exonuclease 5' – 3' function of the polymerase; the next 40 cycles consisted of a 
step of denaturing at 95°C for 15 seconds and a step at 60°C for 1 minutes, in 
which both the annealing of primers and probe and the extension of the filament of 
DNA take place.  
To minimize the experimental error, the quantification of cDNA from different 
samples is more reliable if it is considered a reference gene internal into the 
system. Through this strategy it is possible to have a "relative" quantification, that 
is based on the difference between the levels of expression of a target gene in 
different samples evaluated compared with a reference gene, which must equally 
be expressed in all the analyzed samples. Usually, the genes used as reference are: 
the gene for β-actin, the Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
the β2-microglobulin, or the 18S rRNA.  
The analysis of the Real time PCR was already described for viral titration. 
 
HPLC analysis for the quantification of haemoglobins in cultured 
erythroid precursor cells 
 
The relative (%) and absolute (pg/cell) concentration of HbA (adult 
haemoglobin) compared to total haemoglobins was determined by separating and 
quantifying the haemoglobins using HPLC. The instrument used for the analysis is 
a HPLC Beckman Coulter System Gold 126 Solvent-166 Detector Module 
(Beckman Coulter, Milan, Italy), set at a wavelength of 415 nm to selectively 
detect the haemoglobins present in pellets of cells harvested from cultured 
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erythroid precursors, the eleventh day of phase II, and lysated before 
chromatography. The cells were collected by centrifugation at 1,600 rpm for 5 
minutes at 4°C, washed with PBS and resuspended with a volume of water 
dependent on the quality of the cell pellet (colour and cell number). The cellular 
suspension was then strongly vortex, incubated for 15 minutes on ice and 
centrifuged at 14,000 rpm for 5 minutes at room temperature. The supernatant was 
finally collected and used for the analysis.  
To separate the haemoglobins a cation – exchange column Syncropak CCM 
103/25 was used, eluding with a gradient of sodium acetate present in the mobile 
phase, which consist of aqueous BisTris-KCN-buffers.  
To exactly identify the retention times, commercial standards were used: 
purified HbA (adult haemoglobin, Sigma-Aldrich) and HbF (fetal haemoglobin) 
present in the samples of haemoglobins AFSA2 (Alpha Wassermann Italy) or in 
the standard of haemoglobins AF (Analytical Control Systems, Inc. USA). 
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RESULTS 
 
 
PRODUCTION OF AN EXPERIMENTAL MODEL OF β0-
THALASSEMIA 
 
The β039 mutation is characterized by the substitution C  T in the first base 
of the codon 39, contained in the second exon of the β-globin gene. Such 
substitution causes the creation of a premature translation termination codon, 
leading to the inhibition of the synthesis of β-globin chains. Since this mutation is 
of particular importance both for the severity of the disease that occurs and for its 
wide distribution and frequency in the Mediterranean countries, we decided to 
develop an experimental model of β-thalassemia that could be used to test new 
therapeutic strategies aimed at its correction. We also decided to produce cellular 
lines expressing βwt-globin gene at various levels to be used as experimental 
control.  
In figure 19 is presented the schematic representation of the strategy used to 
produce the cellular model. The first step of this strategy was the production of 
two lentiviral vector containing the βwt- or β039-globin gene under the control of 
its promoter and the locus control region (LCR). The obtained vectors were then 
used to create lentiviral particles, essential for the infection of human erythroid 
K562 cells. The infected cells were then subjected to cell cloning by limiting 
dilution in order to isolate cell clones containing at least one copy of the vector 
using a fluorescence microscope. Such clones were also characterized by real time 
PCR and FACS analysis. 
 
Production of the pCCL.β039.PGW and pCCL.βwt.PGW lentiviral vectors 
 
To create a cellular model with an expression of the βwt- or β039-globin gene 
stable over time, we decided to insert these genes into a third generation lentiviral 
vector. Vectors of this type, in fact, have a number of elements that make the 
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β-globin gene
PRODUCTION OF THE 
LENTIVIRAL VECTOR 
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LENTIVIRAL PARTICLE
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CELL CLONING BY 
LIMITING DILUTIONS
DETECTION OF POSITIVE CLONES AT 
FLUORESCENCE MICROSCOPE
Figure 19 – Schematic representation of the experimental strategy used to produce the β-
thalassemia ex vivo model. The β-globin β039 gene was introduced into a lentiviral vector, 
subsequently utilized to produce viral particles with the function to infect K562 cells. The transduced
K562 cells were, then, subjected to cellular cloning by limiting dilution in order to isolate clones, in 
which at least a copy of the vector was integrated. Such clones were detected at the fluorescence
microscope and, finally, characterized through quantitative real time PCR and FACS analysis.
β-globin p omoter
CHARACTERIZATION OF POSITIVE 
CLONES BY REAL TIME PCR AND 
FACS ANALYSIS
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integration of the transgene into the cellular genome safe and efficient: two 
modified viral LTR (Long Terminal Repeat), which are important for the reverse 
transcription, integration and gene expression; the ψ packaging sequence required 
for the incapsidation of genomic RNA, which has to be transferred; the trans-
active element REV-RRE (Rev Responsive Element), which is required for 
processing and transport of viral RNA outside the nuclear compartment 
[Stathopulos, 2003]. 
In figure 20 is schematically presented the experimental strategy for the 
production of the lentiviral vector containing the β039-globin gene. The first phase 
of this strategy included the use of the third generation lentiviral vector dTNS9 
MluI(-), 11,459 bp long (figure 20a), supplied by Prof. Stefano Rivella (Weill 
Medical College of Cornell University, New York). This vector contains a βwt-
globin gene, deleted of part of the second intron, under the control of its promoter 
and a small β locus LCR, including however large areas of hypersensitive sites 
HS2 (840 bp) , HS3 (1308 bp) and HS4 (1069 bp) [May et al, 2000]. 
The first step was made to remove a sequence of about 3 kilobases (kb), 
containing restriction sites that could interfere with the following digestions. We 
therefore digested the vector dTNS9 MluI(-) with PmeI and SmaI endonucleases 
(table 3), generating two fragments with blunt ends. The digestion products were 
purified by phenol-chloroform extraction, precipitation and Microcon® YM-100 
(Millipore Corporation) and subjected to ligation reaction. Such reaction was set 
up in the absence of PEG (polyethylene glycol), which has the function to increase 
the viscosity of the solution, and in a more diluted way so as to facilitate 
intramolecular ligation of the vector (8,431 bp), containing the resistance to the 
ampicillin, and to completely remove the unwanted sequence of 3,027 bp. The 
reaction was, therefore, set up using 130 ng of vector and 5 U of T4 DNA ligase 
(MBI Fermentas) by incubation at 22°C over night. The ligation products were 
finally used for the transformation of ultra-competent bacteria JM109, using Petri 
plates added with ampicillin, required for the selection of clones containing the 
vector. 
Colonies grown in the plate were analysed by Rapid Disruption, enabling the 
identification of the construct of interest through its molecular weight. The vector 
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was then purified using FlexiPrep kit (Pharmacia Biotech) and its identity was 
confirmed by a subsequent restriction reaction, which produced, following the 
digestion with NcoI and SwaI (table 3), 2 expected fragments, 7240 bp and 1191 
bp long (data not shown). In this way we produced the vector dTNS9 MluI(-
)PmeI(-)SmaI(-).  
 
The second step of the cloning strategy (figure 20a) was the replacement of 
the βwt-globin gene present in dTNS9 MluI(-)PmeI(-)SmaI(-) vector, with the 
β
039-globin gene, contained in pSL1180DT+β039 vector, produced by site-
directed mutagenesis of the pSL1180DT+βwt construct, kindly supplied by Prof. 
Stefano Rivella (Weill Medical College of Cornell University, New York). It was 
therefore necessary to digest both vectors with the restriction enzymes NcoI and 
SwaI (table 3), resulting in production of fragments with blunt and sticky ends. 
Such fragments were separated by electrophoresis on agarose gel and purified with 
QIAquick Gel Extraction Kit (QIAGEN). This method involves the use of columns 
containing a silica membrane able to bind the DNA, which is then purified from 
contaminants and eluted. 
The fragments were then subjected to a ligation reaction, set up using 5 U of 
T4 DNA ligase (MBI Fermentas), 100 ng of vector and a molecular ratio 
vector:insert equal to 1:6; was then performed an incubation at 22°C for 1 hour 
and at 16°C over night. The ligation products were then used for the 
transformation of a different strain of E. Coli: the XL1-blue, because the expected 
vector is fairly large (figure 20a) and these bacteria should be able to host it more 
easily. The grown colonies were again analysed by Rapid Disruption, thus 
identifying the vector of interest by analysis of molecular weight, which was later 
confirmed, after isolation of the vector by QIAGEN Plasmid Purification Mini Kit 
(QIAGEN), by restriction analysis using the ClaI and XbaI enzymes (figure 21a). 
To confirm the presence of the β-globin gene within the vector, the relative 
bacterial clone was subjected to heat lysis and the resulting supernatant was used 
as a template for a PCR reaction, using the BGF1 and BGR1 primers (Table 1), 
specific for the human β-globin gene. The existence of the PCR product, identified 
by electrophoresis on agarose gel, demonstrated the presence of the gene in the 
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vector (figure 21b). In that way we, therefore, obtained the vector dTNS9-β039, 
8,432 bp long. 
The third step of the cloning (figure 20b) provides for the replacement of β-
globin gene with the mutation β+IVSI-110, present in the third generation 
lentiviral vector pCCL.β+IVSI-110.PGW supplied by Prof. Stefano Rivella (Weill 
Medical College of Cornell University, New York), with the β039-globin gene 
carried by dTNS9-β039 vector.  
So, we performed the enzymatic digestion of pCCL.β+IVSI-110.PGW and 
dTNS9-β039 with ClaI and XbaI restriction enzymes (table 3). The obtained 
fragments owned sticky ends and those of interest, the vector (10,996 bp) and the 
insert (2,811 bp), were purified from agarose gel using QIAquick Gel Extraction 
Kit (QIAGEN). The ligation reaction was finally carried out using 50 ng of vector, 
a molecular ratio vector:insert equal to 1:4 – 1:8 and incubating over night at 
16°C. The product of ligation was then used to transform ultra-competent TOP10 
bacteria, optimal for large vectors, using again ampicillin for the clones selection. 
Also in this case, clones of interest were identified through analysis of the 
molecular weight of the internalized construct after Rapid Disruption.  
The recombinant clones were then subjected to heat lysis and used as template 
for PCR reaction with BGF1 and BGR1 primers. The identification of the desired 
PCR product by electrophoresis confirmed the presence of the β-globin gene in the 
vector (data not shown). The obtained vector, called pCCL.β039.PGW, was finally 
purified by QIAGEN Plasmid Purification Midi Kit (QIAGEN). 
The third generation lentiviral vector containing the βwt-globin gene was 
produced through only the third step of the cloning strategy. The β+IVSI-110-
globin gene present in the pCCL.β+IVSI-110.PGW vector was replaced with the 
βwt-globin gene, collected from the dTNS9 Mlu(-)Pme(-)SmaI(-) vector, by 
digestion of both the constructs by ClaI and XbaI endonucleases and ligation of 
the desired fragments of 10,996 bp for the vector and 2,811 bp for the insert, 
purified from agarose gel using QIAquick Gel Extraction Kit (QIAGEN). Also in 
this case we used the ligation product to transform ultra-competent TOP10 
bacteria and the grown colonies were analysed by Rapid Disruption, so as to 
identify the internalized vector through analysis of the molecular weight. The 
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presence of the vector in the selected clones was confirmed though heat lysis and 
PCR reaction with BGF1 and BGR1 primers. The pCCL.βwt.PGW vector was 
finally purified by QIAGEN Plasmid Purification Midi Kit (QIAGEN). 
At this point, the pCCL.βwt.PGW and pCCL.β039.PGW vectors were used as 
templates for PCR reactions, performed using two primers designed by us on the 
vector, upstream (LV1F) and downstream (LV1R) of the insert (table 1), and 
purified with Microcon® YM-100 (Millipore Corporation). The PCR products were 
then used as templates for sequencing the insert present in the vectors. The 
fragments obtained in the sequence reaction were then purified using 
Multiscreen™ (Millipore Corporation), separated by electrophoresis on 
polyacrylamide gel and analysed using the sequencer ABI PRISM™ 377 DNA 
Sequencer (Perkin-Elmer Applied Biosystems). Table 1 lists all the primers used, 
which made it possible to sequence entirely the insert, thus, highlighting the lack 
of anomalies in the nucleotide sequence, except the expected β039 mutation in 
pCCL.β039.PGW vector. The portion of electropherogram shown in figure 22 was 
obtained by sequencing the LV1F-LV1R PCR product with BGR1 reverse primer 
(table 1), using the pCCL.β039.PGW vector as template. 
The sequencing is a very important step in the cloning strategy for several 
reasons. It is essential: 1) to check and determine the presence of the β039 
mutation in the pCCL.β039.PGW vector, as may exist the possibility that a 
mutation occurs spontaneously; 2) to verify that the ends of the insert present in 
both the vectors are intact; 3) to verify the absence of any other type of mutation in 
both the pCCL.βwt.PGW and pCCL.β039.PGW vectors. 
With this strategy, we have thus obtained two third generation lentiviral 
vectors, pCCL.βwt.PGW and pCCL.β039.PGW (13,824 bp long) (figure 20b), 
which possess as well as the insert with the β-globin gene and its promoter: 1) 
functionally important sequences of hypersensitive sites of β-globin cluster LCR; 
2) two modified LTR (deletion in the U3 sequence of the 3' LTR); 3) ψ packaging 
signal; 4) RRE sequence; 5) GFP reporter gene under the control of the promoter 
of phosphoglicerate kinase (PGK), useful for identifying transduced cells; 6) 
WPRE sequence, introduced to increase the levels of GFP expression; 7) 
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Figure 22 – Sequencing of the second exon of the β-globin gene contained into the pCCL.β039.PGW vector. a) Map
of the pCCL.β039.PGW vector. b) Sequence of the region of β039-globin gene corresponding to 1st and 2nd  exons. Box 
highlights the sequence of the reverse primer used for the sequencing. c) Electropherogram, obtained by the sequencing
performed using the BGR1 reverse primer, of the region containing the β039 (C→T) mutation, highlighted by the arrow.
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b)
c)
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insulators, useful to isolate the vector from the surrounding chromatin when 
integrated. 
 
Production and titration of lentiviral particles containing the βwt- or β039-
globin transgene 
 
In figure 23 is schematically presented the strategy for the production of viral 
particles beginning from our pCCL.βwt.PGW and pCCL.β039.PGW vectors. This 
strategy involves the use of three other constructs, called helper vectors, which, 
once inserted into packaging cells together with the lentiviral vector, allow it to 
carry out a replication cycle, resulting in production of viral particles and release 
of such particles outside the cell [Dull et al, 1998]. These helper vectors, kindly 
supplied by Prof. Stefano Rivella (Weill Medical College of Cornell University, 
New York), are essential because they provide structural and regulatory elements, 
absent in the pCCL.βwt.PGW and pCCL.β039.PGW vectors and without which 
they can not be expressed. The capside, which allows to enclose and protect the 
lentiviral genome, is formed by the G glycoprotein of vesicular stomatitis virus 
(VSV-G), expressed by pMD2.VSVG construct (5824 bp), and the protein encoded 
by the gag structural gene present in pMDLpg.RRE vector (8895 bp), which also 
contains the pol gene, encoding enzymes necessary for the viral cycle; all these 
genes are under the control of the strong CMV promoter. The pMDLpg.RRE 
construct carries also a small sequence of the RRE regulator, which binds the REV 
protein expressed by the pRSV.REV vector (4174 bp) under the action of the Lac 
promoter, with the function to mediate the transport of the lentiviral genome into 
the cytoplasm. 
For the production of viral particles, we used as packaging cells the 293T cell 
line. Such cells are tumor cells of human embryonic kidney that grow in adhesion. 
Because of their reduced ability to adhere, their treatment requires caution. 
The day before the transfection of 293T cells, we plated 4.5 x 106 cells in 10 
cm-diameter plates, using 10 ml of D-MEM (Dulbecco's Modified Eagle Medium) 
supplemented with 10% FBS (Fetal Bovine Serum), with the aim to have at the 
time of transfection, the cells well adhered to the support and in number of 9 x 106, 
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taking into account that their population doubling time is about 24 hours. Two 
hours before the transfection, we changed medium of the plated cells and replaced 
it with I-MDM (Iscove's Modified Dulbecco's Medium) supplemented with 10% 
FBS, necessary for the trasfection process. The transfection of 293T cells was, 
therefore, carried out preparing, initially, a mixture with the three helper vectors, 
the lentiviral vector, pCCL.βwt.PGW or pCCL.β039.PGW, and calcium chloride 
(CaCl2). A 2X HBS (HEPES-buffered saline) solution was then added and the 
consequent reaction with CaCl2 determined the production of calcium phosphate 
salts (CaPO4). Immediately after the addition of HBS, the solution was added 
dropwise to the cells, then incubated at 37°C in humidified atmosphere of 5% 
CO2/air for about 16 hours. At the end of the incubation, we changed the medium 
to eliminate residual CaPO4 salts. Through perforation of the cellular membrane 
performed by the salts of calcium phosphate during the 16 hours of incubation, 
constructs penetrate inside the cell and the lentiviral vector, which owns the two 
LTR sequences, integrates into the cell genome. When, through the transcriptional 
machinery of the cell, the lentiviral genome is transcribed, thanks to the presence 
of structural and regulatory proteins expressed by the other viral constructs, it is 
incapsidated inside the protein structure of the virus, forming a viral particle. After 
24 hours, the medium of transfected 293T cells, containing the viral particles 
produced, was collected, filtered and then placed at -80°C. Fresh medium was then 
added to the cells and finally collected and filtered after another 24 hours. 
 
The viral particles, identified with the day of the medium collection, then day 1 
and day 2, own a viral titre, namely a particular transducing effect. Each of these 
particles is a unit of infection, that is the smallest amount of virus capable of 
infecting a target cell [Zhang et al., 2004].  
Figure 23 shows the strategy for the determination of the viral titre, the first 
phase of which consists in the infection of Hela cells, a tumor cell line of human 
cervix, with scalar concentrations of the lentiviral particles solution. Of particular 
importance for the determination of the titre is the fact that each freezing - thawing 
cycle makes the lentiviral particles half their transducing effect. Precisely for this 
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Figure 23 – Schematic representation of experimental strategy for the production and titration of lentiviral particles
containing the β-globin transgene. The lentiviral (pCCL.βwt.PGW or pCCl.β039.PGW) and helper vectors were used to
transfect, through calcium phosphate salts, 293T packaging cells, which, 24 hours after the transfection, began to release
defective viral particles in the supernatant. Such particles were, therefore, collected and titered through infection of HeLa
cells. Titration was performed through both flow cytometry (FACS), which detected the percentage of GFP-positive cells, 
and quantitative real time PCR, which allowed to calculate the exact number of vectors per cell.  
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reason, all the produced aliquots of viral particles were frozen at -80°C 
immediately after their filtration. One of these aliquots was then thawed to 
perform the titration, so that the calculated titre was the same as in the other 
aliquots still frozen. A comparison between different types of titration is reported 
in Sastry et al [2002]. 
To determine the titre of the day 1 viral solution, we plated Hela cells, 24 hours 
before infection, in three wells at a concentration of 5 x 104 cells/well in 1 ml of E-
MEM (Minimum Essential Medium Eagle) supplemented with 10% FBS. Because 
also these cells have a population doubling time of about 24 hours, at the time of 
infection, they have certainly reached the optimal concentration of 1 x 105 
cells/well. As for the transfection, two hours before the infection the medium was 
replaced with I-MDM. So, after 24 hours from the plating, we added to the Hela 
cells the lentiviral solution, doing a serial dilution in the three wells, so that the 
particles present in the second and third well were, respectively, diluted 1:10 and 
1:100 compared to those in the first (i.e. we inoculated 500 µl, 50 µl and 5 µl of 
lentiviral solution). In order to significantly increase the efficiency of infection, we 
added to each sample a trasducing agent, the 100X polybrene (800 µg/ml, 
CHEMICON). The plate was then incubated at 37°C in humidified atmosphere of 
5% CO2/air for about 16 hours, after which, we changed the medium of the cells, 
to remove residual viral particles. 
After about 72 hours from the infection, the cells were washed, detached and 
centrifuged. Half of each sample was then transferred to a tube for flow cytometer 
(FACS) analysis, leading up to 500 µl with 1X DPBS (Dulbecco's Phosphate 
Buffered Saline), while the other half was plated in a new well and incubated for 
another 72 hours, in order to obtain a sufficient number of cells from which we 
could extract the genomic DNA. 
 
Use of the flow cytometer (FACS) for the calculation of the viral titre 
(GFP titre) 
 
The transduced Hela cells, having integrated the viral genome of 
pCCL.βwt.PGW or pCCL.β039.PGW, express the GFP protein, which is detected 
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when excited with fluorescent light. This feature allows us to analyze the infected 
cells with the flow cytometer or FACS (flow-activated cell sorting) (FACScan, 
Becton-Dickinson) using the Cell Quest Pro software (Becton-Dickinson), and to 
determine the GFP titre obtained from the proportion of cell fluorescence detected 
by the cytometer. 
 
Flow cytometer 
 
In figure 24 is schematically presented the principle underlying the flow 
cytometer. The monodisperse cell suspension, contained in the tube for FACS, is 
driven by a laminar flow in a fluidic system to the point of measurement, through 
a flow chamber, in which occur the gradual dilution and the cells alignment in a 
single row, maintained in this position for the presence of an isotonic saline 
solution that surrounds them, in order to avoid the formation of cell clusters. 
Arrived at the point of measurement, the cells are hit by a light beam from a 
source of excitement, the argon ion laser, centred on a wavelength of 488 nm 
(blue). The cell emits  signals related to its physical and morphological 
characteristics, based on phenomena of diffraction (Forward Light Scatter) and of 
reflection and refraction (Sideward Light Scatter). The combination of these two 
signals permits to create a diagram of dispersion or cytogram, where it is possible 
to visualize different cell populations based on their physical characteristics. 
If a fluorochrome is present in the cells, as in our case, when excited by light 
beam it emits a signal corresponding to a determined wavelength. This signal is 
collected by lenses, selected by beam separator mirrors, optical filters and 
semitransparent mirrors (dichroic) and sent to the appropriate sensor 
(photomultiplier or photodiode), which measures the amplitude. The fluorescence 
signals are measured as pulses of amplitude proportional to the number of 
fluorochrome molecules present on or inside the cell.  
The amplified signal from each sensor are digitalized, associated with each 
other and sent to an analyzer – elaborator that provides the data presentation and 
their statistical definition. Every single value of a parameter constitutes an event, 
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Figure 24 – Schematic representation of the operation and analysis of flow cytometer. a) the cellular suspention put 
inside the cytometer is hit by a light beam emitted from an argon ions laser at a wavelenght of 488 nm. The cell hit by the 
light beam emits a signal corresponding to a particular wavelenght, which is collected by lens, selected by beam separation
mirrors and optical filters and sent to the relative sensors (PMT and photodiodes), which misure its proportionality: FSC
(Forward Light Scatter) based on the phenomenon of diffraction and related to the size of the cell; SSC (Sideward Light 
Scatter) based on the phenomena of reflection and refraction and related to the morphology of the cell; FL1, FL2, FL3 related
to the green, red-orange and red fluorescences, respectively. The combination of the signals detected by FSC and SSC permits
to create a diagram of dispersion or cytogram (b), where it is possible to recognize different cellular populations, based on 
their physical characteristics. c) Example of cytogram of cellular dipersion based on the fluorescence emitted by the cells
labelled with fluorochromes, in this case for the green, FL1, and red-orange fluorescence, FL2. d) The analysis of the 
fluorescence is carried out by a histogram showing the detected fluorescence intensity on the x-axis, along with the number of
beaming cells on the y-axis: each cellular population generates a peak with gaussian distribution, quantifying by the parameter
of median.
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the set of events, relative to the measured data, which accumulate in the channels, 
are represented through a distribution diagram or histogram [Brando, 1990] 
 
Calculation of the viral titre (GFP titre) 
 
The first step of the FACS analysis of the transduced Hela cells was the 
configuration of channels and their parameters, through which data are collected: 
FSC (Forward Light Scatter) and SSC (Sideward Light Scatter), that collect data 
of the physical and morphological characteristics of cells, and FL1 (FL-1 Height), 
which receives data on the green fluorescence emitted by GFP. In addition, we set 
the maximum number of cells, called events, which should be counted by the 
instrument (20,000 cells).  
To complete the configuration, we analysed untransduced Hela cells, in order 
to act on the obtained cytogram and distribution diagram (histogram), so as to set 
additional parameters. In the FSC - SSC cytogram in figure 25, it is possible to 
view a cloud that corresponds to the cell distribution. Such cloud is not entirely 
uniform due to the presence of dead cells, identifiable because positioned near the 
convergence of the axes of the graph. We, therefore, performed an electronic 
selection of  the living cells to be analysed, separating them from dead ones, an 
option called gate, establishing a "gate" that enables entry to the analysis system 
only of events that have values within the set limits [Brando, 1990]. In the 
histograms (Counts - GFP) of untransduced Hela cells (data not shown), the 
parameters are set so that the peak formed by cells was placed totally on the left of 
the value of fluorescence equal to 101, which is usually used as threshold. 
Finished the parameters configuration, we analysed the HeLa cells infected 
with pCCL.βwt.PGW and pCCL.β039.PGW viral particles: from the obtained 
histograms (figure 25a,c) we derived the proportion of GFP - positive cells 
(figure 25b,d) of each sample. These percentages were found to be much lower 
than expectations, which predicted: about 100% for cells transduced with the 
undiluted virus, indicating a saturation of the system, about 30% for Hela infected 
with 1:10 dilution and about 2 – 3% for cells transduced with the virus diluted 
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1:100. The percentage of fluorescent cells obtained with FACS is an essential 
factor to calculate the viral GFP titre, which is determined by the formula: 
  
GFP titre = (F x Co/V) x D  
 
where F is the percentage of fluorescent cells; Co, the total number of infected 
cells; V, the total volume in which it was performed the infection; D, the dilution 
factor of the virus. The unit of measurement of the viral titre is TU/ml, namely 
transducing units per ml [Sastry et al., 2002]. 
This formula expected to use, for calculating the viral titre, the data relative to 
the sample with the proportion of fluorescent cells that comes closest to 30%. This 
is because it is plausible to think that when only 3 out of 10 cells are GFP-positive, 
with a good chance they were infected by a single virus, namely a single 
transducing unit. The titre calculated using these assumptions is approaching the 
real titre of the viral particles. The choice between our samples was difficult 
because we got the percentages (figure 25b,d) significantly lower than expected. 
In conclusion, our preference fell on the samples 2 (pCCL.βwt.PGW: 14.68%; 
pCCL.β039.PGW: 9.48%), as the first and third were too differed from the ideal 
proportion of 30%. The GFP titres were calculated as 3 x 105 and 1.8 x 105 TU/ml 
for the pCCL.βwt.PGW and pCCL.β039.PGW viral particles respectively, 
relatively low viral titres that allows to explain the low percentage of the obtained 
GFP-positive cells.  
A major limitation of GFP titre is not to consider two important situations: 1) 
not always an infected cell expresses the GFP protein at levels that exceed the 
FACS threshold of detection, and 2) even assuming that with a percentage of 
fluorescent cells equal to 30%, in most cases, a single infection happened, this 
does not exclude the possibility of multiple infections. 
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Use of the quantitative real time PCR assay for the calculation of the viral 
titre (DNA titre) 
 
After further 72 hours of incubation, the Hela cells infected with scalar 
quantities of pCCL.βwt.PGW and pCCL.β039.PGW viral particles were lysated 
and their DNA extracted by phenol - chloroform extraction and 70% ethanol 
precipitation. This DNA was then quantified with a spectrophotometer and used as 
a template for the reaction of quantitative real time PCR, so as to determine the 
number of vectors integrated into the genome of the different cell samples. 
Essential data for being able to calculate the viral DNA titre. 
 
Calculation of the viral titre (DNA titre) 
 
Since for calculating the viral DNA titre it is needed to quantify the number of  
pCCL.βwt.PGW or pCCL.β039.PGW vectors integrated into Hela cells, used for 
the titration, it was necessary to design a pair of primers and an oligonucleotidic 
probe both for the β-globin gene, present in the vectors, and for a gene to be used 
as reference. The choice of reference gene is arbitrary, with the only condition that 
it must be present in two copies in the genome, one for each allele, as it must be 
used as a reference to determine the increase in the number of β-globin genes in 
transduced cells. Making a proper normalization of the experiment is essential as 
cell populations may be in different replication stages, and because proliferating 
cells contain a double set of genetic information in comparison with non-
proliferating cells, comparing two populations without first having standardized 
data on a known gene leads to wrong conclusions [Huggett et al., 2005]. In our 
case, having decided to use the γ-globin gene for standardization, we had to design 
a probe that can discriminate Aγ gene from Gγ gene. Table 2 shows the sequences 
of primers and TAMRA probes used in experiments. Their design was carried out 
using the Primer ExpressTM version 2.0 software.  
The reactions of real time PCR were prepared using the TaqMan® Universal 
PCR Master Mix 1X (Applied Biosystems), containing the DNA polymerase, 
dNTPs and saline buffer, the PFβ and PRβ primers and Pβ probe for the 
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amplification reactions of β-globin gene and PFγ and PRγ primers and Pγ probe 
for the amplification reactions of γ-globin gene. The step of annealing - elongation 
was done at 60°C. To normalize the data obtained, we decided to amplify, in the 
same conditions of samples, scalar quantities of a control genomic DNA, extracted 
from untransduced Hela, used as standard. 
The graphs obtained show, in the x-axis the amplification cycles and in the y-
axis the values of fluorescence (∆Rn) (data not shown). After establishing a 
threshold value of fluorescence (0.034) we were unable to get the threshold cycle 
(Ct) of each sample obtained both with the Pβ probe and with the Pγ probe. The 
Cts obtained with the DNA from HeLa cells infected with pCCL.βwt.PGW and 
pCCL.β039.PGW are shown in figure 26a and figure 26c, respectively. 
We used the Cts obtained with the DNA from untransduced Hela (standard) to 
set up two different calibration curves, for the β-globin and γ-globin genes, 
subsequently used for the normalization of the samples (data not shown). The 
results were then analysed and the final data are reported in histograms of figure 
26 (b and d), where it is possible to estimate the fold of β-globin compared to γ-
globin genes. As expected, samples 1 (Hela infected with the undiluted lentiviral 
solution) present the largest increases of β-globin respect to γ-globin genes, while 
samples 2 (Hela infected with the lentiviral solution diluted 1:10) and samples 3 
(Hela infected with the lentiviral solution diluted 1:100) show smaller increases. 
These data reflect the number of vectors in each cell, taking into account that the 
fold of β-globin compared to γ-globin genes in untransduced Hela cells is equal to 
1. 
Using these data, we calculated the viral DNA titre, according to the formula:  
 
DNA titre = (F x Co/V) x D  
 
where F is the subtraction of the fold of β-globin gene of untransduced HeLa 
cells from the same fold of the chosen sample; Co, the total number of infected 
cells; V, the total volume of infection; D, the dilution factor of the virus. Even in 
this case the unit is TU/ml [Sastry et al., 2002]. 
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Of course, even for the calculation of DNA titre it is necessary to choose only 
one of the samples. Our choice fell on samples 2, obtaining viral titres of 6 x 105 
and 4.5 x 105 TU/ml for the pCCL.βwt.PGW and pCCL.β039.PGW viral particles 
respectively, so as to make a more accurate comparison with the GFP titres 
previously calculated, because the titre of a lentiviral vector varies according to 
the conditions of the infective process: the volume of inoculum, the number of 
target cells, cell type and viability/susceptibility, vector exposure time for uptake 
and vector half life. Furthermore, the VSV-G envelope binds to its target in cell 
membranes which are known to be phospholipids, such as phosphatidylcholine 
(PC) and phosphatidylserine (PS), (the receptors for VSV-G). PC is the most 
abundant membrane phospholipid while PS domains are present in much smaller 
quantity but bind more strongly and fuse faster with the VSV-G protein. This issue 
is probably one of the most overlooked variables in vector transduction. 
Membrane phospholipid movement is highly dynamic. Its biosynthesis and 
degradation are very much dependent on cell type and positions in the cell cycle 
and/or metabolic activity. Also, the rate of degradation is rapid in G1, slows 
drastically during S phase, and picks up the pace again as cells exit mitosis and re-
enters G1, which suggests that the cell cycle phase may be an important variable 
for VSV-G protein coated lentiviral transduction. This can affect the success of 
infection and, therefore, the viral titre. The variation of these parameters can result 
in a difference in the viral titre in different aliquots of the same viral stock, hence 
the viral titre is not a value that exactly indicates how many infectious units per ml 
were added to the cells [Zhang et al., 2004]. 
 
Comparison between GFP titre and DNA titre 
 
Comparing the calculated viral titres, 
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 GFP titre DNA titre 
pCCL.βwt.PGW 3 x 105 TU/ml 6 x 105 TU/ml 
pCCL.β039.PGW 1.8 x 105 TU/ml 4 x 105 TU/ml 
 
it is possible to note how the DNA titres have a value far greater than the GFP 
titre. This may depend on the limits of the FACS analysis previously exposed, 
which may cause an underestimation of the viral titre. This conclusion was also 
confirmed by the work of Sastry et al [2002], who noted in their experiments that 
the viral titre obtained by real time PCR was up to ten times higher than that 
calculated by FACS and also more accurate and reliable, because not 
underestimated. For this reason, we decided, for future infections, to consider only 
the DNA titre. 
 
Transduction of K562 cells 
 
As far as studies on erythropoiesis, the K562 cell line [Lozzio and Lozzio, 
1975] is well known as a useful experimental model system to study the 
expression of embryo-fetal globin genes, as well as their modulation [Rutherford 
et al, 1979; Rutherford et al, 1981; Osti et al, 1997; Bianchi et al, 2000; Bianchi et 
al, 2001]. Interestingly, especially for reaching the aims of our study, K562 cells 
express the β-globin gene at very low levels both in their uninduced state as well 
as after erythroid differentiation stimulated by a variety of chemical inducers, such 
as cytosine arabinoside [Cortesi et al, 1999], mithramycin [Bianchi et al, 1999; 
Fibach et al, 2003], rapamycin [Mischiati et al, 2004; Fibach et al, 2006]. 
In deciding the volume of viral solution to be used for transducing the human 
erythroid K562 cell line, we based our decision on MOI (multiplicity of infection), 
a parameter used to predict the viral infectivity in a population of target cells and 
therefore assume how many events of gene transfer can take place. This parameter 
is based on the viral titre, precisely the DNA titre, and the concentration of cells to 
be infected, according to the ratio [Zhang et al., 2004]:  
 
MOI = (TU/ml)/(cells/ml) 
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Usually, the MOI is decided arbitrarily by the researcher, according to the 
experiment to be performed. In our case, we chose to infect cells with different 
MOIs, from 0.5 to 2, because the objective was to obtain cell lines incorporating a 
number of vectors relatively low but variable. 
So, we carried out various infections of K562 cells using the pCCL.βwt.PGW 
and pCCL.β039.PGW viral particles, which have a DNA titre of 6 x 105 and 4 x 105 
TU/ml, respectively. For each of these infections were plated 105 cells in 50% of 
RPMI (Roswell Park Memorial Institute) and 50% of I-MDM media added with 
10% FBS. After two hours, we added the volume of viral solution calculated 
depending on the chosen MOI and the 100X polybrene (800 µg/ml, CHEMICON), 
necessary to facilitate the transduction. After about 16 hours, we changed the 
medium of the cells, with the purpose to remove all residual viral particles and 
because the K562 cells grow better in RPMI medium. 
For the following 7 days, the transduced K562 cells were incubated at 37°C in 
humidified atmosphere of 5% CO2/air in order to recover from trauma caused by 
viral infection and therefore be subjected to cell cloning. This was done by 
limiting dilutions of the cell culture to obtain the final concentration of 4 cells/ml. 
This suspension was then divided into 96 wells, 100 µl/well, so as to have 4 cells 
per 10 wells. In fact, to be relatively safe to isolate almost entirely single clones it 
would recommend to aliquot a cell suspension with a concentration of 2 cells/ml, 
but, as with low MOIs the proportion of infected cells may be very limited, with a 
concentration of 2 cells/ml we could not isolate almost any positive clone.  
Once the cloned cells were expanded, they were analysed by fluorescence 
microscope to identify, through the green fluorescence emitted by GFP, the 
infected clonal lines. In all, we  isolated seven βwt-globin K562 cell clones and six 
β
039-globin K562 cell clones, whose images are shown in figures 27 and 28, 
respectively. It's easy to note that the emitted fluorescence intensity is different 
depending on the clone, certainly due to different numbers of integrated vectors. 
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Characterization of K562 cell clones 
 
Once obtained the βwt-globin and β039-globin K562 cell clones it was 
necessary to characterize them in terms of the genome and transcriptosome, in 
order to determine not only the number of integrated vectors, but also the presence 
of the expected β-globin transcript, βwt and β039 respectively, essential for an ex 
vivo model of β-thalassemia, to be used to test new therapeutic strategies aimed at 
correcting nonsense mutations. 
 
Analysis of integration and GFP fluorescence of the βwt-globin and β039-
globin K562 cell clone 
 
The first step was to extract the genomic DNA of βwt-globin and β039-globin 
K562 cell clones by cell lysis, phenol – chloroform extraction and 70% ethanol 
precipitation. Once quantified using the spectrophotometer, the DNA was used as 
a template in quantitative real time PCR reactions in order to determine the fold of 
β-globin transgenes integrated into the cellular genome. This type of analysis has 
two main purposes: 1) relating the fold of β-globin transgenes present in a single 
cell to the MOI used for the infection; 2) choosing the clone suitable for the type 
of experiment to be carried out, as the greater or lesser expression of β-globin gene 
changes the experimental condition. 
The performed real time PCR assay faithfully reflects the reactions made for 
the determination of DNA titre, because it is always based on the recognition of β-
globin genes in genomic DNA. In this case, the choice of γ-globin gene as 
reference gene is of great importance because of the karyotype of the K562 cell 
line. In fact, such cells do not present a normal diploid karyotype, as they derived 
from a pleural effusion of a patient with chronic myelogenous leukemia (CML), 
which is a clonal malignant disorder of the pluripotent hematopoietic stem cell, 
presenting complex translocation, with three, four or five chromosomes involved. 
So, in K562 cells most chromosomes are in three or more copies, making very 
difficult to identify a correct and suitable reference gene [Gribble et al, 2000; 
Naumann et al, 2001]. γ-globin gene is a good choice because of its location on 
 159 
the chromosome 11 close to the β-globin gene. In that way, we were absolutely 
sure that the ratio between β- and γ-globin genes was always equal to 1 in 
untransduced K562 cells. Unfortunately, it is probable that there exist different 
sublines of K562 with slightly different karyotype. Precisely because of this, not 
knowing the exact number of chromosomes 11 in our original K562 cell line, we 
were not able to determine the exact number of integrated vectors, but we limited 
ourselves to determine the fold of β-globin transgenes integrated into the genome 
of each clone.  
Even in this case, we obtained, for each sample, as result of the real time PCR 
assay, a graph with the amplification curves of both the β- and γ-globin genes. 
These curves and the Cts, determined following the choice of the threshold 
(0.034), of the βwt-globin and β039-globin K562 cell clones are shown in figure 
29 and 30, respectively. From these profiles is immediately evident that, in all the 
samples, the β-globin gene is present in a number of copies greater than the γ-
globin gene, because its amplification curve always takes fewer cycles to reach the 
threshold. It was, however, by analysis of data and determination of the fold of β-
globin compared to γ-globin gene (figure 31) that we could say that these clones 
actually contained at least one copy of the vector. 
Once determined the fold of the β-globin transgenes integrated in each clones, 
we decided to verify if there was a correlation between this parameter and the 
emitted GFP fluorescence intensity. With this purpose, we analysed each clone by 
flow cytometer (FACS), following the same configuration procedure used for the 
titration of the lentiviral particles, but using original K562 cells instead of 
untransduced HeLa cells to set the FSC, SSC and FL1 parameters. From the 
histogram (counts - GFP), we obtained the median of the GFP fluorescence 
emitted by each clone, shown in figure 31. We decided to consider the median, 
instead of the arithmetic mean, because it is the value that corresponds to the 
middle item in a ranked list of all measurements. It’s robust because it does not 
necessarily move in response to small numbers of outliers, or to skewing of the 
tails of a distribution, whereas the mean is tugged by both. 
From the histogram in figure 31 it is possible to note that the two parameters, 
fold of β-globin transgenes and median of GFP fluorescence, have similar trends,
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Figure 29 – Real time PCR analysis of β-globin gene using genomic DNA from βwt-globin K562 cell clones.
The representative profiles show the amplification of β- (blue circles) and γ-globin (pink squares) genes. For each
clones both the threshold cycles (Ct), obtained with the Pβ and Pγ probes, are reported.
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Figure 30 – Real time PCR analysis of β-globin gene using genomic DNA from β039-globin K562 cell clones.
The representative profiles show the amplification of β- (blue circles) and γ-globin (pink squares) genes. For each
clones both the threshold cycles (Ct), obtained with the Pβ and Pγ probes, are reported.
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Figure 31 – Analysis of integration and GFP fluorescence of the βwt-globin and β039-globin K562 cell clones. In the 
histograms are reported both the fold of β-globin transgenes (violet boxes) integrated into the genomic DNA of the βwt-
globin (a) and β039-globin (b) K562 clones respect to the original K562 cells and the median of GFP fluorescence (green 
boxes) emitted by each clone. The data represent the averages ± SD of three indipendent determinations. In order to
determine the integration efficiency of the βwt-globin and β039-globin genes by real time PCR, the obtained Ct values
were compared to those obtained using primers amplifying γ-globin gene sequences. 
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indeed clones with greater fold of β-globin genes present a higher median of 
fluorescence, unless a few cases. This result is expected because the GFP gene in 
the vector is under the control of the constitutive PGK promoter, which is less 
affected by the state of the chromatin surrounding the site of insertion.   
 
Detection of the βwt- and β039-globin transcripts by non-quantitative real time 
RT-PCR assay 
 
From each K562 cell clone, RNA was extracted by Trizol, precipitated with 
70% ethanol and quantified using a spectrophotometer. The RNA was then reverse 
transcribed, after treatment with DNase to remove any residual genomic DNA. 
The reverse transcription reaction was performed using 1µg of templates and 
oligodT primers, specific for the poly-(A) tail of the RNA messengers. After an 
incubation for 5 minutes, we added a mixture  containing the enzymes: 
Recombinant RNasin Ribonuclease inhibitor and Improm-IITM reverse 
transcriptase. After the necessary thermal steps of annealing and elongation, we 
obtained the cDNA of all K562 cell clones, to be used in non-quantitative real 
time PCR, using probes able to discriminate between βwt and β039 transcripts. 
Since designing probes able to discriminate two sequences differing by only 
one nucleotide is particularly complicated, we decided to use for our purpose a 
Genotyping kit designed by Applied Biosystems for the mutation β039. It consists 
of a 40X MIX containing the forward PF and reverse PR primers and two 
TaqMan® MGB probes, the Pβ039 labelled in 5' with the fluorochrome FAM and 
the Pβwt labelled in 5' with VIC. As these fluorochromes have a different 
wavelength of emission and as the probes have different nucleotide sequences and 
specificity, they may act in the same sample and be recognized together. Usually, 
this kind of kit is used to detect the absence or presence in heterozygosity or 
homozygosity of a mutation in the genomic DNA. Our intention, however, was to 
use as template the cDNA from the clonal lines, so trying to obtain greater 
specificity, we carried out experiments at different annealing – elongation 
temperatures, up to 65°C, and with various amounts of template, from 20 ng to 
100 ng. At the end, given the results obtained in the tests, we decided to perform 
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the reactions with 50 ng of cDNA at a temperature of annealing –elongation of 
60°C. 
In figure 32 are presented the profiles derived from the non-quantitative real 
time RT-PCR analysis of the β039-globin K562 cell clones. It is easy to notice the 
presence of amplification curves obtained with both Pβ039 and Pβwt probe in all 
samples. This result implies the existence in these clones of two β-globin 
transcripts, wild type and mutated, the first due to the copies of the endogenous β-
globin gene, the second due to the transgenes. Taking into consideration the Ct 
obtained by the various curves and comparing the two curves of each sample, it is 
possible to note that the β039-globin transcript is far more represented than the 
βwt, because the relative amplification curve employs a fewer number of cycles to 
reach the threshold. 
Of course, also the transcripts of βwt-globin K562 cell clones were analysed 
using the Genotyping kit. In this case, we obtained anyway the amplification curve 
with the Pβ039 probe (data not shown), but it was totally atypical and with a Ct 
higher than 30. This result suggests the existence of a possible cross-hybridization 
of the mutated probe with the wild type transcript but it does not preclude the use 
of the kit, because the amplification curves and Cts obtained with the mRNA from 
β
039-globin K562 clones are significantly different from those obtained with the 
βwt-globin K562 clones. So, the cross-hybridization can be consider negligible.  
 
Quantification of the βwt- and β039-globin transcripts by quantitative real time 
RT-PCR assay 
 
Once identified the β-globin transcript produced by all the K562 cell clones, 
we felt necessary to quantify it so as to be able to choose clones to be used as 
β
039-thalassemia cellular model and control model, based on the content of β-
globin mRNA. In fact, it is more reliable to compare clones accumulating similar 
amounts of β-globin sequences, especially when the aim is to test therapeutic 
strategies able to alter the mRNA processing.  
In this respect, we performed the real time RT-PCR analysis on the RNA from 
logarithmically growing cells as already explained, using the Genotyping kit so as 
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to discriminate between the two β-globin transcripts, mainly in the case of the 
β
039-globin K562 cell clones. For the quantification it was necessary to identify a 
standard sample to be used as reference so as to analyse all the clones in 
comparison to it. Because we could not use the original K562 cells as standard, 
due to absence of β039 mRNA, we decided to use the βwt-globin and β039-globin 
K562 cell clones with the lowest fold of β-globin transgenes (wt1 and m3) as 
standard for the quantification of the β-globin transcripts in the βwt-globin and 
β
039-globin K562 cell clones respectively.  
Although real time RT-PCR is widely used to quantify biologically relevant 
changes in mRNA levels, there remain a number of problems associated with its 
use. These include the inherent variability of RNA, variability of extraction 
protocols that may co-purify inhibitors and different reverse transcription and PCR 
efficiencies. Consequently, it is important that an accurate method of 
normalisation is chosen to control for this error. Normalising to a reference gene is 
a simple and popular method for internally controlling for error in real time RT-
PCR. This strategy targets RNAs encoded by genes, which have been collectively 
called housekeeping genes and benefits from the fact that all the steps required to 
obtain the final PCR measurement are controlled for. The procedure is simplified 
as both the gene of interest and reference gene are measured using real time RT-
PCR. The most commonly used reference genes include β-actin, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), hypoxanthine-guanine phosphoribosyl 
transferase (HPRT) and 18S ribosomal RNA [Huggett et al, 2005]. In this case, we 
chose the GAPDH, of which we had a commercial kit designed for real time PCR 
(from Applied Biosystems).  
The cDNA obtained from the RNA isolated from each clone was then 
amplified using the Genotyping kit and GAPDH kit to detect the β-globin and 
GAPDH transcript respectively. 
The results gave clear evidence that within the βwt-globin K562 cell clones, 
high expression (relative to wt1) was detected in wt6 and low expression in wt3, 
wt5 and wt7 clones (figure 33a); on the other hand, within the β039-globin K562 
clones, the β-globin gene was highly expressed (in comparison to m3) in m1, m4, 
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Figure 33 – Quantitative real time RT-PCR analysis of β-globin mRNA from K562 cell clones. a,b) 
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amplifying GAPDH (c) and β-globin (d) mRNA sequences. Two different probes were used for the β-globin
mRNA: Pβwt and Pβ039, contained in the Genotyping Kit and labelled with FAM and VIC, respectively.
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m5 and m6 K562 cell clones and poorly expressed in m2 K562 clone (figure 33b). 
Despite the fact that no silencing effect was noted, no clear relationship is evident 
between levels of gene expression and number of integration units. This is 
however expected, since transcription might depend also on the site of integration. 
Moreover, in β039-globin K562 cell clones the accumulation of β-globin mRNA 
sequences is affected by the known effect of nonsense mediated mRNA decay 
(NMD), which can significantly reduce but not totally eliminate the nonsense β039 
transcript [Holbrook et al, 2004; Stalder and Mühlemann, 2008]. After 
comparative analysis of the RT-PCR data, clones wt3 (βwt-globin K562 cells) and 
m5 (β039-globin K562 cells) were selected for the experiments employing 
possible corrections with aminoglycosides, due to the fact that, among the βwt-
globin and β039-globin K562 cell clone sets, they express similar, although not 
identical levels of β-globin mRNA molecules, as depicted in figure 33 (c and d). 
Interestingly, clone m5 displays higher β-globin gene integration units and GFP 
production in respect to clone wt3 suggesting, as expected, NMD affecting β039-
globin mRNA, although in this case the large number of mutated transgenes 
present into the cells may induce the saturation of the process, leading to the 
accumulation of a significant amount of nonsense transcripts. The differential 
expression of β-globin mRNA between m5 and wt3 are maintained when the 
culture conditions were changed from expansion to differentiation, by treating 
cells with cytosine arabinoside (data not shown). 
 
USE OF THE EXPERIMENTAL MODEL SYSTEM TO 
CHARACTERIZE THE READ-THROUGH ACTIVITY OF 
AMINOGLYCOSIDES 
 
As already mentioned, the β039-thalassemia mutation is a nonsense mutation. 
In fact, the replacement C  T at the first base of codon 39 of the β-globin gene 
sequence causes the development of a premature translation termination codon, 
resulting in inhibition of β-globin protein synthesis. Given the proven read-
through ability of aminoglycosides and their application as possible therapeutic 
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compounds for genetic diseases caused by nonsense mutations [Howard et al, 
1996; Bedwell et al, 1997; Barton-Davis et al, 1999; Du et al, 2002; Howard et al, 
2003; Lai et al., 2004; Pinotti et al., 2006], we decided to test the action of the 
most used aminoglycosides on our experimental model. The aim was to see if the 
read-through activity demonstrated by these compounds, and thus their power to 
correct the nonsense mutations, was also confirmed in β-thalassemia. If that 
happens, it would have production of β-globin chain, which could lead to the 
formation of adult haemoglobin (Hb A). 
 
GENETICIN 
 
From the literature it came out that the aminoglycosides more effective in the 
translational read-through, for the treatment of genetic diseases, are geneticin or 
G418 [Howard et al, 1996; Bedwell et al, 1997, Lai et al, 2004; Pinotti et al, 2006] 
and gentamicin [Barton-Davis et al, 1999; Keeling et al, 2001; Du et al, 2002; 
Wilshanski et al, 2003; Howard et al, 2004]. Given the ready availability of 
geneticin, as a first experiment of treatment with aminoglycosides on our model, 
we decided to use precisely the G418. Once confirmed the practicality of this 
method to correct the β039-globin mutation, we decided to broaden the spectrum 
of aminoglycosides, in order to identify the compound most suitable for the β-
globin gene. 
 
Evaluation of the toxicity of geneticin (G418) 
 
Before we could start the treatment, it was obviously necessary to check the 
geneticin toxicity and, therefore, its action on cell growth of wt3 βwt-globin and 
m5 β039-globin K562 cell clones, with the aim of identifying a range of 
concentrations at which we could use the G418 without causing serious cell 
damage. In this regard, we carried out a curve of growth inhibition with the wt3 
and m5 clones: the cells were plated at a concentration of 3 x 104 cells/ml in 2 ml 
of culture medium, for a total 6 x 104 cells per well, in 12 wells, and treated with 
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scalar concentrations of geneticin from 0 to 1 µg/µl. After 3 days was then 
calculated the total number of cells in each treated sample. 
The obtained data were included in two graphs, one for each clone, along with 
the geneticin concentrations, resulting in curves of cell growth inhibition which 
are shown in figure 34. From the curves we were able to determine that the 
geneticin concentration determining 50% cell growth inhibition (IC50) was similar 
for both the clones and about 200 ng/µl. We therefore decided to treat the cells 
with the following concentrations of aminoglycoside: 100 ng/µl, 200 ng/µl and 
400 ng/µl, so as to have a larger view of the G418 activity and identify the optimal 
concentration for the treatment. 
 
Evaluation of the effects of geneticin on original K562 cells 
 
Before starting the treatment of our cellular models with G418, it was 
necessary to determine whether it could have an induction effect on the expression 
of β-globin gene in original K562 cell line, from which we started to get our 
clones. We plated 3 x 104 cells/ml in 4 ml of RPMI supplemented with 10% FBS 
for a total of 1.2 x 105 cells, in 2 wells. One of the two samples were then treated 
with 400 ng/µl geneticin, while the second was kept as control. Both were then 
incubated at 37°C in humidified atmosphere of 5% CO2/air for 72 hours. The 
choice of the geneticin concentration was due to the fact that 400 ng/µl is the 
highest concentration among those chosen for the treatment of wt3 and m5 clones 
and is the concentration that was proven to be more effective [Pinotti et al, 2006].  
After incubation for 72 hours, we collected from each well 1.5 x 106 cells 
which were labelled with the monoclonal antibody (MoAb) against the β-globin 
chain, to enable the detection of its production by immunohistochemistry and 
FACS analysis. To this purpose, we used the BD Cytofix/Citoperm™ Kit (BD 
Biosciences Pharmingen).  
Figure 35 summarizes the basic concepts of the intracellular labelling 
technique, which includes three steps: 1) permeabilization of the cell membrane; 
2) treatment with an inhibitor of aspecific binding sites; 3) incubation of the 
permeabilized cells with an antibody specific for the desired protein. The labelled 
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Figure 34 – Inhibition effects of geneticin (G418) on βwt-globin wt3 and β039-globin 
m5 K562 cell clones. The cells were incubated for 3 days at increasing concentrations of
G418 and, then, counted using the Bürker chamber. On the x-axis are reported the 
concentrations of geneticin while on the y-axis the total cells counted.
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cells can be either fixed on a slide and analysed by a fluorescence microscope or 
analysed by FACS, so as to have quantitative data about the proportion of 
fluorescent cells and the intensity of the emitted fluorescence. 
The cells were initially permeabilized with 500 µl of BD Cytofyx-Citoperm 
solution, then subjected to incubation first with 300 µl of 1X PBS (phosphate 
buffered saline) 1% BSA (bovine serum albumin) solution, to inactivate the 
aspecific sites which could bind to the antibody, and then with the βglobin-PE 
(PE, phycoerythrin) (Santa Cruz Biotechnology) MoAb, specific for the 
recognition of β-globin chain, diluted 1:10 with PBS - 1% BSA. βglobin-PE is a 
monoclonal antibody labeled with the fluorochrome phycoerythrin (PE), which, 
when excited with light of wavelength equal to 488 nm, emits red fluorescence at 
580 nm. 
The BSA, besides inactivating aspecific binding sites, neutralizes the 
electrostatic charge of the tube wall and prevents it attracts the antibody 
molecules. In the absence of BSA, in fact, the MoAb gradually adheres to the wall, 
stratifying and resulting in gradual reduction of its concentration. So, when it is 
necessary to make dilutions of the antibody, it is convenient to restore the 
concentration of BSA.  
After incubation with the antibody, we divided the cells of the two samples so 
as to be fixed on a slide and analyzed by fluorescence microscope (1/3 of total 
cells) and at the same time analyzed by FACS (2/3 of total cells). 
 
FACS analysis 
 
The FACS analysis was performed by FACScan (Becton-Dickinson), using the 
Cell Quest Pro software (Becton-Dickinson), whose principle has already been 
widely described and summarized in figure 24.  
As usual, the first step was to set the channels of the instrument with its 
parameters: FSC and SSC, which elaborate the data of physical and morphological 
characteristics of the cells, and FL2 (FL-2 Height), a channel able to analyse data 
on the red - orange fluorescent. Original K562 cells labelled with the βglobin-PE 
MoAb can be fluorescent only if they contain β-globin chains, as the antibody is 
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specific for this protein, furthermore these cells do not have, unlike our clones, the 
GFP reporter gene and then they are not able to emit the green fluorescence. For 
this reason, it was not necessary to configure the FL1 parameter.  
Figure 36 shows the diagrams obtained from the FACS analysis of the two 
samples: K562 untreated (a) and treated with 400 ng/µl G418 (b). It may be noted 
in addition to the FSC - SSC cytogram (I), where the cells are distributed based on 
their morphology, a βglobin-PE histogram (II), with on the x-axis the red 
fluorescence and on the y-axis the number of emitting cells. By comparing the two 
FSC - SSC cytograms, it is possible to note a slight movement of the cloud of 
treated K562 cells (b) to greater values of SSC. This shift indicates an increased 
granularity of cytoplasm and is certainly due to the toxic effect of the G418 on 
cells. Precisely because of the presence of a different cellular distribution between 
the two samples, due to the aminoglycoside action, we decided not to draw any 
gate in the cytogram in order to analyze the totality of the cells.  
From the histograms for the red fluorescence (IV), it is possible to notice a 
slight shift of the cells treated with G418 beyond the fluorescence threshold of 101. 
The magnitude of that shift is shown in the table (figure 36c): the control K562 
had a proportion of red fluorescent cells equal to 0.31%, as expected because of 
the low expression of β-globin gene in these cells, while in K562 treated with 
geneticin this percentage increased to 2.09%. Similarly, the median of the 
intensity, a value that indicates the midpoint of the distribution of fluorescent cells, 
changed from 3.13, in control cells, to 4.96 in the treated sample. 
The fact that the control sample presented a weak fluorescence, maybe due to 
spontaneous fluorescence background, is normal and is the limiting factor of the 
resolving power of the instrument [Brando, 1990]. 
 
Immunohistochemistry analysis 
 
In parallel with the FACS analysis, we proceeded with the fixation of the 
labelled cells on a slide so as to be analyzed using a fluorescence microscope to 
verify the presence or absence of β-globin chains. The used slide was previously 
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Figura 36 – Effects of geneticin (G418) on the β-globin production in original K562 cells. In 
figure, are presented diagrams obtained through FACS analysis of original K562 cells, labelled with
βglobin-PE MoAb: (a) untreated; (b) incubated for 3 days with 400 ng/µl G418. For each samples are 
reported: cells distribution diagram based on morphological parameters FSC and SSC (I) and 
histogram relating the emitted red fluorescence to the number of beaming cells (II). Data on the 
percentage of cells emitting red fluorescence and the intensity of that fluorescence are shown in table
(c). Moreover, there are reported the images obtained at fluorescence microscope of the cells labelled
with βglobin-PE and fixed on a slide: control K562 not treated (d), K562 incubated for 72 hours with
400 ng/µl G418 (e).
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treated with 30 µl of poly-L-lysine diluted 1:10, to facilitate cell adhesion to glass. 
Cells were then fixed with 4% formalin. It was therefore possible to analyse the 
cells using a fluorescence microscope, which permits, through the emission of 
fluorescent light and with the appropriate filter, to verify the presence of red 
fluorescence. As shown in figure 36d, the cells treated with G418 did not emit any 
fluorescence, as well as the untreated cells. 
The obtained data appear to be discordant with each other, because the FACS 
was unable to find a slight increase in the proportion of fluorescent cells, which, 
however, was not brought out by the immunohistochemistry. This can be 
explained considering that the FACS sensitivity is greater than the human eye 
perceptivity, and taking into account that the increase in the proportion of red cells 
and fluorescence intensity is really minimal. 
 
Evaluation of the effects of geneticin on β-globin production in wt3 βwt-
globin and m5 β039-globin K562 cell clones  
 
The wt3 βwt-globin and m5 β039-globin K562 cell clones cells were plated, as 
previously explained, in 4 wells: an untreated control and three samples treated 
with scalar concentrations of geneticin (100 ng/µl, 200 ng/µl and 400 ng/µl). To 
have a positive control for the red fluorescence, we decided to label with βglobin-
PE MoAb erythroid precursor cells, isolated from healthy donors and treated with 
erythropoietin, which express the β-globin gene at good levels. After the usual 3 
days of incubation, cells were subjected to the permeabilization treatment and 
incubated with βglobin-PE antibody and then divided in order to analyse their 
ability to emit red fluorescence, which depends on the amount of β-globin chains 
present, using both the FACS and fluorescence microscope. 
 
FACS analysis 
 
First of all, we decided to treated the wt3 K562 clone to be used as a control of 
the geneticin activity, because it did not express β039-globin mRNA but only βwt 
transcripts at high level which should not be affected by the aminoglycoside 
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action. We considered this experiment as a further control, besides that performed 
using original K562, just because the wt3 K562 cells present a high number of 
βwt-globin genes and so a potential enhancing effect of the G418 on gene 
expression can be point out more easily. 
The FACS analysis of these cells led to further steps in the calibration of the 
instrument, because they express two different fluorescences (GFP and PE), which 
have different wavelengths of emission and, for this reason, are recognized by two 
different photomultipliers. It may, however, happen that a negligible radiation of 
the wrong colour arrives to a sensor, because of the optical filters and amplitude of 
the fluorochrome emission band. This problem can be rectified through the system 
of signal electronic correction called compensation: process that aims to subtract 
from a specific fluorescence channel a fixed signal relative to the emission of 
another fluorochrome [Brando, 1990].  
After configuring parameters as previously described using original K562, 
which can not emit any fluorescence, we compensated the green (FL1) and red 
fluorescence (FL2) channels, according to the fluorescence emitted by the 
unlabelled wt3 K562 cells (GFP) and erythroid progenitors labelled with βglobin-
PE MoAb, respectively. 
Figure 37 presents all the diagrams obtained in the FACS analysis of our 
samples: wt3 K562 clone cells untreated (a) and treated with 100 ng/µl (b), 200 
ng/µl (c) and 400 ng/µl G418 (d). Comparing FSC - SSC cytograms (I) we had the 
confirmation of the aminoglycoside action on the cell morphology, as in the 
sample treated with the greatest concentration (d) the resulting cloud of cells is 
moved up and enlarged. Analysing, however, the βglobin-PE - GFP cytograms 
(II) it is possible to observe that the cloud is almost in the same position, unless a 
slight shift up in the samples treated with the two greatest concentrations of G418 
(c and d). This trend is confirmed by histograms of red fluorescence (IV), where it 
is possible to note a minimal movement of the peak of wt3 K562 clone cells 
treated with 200 ng/µl and 400 ng/µl G418 compared to untreated cells. To 
facilitate the visualization of the peaks shift, we set up an unique histogram for the 
red fluorescence with the peaks of all samples (figure 37e). In addition, through 
the analysis carried out by the instrument, we could obtain precise data on both the 
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were, then, overlayed in a unique histogram (e). 
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proportion of red fluorescent cells and fluorescence intensity. These data are 
summarised in the histogram in figure 38: as expected, the untreated wt3 K562 
clone cells presented a high proportion of red fluorescent cells, corresponding to 
the proportion of β-globin containing cells, and a quite high median of the 
fluorescence. Such parameters did not vary significantly in the treated samples, 
confirming the data previously obtained with original K562 cells. 
At this point, we were ready to verify the translational read-through effects of 
G418 on m5 β039-globin K562 cell clone. Figure 39 presents all the diagrams 
obtained by FACS analysis of our samples: m5 K562 clone cells untreated (a) and 
treated with 100 ng/µl (b), 200 ng/µl (c) and 400 ng/µl G418 (d). Comparing FSC 
- SSC cytograms (I) we had a further confirmation of the aminoglycoside action 
on the cell morphology, as in the sample treated with the greatest concentration (d) 
the cloud of cells is, also in this case, moved up and enlarged and moreover it is 
possible to note the presence of a greater amount of dead cells. Instead, the 
βglobin-PE - GFP cytograms (II) show a marked shift in the cloud of cells beyond 
the threshold set for the red fluorescence, proportionally to the concentration of 
G418 added to the cells. This trend is confirmed by the histograms of red 
fluorescence (IV), where it is possible to note a gradual movement of the peak of 
cells beyond the fluorescence threshold of 101, whereas peaks in the GFP 
fluorescence histograms remain invariable. To facilitate the visualization of such 
shift and its dependence on the concentration of G418, we set up an unique 
histogram for the red fluorescence with the overlay of the samples peaks (figure 
39e). The data on both the proportion of red fluorescent cells and intensity of 
fluorescence shown in figure 40 represent the averages of three independent 
determinations: as expected, the untreated m5 β039-globin K562 cell clone 
presented very small proportion of red fluorescent cells and fluorescence median. 
However, such parameters increased in m5 clone cells treated with G418, 
proportionally to the increase of the concentration, reaching a maximum (about 
50%) in the case of cells treated with 400 ng/µl G418.  
Taking into account that the red fluorescence corresponds to the presence of β-
globin chains inside the cells, we could affirm that the aminoglycoside geneticin 
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was able to induce a translational read-through of the β039 nonsense mutation, 
determining an increase in the production of β-globin. 
 
Immunohistochemistry analysis 
 
In parallel with the FACS analysis, the same cells were fixed on a slide and 
then analyzed using a fluorescence microscope to visually assess the emission of 
red fluorescence. Figure 41 shows the images of the original K562 (a,b) and 
erythroid precursor (c,d) cells, respectively the negative and positive control of the 
immunohistochemistry assay, the wt3 βwt-globin K562  cell clone untreated (e,f) 
and treated (g,h) with 400 ng/µl G418 and the m5 β039-globin K562 cell clone 
untreated (i,l) and treated (m,n) with the same concentration of the 
aminoglycoside. From these images, it appears immediately obvious that the 
addition of geneticin determined no increase in the red fluorescence emitted by the 
treated wt3 clone but clear increment in the red fluorescence emitted by the treated 
m5 clone, indicating an increase in the β-globin containing cells. This result can be 
consider a validation of what previously observed by FACS analysis.  
Although the fluorescence microscope is a method much less sensitive than the 
flow cytometer, it was, however, possible to confirm the presence of β-globin 
chains in β039-globin K562 cells treated with G418, explaining at these levels only 
through a corrective action by the aminoglycoside on the translation of the β039 
transcript. 
 
Evaluation of the effects of geneticin on the content of β-globin mRNA in 
wt3 βwt-globin and m5 β039-globin K562 cell clones  
 
Once proved the effects of geneticin as translational corrector of the β039 
nonsense mutation, we wondered if the treatment with G418 prevents or, at least, 
limits the decrease in β039-globin mRNA abundance attributable to NMD, as 
already reported in several papers [Bedwell et al, 1997; Holbrook et al, 2004]. In 
fact, aminoglicosides, binding the decoding centre of the ribosome and decreasing 
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the accuracy requirements for codon-anticodon pairing, suppress stop codons and, 
instead of chain termination, an amino acid is incorporated into the polypeptide 
chain. Thus, transcripts containing PTCs are not recognized by the NMD 
machinery.  
In this respect, we performed a quantitative real time RT-PCR assay on the 
RNA isolated from logarithmically growing wt3 and m5 K562 clones cells, 
untreated and treated with scalar concentrations of G418 (100 ng/µl, 200 ng/µl and 
400 ng/µl). The reactions were performed as previously explained, using the 
Genotyping Kit so as to discriminate between the two β-globin transcripts (table 
2), especially in the case of the m5 β039-globin K562 cell clone, and the GAPDH 
kit to normalize the data. The quantification of the β-globin gene expression in the 
treated samples was carried out relatively to the untreated sample, used as 
standard, and so the β-globin mRNA content in treated cells was determined as a 
fold respect to control cells (standard).  
The obtained data are presented in figure 42 as averages ± SD of three 
independent determinations. It is easy to note that the treatment with G418 
determined no significant increase in the β-globin mRNA content in wt3 clone 
cells, also at the greatest concentration, but a clear increment in the β-globin 
mRNA content in m5 clone cells, proportionally to the increased concentration of 
the aminoglycoside. Such result confirms that geneticin is able to partially rescue 
the nonsense β039 transcripts, leading to a production of full length proteins.  
 
Evaluation of the effects of geneticin on the protein expression in m5 β039-
globin K562 cell clone 
 
Since Manuvakhova et al [2000] demonstrated that the sequence context 
beyond the termination codon can influence the level of read-through induced by 
several aminoglycosides and other translation factors present in the complete 
translation system may also influence the overall efficiency of translation 
termination, we decided to evaluate if geneticin can affect the recognition by the 
ribosome of premature as well as normal stop codons, resulting in a substantial 
alteration of the protein expression. 
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In this regard, some colleagues performed two-dimensional gel electrophoreses 
using cytoplasmic extracts from m5 β039-globin K562 clone cells untreated and 
treated with 400 ng/µl G418. Proteins in the extracts were separated first by their 
isoelectric point using 7 cm long pH 3 – 10 immobilized linear pH gradient strips 
and then according to the molecular weight on acrylamide gels, which were finally 
stained with Bio-Safe Coomassie Stain (Bio-Rad, Hercules, CA, USA). For each 
sample four different gels were carried out in order to confirm that any changes 
were real and not due to variables in a single electrophoresis. In figure 43 are 
shown two representative gels obtained with extracts from m5 K562 clone cells 
untreated (a) and treated with 400 ng/µl G418 (b), where it is possible to note that 
only 5 out of 350 spots significantly increased or decreased their intensity 
following treatment with geneticin. Two of these spots are reported in figure 43 (c 
and d). These preliminary results allow us to say that treatment with G418 
negligibly affect protein expression in our m5 K562 clone.  
 
GENTAMICIN 
 
Since geneticin is poorly used in clinical trials because of its high toxicity, we 
decided to verify if gentamicin, which shows a clear read-though activity [Barton-
Davis et al, 1999; Keeling et al, 2001; Du et al, 2002; Wilshanski et al, 2003; 
Howard et al, 2004] and lower toxicity, allowed a significant translational read-
through of the β039-globin mRNA in our cellular model. 
 
Evaluation of the toxicity of gentamicin 
 
Of course, as with geneticin, we first checked the cellular toxicity and growth 
inhibition effects of gentamicin on our model, so as to identify a range of 
concentrations to be used without seriously damaging the cells. Since we 
previously determined that there were not significant differences in treatment 
 
 
 
 188 
 
 
 
 
 
 
150
75
50
37
25
20
100
Isoelectric point
+ -
M
o
le
cu
la
r
W
ei
gh
t(
kD
a)
a) c) (-) G418
150
75
50
37
25
20
100
Isoelectric point
+ -
M
o
le
cu
la
r
W
ei
gh
t(
kD
a)
b) d) (-) G418
m5 β039-globin K562 clone treated with G418
m5 β039-globin K562 clone untreated
Figure 43 – Proteomic analysis of m5 β039-globin K562 cell clone treated with genetic (G418). Two-
dimensional electrophoresis of the cytoplasmatic extracts of m5 β039-globin K562 cell clone untreated (a) and 
treated with 400 ng/µl G418 (b) stained with Bio-Safe Coomassie Stain. Examples of a decreased (c) and 
increased spot (d) after the treatment, identified through the analysis of four different gels. For the assay a 7 cm 
long pH 3 – 10 immobilized linear pH gradient strips were used.
M
o
le
cu
la
r
W
ei
gh
t(
kD
a)
M
o
le
cu
la
r
W
ei
gh
t(
kD
a)
M
o
le
cu
la
r
W
ei
gh
t(
kD
a)
M
o
le
cu
la
r
W
ei
gh
t(
kD
a)
 189 
response between wt3 and m5 K562 clones, we decided to perform a curve of 
growth inhibition using only m5 β039-globin K562 clone cells, which were plated 
and treated as previously described, but using scalar concentrations of gentamicin 
from 0 to 2 µg/µl. 
The obtained data are summarized in the graph on figure 44, where it easy to 
note that the resulting curve is linear with a minimum slope and so we could not 
identify a gentamicin concentration determining 50% cell growth inhibition 
(IC50). At this point, since gentamicin showed very low toxicity effects on cell 
growth, we decided to carry out the treatment using concentrations already used 
by other investigators [Pinotti et al, 2006]: 600 ng/µl, 800 ng/µl, 1 µg/µl, 1.2 µg/µl 
and 1.4 µg/µl. 
 
Evaluation of the effects of gentamicin on β-globin production in original 
K562, wt3 βwt-globin and m5 β039-globin K562 cell clones  
 
Having regards to the greater sensitivity shown by FACS compared to 
immunohistochemistry, we decided to only use the flow cytometer to determine 
the effects on β-globin chain production after treatment with the aminoglycoside.  
As done with geneticin, also in this case, we first treated the control cells with 
gentamicin, so as to determine if this compound had enhancing effects on gene 
expression. Original K562 cells were treated with the two greatest concentrations 
(1.2 µg/µl and 1.4 µg/µl) of gentamicin while the wt3 βwt-globin K562 clone cells 
were treated with all the decided concentrations of the aminoglycoside (600 ng/µl, 
800 ng/µl, 1 µg/µl, 1.2 µg/µl and 1.4 µg/µl). These cells were plated, treated for 72 
hours, labelled with βglobin-PE MoAb and analysed by FACS as previously 
described. In figure 45 are summarized the data regarding the proportion of red-
fluorescent cells and fluorescence medians obtained analysing the original K562 
(a) and wt3 clone (b) cells untreated and treated with gentamicin. No significant 
differences are demonstrated between untreated and treated original K562 cells, 
meaning that gentamicin is not able to induce gene expression, in these cells. 
Whereas in the case of the wt3 K562 cell clone, it is possible to note that the 
proportion of red-fluorescent cells varies independently from the gentamicin 
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concentration, which lead us to believe that the increased presence of β-globin 
containing cells in same treated samples should not depend on a possible induction 
effect on gene expression of the compound. This conclusion is confirmed by the 
fact that the median of the fluorescence emitted by the clone cells do not vary 
significantly after treatment with gentamicin. 
At this point, we treated the m5 β039-globin K562 clone cells with scalar 
concentrations of gentamicin (600 ng/µl, 800 ng/µl, 1 µg/µl, 1.2 µg/µl and 1.4 
µg/µl) with the aim to verify a possible translational correction effect of this 
aminoglycoside on the nonsense β039 mutation. The cells were plated, treated, 
labelled with βglobin-PE MoAb and analysed by FACS as formerly explained. 
The data shown in figure 45c are the averages ± SD of three independent 
determinations and indicate a clear increase in the proportion of red-fluorescent 
cells and fluorescence intensity after treatment with gentamicin, proportionally to 
the concentration increase. As expected, this increment shown to be much smaller 
than that obtained after treatment with G418. So, we can confirm that geneticin is 
a stronger translational read-through inducer respect to gentamicin. 
 
OTHER AMINOGLYCOSIDES 
 
Given the existence of other types of aminoglycosides, different from those 
previously analyzed, we decided to test the translational corrective action of some 
of them on our β039-thalassemia cellular model. We analysed the effects on the β-
globin chains production of seven  aminoglycosides (neomycin, paromomycin, 
kanamycin, amikacin, streptomycin, tobramycin, higromycin), which showed 
almost no corrective activity. Only three of them (amikacin, streptomycin and 
tobramycin) are reported as examples.  
 
Evaluation of the toxicity of amikacin, streptomycin and tobramycin 
 
As done with gentamicin, we carried out an inhibition curve for each 
aminoglycoside to check their toxicity and inhibition effects on cellular growth 
and find their IC50, using the m5 β039-globin K562 cell clone. The cells were 
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plated as previously described, incubated with scalar concentrations of 
aminoglycoside, from 0 to 1.2 µg/µl, and counted after 3 days. The data obtained 
by the treatment with amikacin, streptomicyn and tobramycin are summarized in 
the graphs in figure 46, where it easy to note that the treatment with the three 
aminoglycosides (amikacin (a), streptomycin (b) and tobramycin (c)), did not 
induce any inhibition in cell growth. For this reason, we decided to use these 
compounds at the following concentrations (similar to gentamicin): 800 ng/µl, 1 
µg/µl and 1.2 µg/µl. 
 
Evaluation of the effects of amikacin, streptomycin and tobramycin on β-
globin production in original K562, wt3 βwt-globin and m5 β039-globin K562 
cell clones  
 
Original K562, wt3 βwt-globin and m5 β039-globin K562 clones cells were 
plated, incubated for 3 days with scalar concentrations of amikacin, streptomycin 
and tobramycin (800 ng/µl, 1 µg/µl and 1.2 µg/µl), labelled with βglobin-PE 
MoAb and analysed by FACS as formerly explained. The maximum effects 
obtained after the treatment of the m5 clone cells with these aminoglycosides are 
summarized in figure 47a, where are reported the proportion of red-fluorescent 
cells and fluorescence medians of the m5 clone cells untreated and treated with 1 
µg/µl amikacin, 800 ng/µl streptomycin and 800 ng/µl tobramycin, the most 
effective concentrations. These results show that amikacin and tobramicin could 
not induce any significant increase in the proportion of β-globin containing cells, 
whereas streptomycin determined a slight augment of red-fluorescent cells, 
demonstrating a weak translational read-through activity. In the table of figure 
47b are compared the proportions of β-globin containing cells, determined by 
FACS analysis, of the original K562, wt3 βwt-globin and m5 β039-globin K562 
clones cells untreated and treated with geneticin, gentamicin, amikacin, 
streptomycin and tobramycin, at the most effective concentration. It is possible to 
note that the treatment with each aminoglycoside had no effect on the proportion 
of β-globin containing cells in control cells (original K562 and wt3 clone) whereas 
some of them, geneticin in particular, induced a clear increase in the production of 
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Figure 46 – Inhibition effects of amikacin, streptomycin and tobramycin on m5 
β039-globin K562 cell clone. The cells were incubated for 72 hours at increasing
concentrations of amikacin (a), streptomycin (b) and tobramycin (c) and, then, counted
using the Bürker chamber. On the x-axis are reported the aminoglycoside
concentrations while on the y-axis the total cells counted.
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Figure 47 – Effects of aminoglycosides on the β-globin production in original K562, wt3 βwt-globin and m5 
β039-globin K562 cell clones. a) In the histogram are presented both the proportion of red-fluorescent cells (green 
boxes), corresponding to the proportion of β-globin containing cells, and the median of the emitted red
fluorescence (orange boxes) of the m5 β039-globin K562 cell clone, untreated or incubated for 3 days with 1 µg/µl 
amikacin, 800 ng/µl streptomycin and 800 ng/µl tobramycin. Cells were labelled with the βglobin-PE MoAb and 
analyzed by FACS. b) In the table are summarized the most significant FACS results obtained with the treatment 
of original K562, wt3 βwt-globin and m5 β039-globin K562 cell clones with geneticin (G418), gentamicin, 
amikacin, streptomycin and tobramycin. Results are presented as proportion of β-globin containing cells, detected
by FACS analysis. The data represent the averages ± SD of three indipendent determinations.
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β-globin chains in our β039-thalassemia cellular model. From these data, we could 
deduce that aminoglycosides are able to interact with the recognition of premature 
β
039 termination codon by the ribosome, leading to a production of full length 
proteins.  
 
ISOLATION OF ERYTHROID PRECURSOR CELLS FROM β039-
THALASSEMIA PATIENTS 
 
Once determined the ability of some aminoglycosides to rescue β039-globin 
transcrips from NMD and induce a transcriptional read-through of the premature 
termination codon with the subsequent production of full length β-globin chains in 
our β039-thalassemia model, we decided to test the read-though activity of the 
most active aminoglycoside studied (geneticin) on erythroid progenitors isolated 
from β039-thalassemia patients. For this reason, we had to identify some 
thalassemia patients carrying the β039 mutation in homozygous, sequencing their 
β-globin gene alleles.  
 
Genotype characterization of β-thalassemia patients 
 
Following the sign of informed consent, a few ml of blood were collected from 
β
0
-thalassemia patients, so as to extract genomic DNA to be used for sequencing 
β-globin gene. The DNA extraction was performed using the QIAGEN Blood & 
Cell Culture DNA Mini Kit (QIAGEN), starting from 1 ml of whole blood. The 
genomic DNAs were used as templates for PCR reactions, performed using two 
primers designed by us upstream (BGF) and downstream (BGR) the β-globin gene 
(table 1) and purified with Microcon® YM-100 (Millipore Corporation). The PCR 
products were then utilised as templates for sequence reactions using primers 
amplifying the β-globin gene. The fragments obtained in such reactions were then 
purified by Multiscreen™ (Millipore Corporation), separated by electrophoresis 
on polyacrylamide gel and analysed using the sequencer ABI PRISM™ 377 DNA 
Sequencer (Perkin-Elmer Applied Biosystems). Table 1 lists all the primers used, 
which made it possible to sequence entirely the β-globin gene. In figure 48a are 
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GACTCAAAGAACCTCTAGGTCCAAGGGTAGA GACTCAAAGAACCTCTAGGTCCAAGGGTAGA
GACTCAAAGAACCTCTAGGTCCAAGGGTAGA
……agacc tcaccctgtg gagccacacc ctagggttgg ccaatctact cccaggagca
gggagggcag gagccagggc tgggcataaa agtcagggca gagccatcta ttgcttacat
ttgcttctga cacaactgtg ttcactagca acctcaaaca gacaccatgg tgcacctgac
tcctgaggag aagtctgccg ttactgccct gtggggcaag gtgaacgtgg atgaagttgg
tggtgaggcc ctgggcaggt tggtatcaag gttacaagac aggtttaagg agaccaatag
aaactgggca tgtggagaca gagaagactc ttgggtttct gataggcact gactctctct
gcctattggt ctattttccc acccttaggc tgctggtggt ctacccttgg accTagaggt
tctttgagtc ctttggggat ctgtccactc ctgatgctgt tatgggcaac cctaaggtga
aggctcatgg caagaaagtg ctcggtgcct ttagtgatgg cctggctcac ctggacaacc
tcaagggcac ctttgccaca ctgagtgagc tgcactgtga caagctgcac gtggatcctg
agaact…… Blue: exons
T: β039 mutation
Reverse primer BGR1
Patient PS Patient CO
Patient FB
Figure 48 – Sequencing of the second exon of the β-globin gene of β039 thalassemia patients. a) Sequence of the 
region of β039-globin gene corresponding to 1st and 2nd exons. Box highlights the sequence of the reverse primer
used for the sequencing. b) Elettropherograms, obtained by the sequencing performed using the reverse primer BGR1, 
of the region containing the β039 (C→T) mutation, highlighted by the circle, of four β039-thalassemia patients.
a)
b)
GACTCAAAGAACCTCTAGGTCCAAGGGTAGA
Patient BA
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shown the nucleotide sequence of the first and second exons of the β-globin gene 
and the primer used to detect the presence of the β039 mutation, which was found 
as unique point mutation in 4 patients. The obtained chromatograms of the region 
containing the mutation are reported in figure 48b. It is possible to note a single 
peak in correspondence to the first base of codon 39, indicating either 
homozygosity for the β039 mutation or heterozygosity for that mutation and a β-
globin gene deletion. The homozygosity for the nonsense mutation was confirmed 
by Dr. Nicoletta Bianchi which performed a quantitative real time PCR to evaluate 
the number of β-globin genes present into the cells.  
 
Isolation and culture of erythroid precursor cells of β039-thalassemia 
patients 
 
To isolate erythroid progenitors from β039-thalassemia patients, 20 ml of blood 
were collected just before the blood transfusion, so as to limit the presence of 
healthy donor cells. The precursor cells were isolated by centrifugation for 
gradient density on Lympholyte-H and, after several washing, plated in phase I 
medium, consisting of α-MEM medium supplemented with 10% FCS, 10% 
conditioned medium (CM), obtained from cell cultures of bladder cancer (cells 
5637), rich in haematopoietic growth factors except the erythropoietin (EPO), and 
1 µg/ml cyclosporine A, which has the function to suppress lymphocyte activation 
and proliferation. In this phase the vast majority of cells are small lymphocytes 
and only a minute fraction of the cell population are various hemopoietic 
progenitors. After 7 days of phase I, medium was changed with the phase II 
medium, consisting of α-MEM supplemented with 30% FCS, 10% deionized 
BSA, 0.01 mM β-mercaptoethanol, 0.001 mM dexamethasone, 10 ng/ml Stem 
Cell Factor and 1 U/ml human erythropoietin (EPO), which stimulates the 
erythroid differentiation. Early in the phase II lymphocytes continue to present the 
most abundant cell type. Proerythroblasts begin to be discernible after a few days 
as large, round, smooth cells. As these cells multiply they form clusters. During 
the intermediate phase, lymphocytes gradually give way to an increasing 
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proportion of proerythroblasts and basophilic normoblasts, which when 
indisturbed form aggregates consisting of hundreds of cells. In late phase II, 
erythroid cells continue to proliferate and mature into polychromatic and 
orthochromatic Hb-containing normoblasts. Within the intermediate and late 
phases, the absolute number and proportion of small lymphocytes diminished 
significantly [Pope et al, 2000]. 
  
USE OF β039 ERYTHROID PROGENITORS TO CHARACTERIZE 
THE READ-THROUGH ACTIVITY OF AMINOGLYCOSIDES 
 
To verify the translational read-through activity of geneticin on erythroid 
progenitors isolated from β039-thalassemia patients, we decided to use the two 
greatest concentrations of G418 previously used with the cellular model (200 ng/µl 
and 400 ng/µl). The reason was that we could always have a limited amount of 
precursor cells so we could not waste them performing an inhibition curve. 
 
Evaluation of the effects of geneticin on β-globin production in β039 
erythroid precursor cells 
 
Erythroid progenitors, after 7 days of phase II, were collected, plated at 106 
cells/ml, treated with 200 ng/µl and 400 ng/µl G418 for 3 days, labelled with 
βglobin-PE MoAb and analysed by FACS as previously described for K562 
clones.  
In figure 49a are reported a representative FSC - SSC cytogram of untreated 
β
039 erythroid progenitors, which shows a heterogeneous population due to the 
variability of cells present in this type of cell cultures, as formerly explained. For 
this reason, we decided to create a gate so as to analyse only the majority of cells, 
with small size, constituted mostly of erythroid precursor cells. Always in figure 
49a are shown representative histograms of red fluorescence obtained by FACS 
analysis of β039 erythroid progenitors untreated (II) and treated with 200 ng/µl 
(III) and 400 ng/µl (IV) G418. In the histogram of untreated cells, it is possible to 
note that the majority of the cells constitute a peak below the fluorescence
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β039 erythroid progenitors
Figure  49 – Effects of increasing concentrations of geneticin (G418) on the β-globin
production in β039 erythroid precursor cells. a) Representative FACS analysis of β039 erythroid
progenitors treated with scalar concentrations (200 ng/µl and 400 ng/µl) and labelled with βglobin-
PE MoAb. In panel (a) are reported: diagram of cells distribution based on the morphological
parameters FSC and SSC (I); histograms relating the emitted fluorescence to the number of emitting
cells of untreated (II) and treated (III, 200 ng/µl; IV, 400 ng/µl) cells. b) Overlay of the peaks
obtained in the three histograms. c) Graph summarizing the proportion of red-fluorescent cells, 
corresponding to the proportion of β-globin containing cells, of β039 erythroid progenitors
untreated and with scalar concentrations of G418. The data represent the averages ± SD of three
indipendent determinations. 
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 threshold of 101, indicating that they are not red-fluorescent cells, whereas a small 
proportion of cells are slightly shift beyond that threshold, probably due to the 
presence of contaminating red blood cells in the culture. Comparing all the 
histograms of red fluorescence demonstrated, after treatment with geneticin, a 
clear shift of the peak of negative cells beyond the threshold of 101, indicating an 
increase in β-globin chains. To facilitate the visualization of this shift, we set up an 
unique histogram for the red fluorescence with overlay of all the peaks (figure 
49b). Moreover, in figure 49c is reported a graph summarizing the proportion of 
red-fluorescent cells, corresponding to β-globin containing cells, obtained in three 
independent treatments of β039 erythroid progenitors with scalar concentrations of 
G418. Such proportion increased significantly and dependently to the geneticin 
concentration and could confirm the ability of such aminoglycoside to induce 
translational read-through of β039 nonsense mutation, determining a production of 
β-globin chains. 
 
Evaluation of the effects of geneticin on adult haemoglobin (HbA) 
production in β039 erythroid precursor cells 
 
As aminoglycosides could induce incorporation of a correct as well wrong 
amino acid at a premature termination codon, producing a full length protein, it 
could be that such protein is not functional, if the incorporated amino acid 
produces structural changes. 
To verify if β-globin chains produced by β039 erythroid precursor cells treated 
with G418 were functional and able to generate HbA, we decided to perform a 
HPLC analysis, which can give us information about the proportion of HbA 
respect to the total Hbs content. β039 erythroid progenitors were therefore plated 
and treated with 200 ng/µl and 400 ng/µl G418, as previously described. After 3 
days, they were collected, washed and lysated by  incubation for 15 minutes in 
water at 4°C. The nuclei and membranes were collected in the bottom of a tube by 
centrifugation and the supernatant, containing Hbs, was loaded on the cation – 
exchange column Syncropack CCM 103/25. In figure 50a are shown 
representative chromatograms obtained by HPLC analysis of β039 erythroid 
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I II
Figure  50 – Effects of increasing concentrations of geneticin (G418) on the HbA production in β039 erythroid
precursor cells. a) Representative chromatograms obtained by HPLC analysis of β039 erythroid progenitors, 
untreated (I) or treated with 400 ng/µl G418 (II). b) Histogram summarizing the proportion of fetal haemoglobin
(HbF), adult haemoglobin (HbA) and type 2 adult haemoglobin (HbA2) respect to the total Hbs content of the β039 
erythroid cells treated with scalar concentrations of G418 (200 ng/µl and 400 ng/µl). The data represent the averages
± SD of three indipendent determinations. 
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progenitors untreated (I) and treated with 400 ng/µl G418 (II). Such histograms 
show a clear increase of the area percentage of the peak corresponding to HbA 
after treatment with the aminoglycoside, indicating an increase in the proportion of 
HbA respect to the total Hbs content and so a production of β-globin chains, able 
to generate normal HbA. This result was confirmed in three independent 
experiments, whose data are presented in figure 50b, where it is possible to note a 
clear increase in HbA proportion and a corresponding decrease in the proportion 
of HbF and HbA2.  
 
Evaluation of the effects of geneticin on the content of β-globin mRNA in 
β
039 erythroid precursor cells  
 
As done with m5 β039-globin K562 cell clone, we demonstrated the capacity 
of G418 to rescue the PTC containing transcripts from the degradation by NMD 
pathway, performing a quantitative real time RT-PCR assay on the RNA isolated 
from β039 erythroid progenitors, untreated and treated with 200 ng/µl and 400 
ng/µl G418. The reactions were performed as previously described, using primers 
amplifying β-globin and GAPDH mRNA sequences (table 2). The quantification 
of the β-globin gene expression in the treated samples was carried out relatively to 
the untreated sample, used as standard, and so the β-globin mRNA content in 
treated cells was determined as a fold respect to control cells (standard). In this 
case, we decided to use the PFβ and PRβ primers and Pβ probe lists in table 2, 
because we did not need to discriminate between βwt and β039 transcripts as β039 
erythroid progenitors only produce mutated β-globin mRNA.  
The obtained data are presented in figure 51 as averages ± SD of three 
independent determinations and show a strong increment in the β-globin mRNA 
content, proportionally to the increase of the aminoglycoside concentration. Such 
result confirms that geneticin is able to partially rescue the nonsense β039 
transcripts, leading to a production of full length proteins.  
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Figure 51 – Effects of increasing concentrations of geneticin (G418) on the content of
β-globin mRNA in β039 erythroid precursor cells. The histogram shows the β-globin
content in β039 erythroid progenitors, untreated or incubated for 3 days with increasing
concentrations (200 ng/µl and 400 ng/µl) of G418. The fold of mRNA content of treated
respect to untreated cells was determined by quantitative real time RT-PCR using primers
amplifying GAPDH and β-globin mRNA sequences. 
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USE OF pCCL.βwt.PGW LENTIVIRAL VECTOR FOR GENE 
THERAPY OF β0-THALASSEMIA 
 
At present, there are two approaches to directly overcome disease caused by 
nonsense mutations: translational read-through induced by aminoglycosides, 
already widely characterized in this work, and gene therapy, which, by introducing 
an exogenous gene into diseased cells, could establish the production of the 
protein of interest, permanently correcting the disease. On the contrary of read-
through approach which requires life-long administrations, gene therapy could be 
a definitive cure for a recessive disease, as those caused by nonsense mutations. 
Unfortunately, many problems remained to be solved, as gene silencing and 
activation of oncogenes.  
With the aim to verify the possible use of our lentiviral vector for gene therapy 
and compare the results with those obtained with aminoglycosides treatment, we 
decided to transduced erythroid progenitors isolated from homozygous β039-
thalassemia patients with pCCL.βwt.PGW. Such vector, as already described, 
presents some important characteristics which make the integration of the 
transgene into the genome safe and efficient, minimizing the effects of the 
surrounding chromatin, which could silence its expression, and the enhancing 
effects of the promoters contained into the vector on oncogenes. The absence of 
gene silencing was demonstrated in our βwt-globin K562 cell clones, cultured for 
more than 3 months without a significant reduction in the expression of GFP and 
β-globin chains. 
Moreover, we decided to test the combined effects of gene therapy with the 
lentiviral vector and fetal haemoglobin induction by treatment with mithramycin, a 
potent HbF inducer [Bianchi et al, 1999; Fibach et al, 2003], to verify if the 
concomitant increases in HbA and HbF could lead to a haemoglobin content 
similar to that of a heterozygous subject.  
Erythroid precursor cells were isolated from β039-thalassemia patients and 
cultured in two-phase liquid cultures as previously described. At the 7th day of 
phase II the cells were transduced with pCCL.βwt.PGW. The progenitors were 
incubated with the volume of lentiviral particles corresponding to a MOI equal to 
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0.3 and the transduction agent polybrene, for 6 hours at 37°C in humidified 
atmosphere of 5% CO2/air, mixing well every 30 minutes, and then plated at 106 
cells/ml. We decided to use a very low MOI so as to obtain a single infection for 
each cell, limiting the introduction of exogenous sequences and mimicking the 
physiological situation. In some experiments the cells were also treated with 30 
nM mithramycin to induce fetal haemoglobin production. We chose to use this 
concentration of mithramycin, because it demonstrated to be effective to induce γ-
globin expression [Bianchi et al, 1999]. 
After 5 days the cells were collected and divided in aliquots to be used for: 1) 
analysis of vector integration by quantitative real time PCR; 2) analysis of the α-, 
β- and γ-globin expression by quantitative real time RT-PCR; 3) analysis of HbA 
and HbF by HPLC assay. 
 
Analysis of integration of pCCL.βwt.PGW vector in transduced β039 
erythroid precursor cells 
 
The evaluation of integration of pCCL.βwt.PGW vector in transduced β039 
erythroid progenitors permitted us to compare the increases in β-globin mRNA 
and HbA content with the number of β-globin transgenes integrated into the 
cellular genome. 
In this respect, we extracted and used the genomic DNA as template for real 
time PCR reactions as formerly explained. Such reactions were performed using 
PFβ and PRβ primers and Pβ probe, UBC and C21orf104 kits for allelic 
quantification (Applied Biosystems) amplifying β-globin, UBC and C21orf104 
DNA sequences respectively, the latter two used as reference genes. The choice of 
the suitable gene for the normalization of PCR analysis in each experiment was 
based on the slope of the standard curves, namely we chose the gene whose slope 
was the most similar to the β-globin one. Of course, the DNA extracted from 
untreated cells was used as standard.  
In figure 52a are presented the fold of β-globin transgenes integrated into the 
genomic DNA of erythroid progenitors isolated from three different β039-
thalassemia patients and  transduced with pCCL.βwt.PGW vector (MOI: 0.3) or 
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Figure 52 – Analysis of integration of the pCCL.βwt.PGW vector in erythroid progenitors from β039-
thalassemia patients. a) On the histogram are reported the fold of β-globin transgenes integrated into the genomic
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transduced with the lentiviral vector and treated with 30 nM mithramycin. As it is 
notable from the histogram, with a MOI equal to 0.3 we obtained at most a 2 time 
increase in the content of β-globin genes. In figure 52 are also shown two 
representative profiles of quantitative real time PCR analysis performed on DNA 
extracted from erythroid progenitors isolated from patient CO, untreated (b) and 
transduced with pCCL.βwt.PGW vector (c), using primers amplifying C21orf104 
and β-globin DNA sequences.  
 
Analysis of the α-, β- and γ-globin mRNA content in transduced β039 
erythroid precursor cells, treated or not with mythramycin 
 
In β-thalassemia, the synthesis of normal α-globin chains from the unaffected 
α-globin genes continues as normal, resulting in the accumulation within the 
erythroid precursors of excess unmatched α-globin. The free α-globin chains are 
not able to form viable tetramers and instead precipitate in red cell precursors in 
the bone marrow forming inclusion bodies. They are responsible for the extensive 
intramedullary destruction of the erythroid precursors and hence the ineffective 
erythropoiesis that underlies all β-thalassemias [Thein, 2005]. For this reason, it is  
very important, for an effective therapy, that the increase in β-like globin genes 
expression does not coincide with an increase in α-globin genes expression, so as 
to reduce the precipitation of the α-globin chains, ameliorating the viability of red 
blood cells.  
In this respect, we decided to evaluate the expression of α-, β- and γ-globin 
genes, the last one mainly because of the treatment with mithramycin, a potent 
HbF inducer, by quantitative real time RT-PCR. The RNA was extracted, reverse 
transcribed using both oligodT and random primers and used as template for real 
time PCR reactions as previously described. Table 2 lists all the primers and 
probes used: PFα, PRα and Pα, PFβ, PRβ and Pβ, PFγ, PRγ and Pγ for the 
amplification and quantification of α-, β- and γ-globin mRNA, respectively. All 
the probes were labelled with the fluorochrome FAM. As reference genes we used 
GAPDH or r18S, choosing the suitable one for each experiment depending on the 
slope of  standard curves.  
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In figure 53 is presented a histogram showing the α-, β- and γ-globin mRNA 
content, expressed as fold in respect to control cells (untreated β039 erythroid 
precursor cells), in β039 erythroid progenitors transduced with pCCL.βwt.PGW or 
trasduced with the vector and treated with 30 nM mithramycin. The data represent 
the averages ± SD of three independent determinations. From these results, it is 
possible to note that the expression of α-globin gene did not change significantly 
among the three samples, while the content of β-globin mRNA increased strongly 
in the progenitors transduced with the lentiviral vector, diminishing after treatment 
with mithramycin, which instead induced a significant increase in the expression 
of γ-globin genes. In figure 54 are shown representative profiles of quantitative 
real time RT-PCR analysis performed on RNA extracted from erythroid precursor 
cells isolated from β039-thalassemia patient CO, untreated and transduced with 
pCCL.βwt.PGW (a) or transduced with the lentiviral vector and treated with 30 
nM mithramycin (b), using primers amplifying r18S, α-, β- and γ-globin mRNA 
sequences. 
 
Analysis of HbA and HbF content in transduced β039 erythroid precursor 
cells, treated or not with mithramycin 
 
The β039 progenitors were collected, washed and lysated as formerly explained 
and the supernatant was loaded on the cation – exchange column Syncropack 
CCM 103/25, to perform a HPLC analysis. In figure 55 are presented 
chromatograms obtained by HPLC analysis of erythroid precursor cells isolated 
from CO (a) and BA (b) β039-thalassemia patients untreated and transduced with 
pCCL.β039.PGW or tranduced with the vector and treated with 30 nM 
mithramycin. In the case of patient CO (figure 55a), it is possible to note a strong 
increase in the area percentage of the HbA peak in the cells transduced with the 
lentiviral vector, diminishing after treatment with mithramycin, which however 
induced a slight increase in the HbF content. On the contrary, in the case of patient 
BA (figure 55b), there were a significant increase in the area percentage of the 
HbA peak following transduction with pCCL.β039.PGW, which did not decrease 
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after treatment with mithramycin, and a strong increase of the proportion of HbF 
after treatment with the HbF inducer.  
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DISCUSSION 
 
 
The β-thalassemia is an autosomal recessive disease characterized by a reduced 
or absent synthesis of β-globin chains, caused by the presence of mutations within 
or near the β-globin gene. Among these is the C → T substitution at the first base 
of codon 39 in the second exon of the gene. Such mutation, known as β039, 
belongs to the nonsense mutations, which lead to the formation of stop codons, 
causing the premature termination of translation. The β-thalassemia caused by the 
presence in homozygosity of this mutation shows a very serious phenotype, 
because the synthesis of β-globin chains is totally absent. 
Actually, there are two approaches to directly overcome diseases caused by 
nonsense mutations: gene therapy, meaning introduction of an exogenous gene 
into diseased cells, and translational read-through induced by aminoglycosides, 
which decrease the accuracy of translational elongation and reduce the efficacy of 
the translation termination machinery. With the aim to study and verify the effects 
and clinical utility of such approaches, we decided to develop lentiviral vectors 
containing the βwt- or β039-globin gene, to be used the first in gene therapy and 
both to produce cellular models, suitable for studying aminoglycosides activity ex 
vivo.  
In this work, we therefore produced two ex vivo cellular models expressing 
βwt- or β039-globin mRNA and used them to characterized the read-through 
activity of aminoglycosides. Once verified such activity in our cellular models, we 
decided to use aminoglycosides to treat erythroid precursor cells isolated from 
β
039-thalassemia patients, which were also used to study the effects of the 
introduction of exogenous βwt-globin genes, through transduction with the 
lentiviral vector. 
The proposed experimental strategy included the use of a third generation 
lentiviral vector, which ensures the integration of the β-globin gene in the cellular 
genome and its expression in a stable way over time. To insert the β039-globin 
gene into this vector, we carried out a series of cloning, starting from a lentiviral 
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vector lacking of some important sequences for the stable expression of the 
transgene (dTNS9) [Sadelain, 2002], where we introduced the β039-globin gene, 
taken from an expression plasmid (pSL1180DT+β039), achieved through site-
directed mutagenesis. This gene with its promoter was finally transferred into the 
final construction, obtaining the pCCL.β039.PGW vector, which contains a 
reduced version of the β cluster control region LCR, which allows efficient 
expression of the gene. Similarly, we introduced the βwt-globin gene, taken from 
the original dTNS9 vector, into the third generation lentiviral vector, obtaining the 
pCCL.βwt.PGW.  
The insert, present in both the viral vectors, was then sequenced with the 
purposes to check and determine the presence of the β039 mutation in the 
pCCL.β039.PGW vector, verify that the ends of the insert were intact and ensure 
the absence of any other type of mutation in both the pCCL.βwt.PGW and 
pCCL.β039.PGW vectors. The results of sequencing clearly revealed the absence 
of anomalies in the nucleotide sequence, except the expected β039 mutation in 
pCCL.β039.PGW. 
Once obtained the lentiviral vectors, as being used as infecting agents, they 
were incapsidated into viral particles using 293T packaging cell line. These cells 
were transfected with the pCCL.βwt.PGW or pCCL.β039.PGW lentiviral vector 
and three other constructs, called helper vectors, which provide structural and 
regulatory elements, not present in the lentiviral vector and necessary for its 
expression. The lentiviral vector integrates into the 293T cellular genome thanks 
to its two LTR (long terminal repeat) sequences. Then, through the transcriptional 
machinery of the cell, the viral mRNA is produced, and thanks to the proteins 
encoded by the three helper vectors, is transported from the nucleus to the 
cytoplasm and incapsidated. It is obtained, thus, a large amount of viral particles 
which must be titrated, to be used in the cell infection. 
The purpose of the titration is to determine the transducing power of a solution 
of viral particles, information essential for subsequent infections. For this reason, 
HeLa cells were transduced with scalar quantities of each virus and then subjected 
either to FACS analysis to determine the viral titre based on the GFP expression 
(GFP titre), whose gene is also contained in the vector, and to quantitative real 
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time PCR assay, to determine the titre based on the number of viral vectors 
integrated into the cellular genome (DNA titre). 
Once performed the FACS analysis, it was necessary to decide which sample 
was the most suitable for calculating the GFP titre. Since it is essential, for 
obtaining an accurate titre, that in the majority of the cells took place a single 
infection, our choice fell on the sample with the percentage of fluorescent cells 
that mostly approaches the 30%. This decision was based on the assumption that, 
when only 3 out of 10 cells are fluorescent, in all probability they were infected by 
a single virus, namely a transducing unit. The obtained viral titres were 3 x 105 
TU/ml (trasducing units/ml) and 1.8 x 105 TU/ml for the pCCL.βwt.PGW and 
pCCL.β039.PGW viral particles respectively, low viral titres compared to values 
found in the literature [Zhang et al, 2004]. 
In the quantitative real time PCR assay, the genomic DNA extracted from 
transduced Hela cells were amplified using probes for the β-globin and Aγ-globin 
genes, the latter used as reference gene. Analyzing the Ct, we were able to 
calculate, in infected cells, the fold of β-globin compared to Aγ-globin genes, a 
fundamental information to determine the DNA titre, which was 6 x 105 TU/ml 
and 4 x 105 TU/ml for the pCCL.βwt.PGW and pCCL.β039.PGW viral particles 
respectively. Such titres were obtained using data on the same samples selected for 
the GFP titres, so that we could make a more accurate comparison with them, 
previously calculated, because the titre of a lentiviral vector varies according to 
the conditions of the infective process: the volume of inoculum, the number of 
target cells, cell type and viability/susceptibility, vector exposure time for uptake 
and vector half life. Moreover, the proportion of phospholipids present in the cell 
membranes, whose biosynthesis and degradation are very much dependent on cell 
type and positions in the cell cycle and/or metabolic activity, can affect the success 
of an infection, because of their binding to the VSV-G protein. The variation of 
these parameters can result in a difference in the viral titre in different aliquots of 
the same viral stock, hence the viral titre is not a value that exactly indicates how 
many infectious units per ml were added to the cells [Zhang et al, 2004]. 
By comparing the GFP titres with the corresponding DNA titres, it is possible 
to note that the latter were two times the first, because of the limitations of the 
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flow cytometer, which include the fact that not always a transduced cell emits 
green fluorescence at levels that exceed the FACS threshold of detection and even 
assuming that with a percentage of fluorescent cells equal to 30%, in most cases, a 
single infection happens, this does not exclude the possibility of multiple 
infections. Such limits may cause an underestimation of the viral titre. Precisely 
for this reason we decided to use for subsequent infections the DNA titre, a choice 
recommended also in the literature, where the DNA titre has been confirmed more 
precise compared to the GFP titre [Sastry et al., 2002]. 
Once calculated the titre of the viral particles containing the pCCL.βwt.PGW or 
pCCL.β039.PGW vector, we transduced K562 cells, chosen for our models 
because they express the β-globin gene at very low levels both in their uninduced 
state as well as after erythroid differentiation stimulated by a variety of chemical 
inducers, such as cytosine arabinoside [Cortesi et al, 1999], mithramycin [Bianchi 
et al, 1999; Fibach et al, 2003], rapamycin [Mischiati et al, 2004; Fibach et al, 
2006]. To do this infection, we based on the MOI (multiplicity of infection), 
parameter decided arbitrarily by the researcher, used to predict the viral infectivity 
in a cell population and, therefore, to assume how many events of gene transfer 
can occur. Following the infection, we performed cell cloning by limiting dilution 
of the transduced K562, in order to obtain individual cell clones, so that the 
resulting cells of the colony possessed all the same genetic characteristics. The 
obtained clones, seven βwt-globin and six β039-globin K562 cell clones, identified 
using a fluorescence microscope, emit fluorescence at different intensities, 
depending on the number of vectors integrated into their genomes. 
We then analysed the integration and GFP fluorescence of the βwt-globin and 
β
039-globin K562 cell clones by quantitative real time PCR and FACS analysis 
respectively, obtaining a fold of β-globin transgenes, respect to the reference gene, 
and a median of the fluorescence intensity for each clone. The choice of γ-globin 
gene as reference gene was of great importance because the K562 cells, deriving 
from malignant cells, present most chromosomes in three or more copies [Gribble 
et al, 2000; Naumann et al, 2001] and thanks to the location of γ-globin gene close 
to the β-globin gene, the ratio between them in control K562 cells is, without 
doubt, equal to 1. Moreover, we chose the median as parameter of the fluorescence 
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intensity, instead of the arithmetic mean, because it is the value that corresponds to 
the middle item in a ranked list of all measurements and does not necessarily move 
in response to small numbers of outliers. The results obtained by these analysis 
show that the two parameters, fold of β-globin transgenes and median of 
fluorescence intensity, have similar trends, unless a few cases, indicating that the 
βwt-globin and β039-globin K562 cell clones contained from one to several copies 
of the vector and that the GFP expression is not dependent on the site of 
integration, due to the fact the GFP gene is under the control of the constitutive 
PGK promoter.  
At this point, it was very important to determine which kind of β-globin 
transcript was expressed by the K562 cell clones. For this reason, we performed a 
non-quantitative and a subsequent quantitative real time RT-PCR analysis using 
the RNA isolated from each clone and a Genotyping kit for the β039 mutation. 
This kit permits, through two probes specific for βwt-globin and β039-globin 
sequences, to determine the type of transcript expressed. The obtained data show 
that the βwt-globin K562 cell clones express only wild type β-globin transcripts 
whereas the β039-globin K562 cell clones produce two β-globin mRNA, wild type, 
due to the copies of the endogenous β-globin gene, and mutated, due to the 
transgenes. In addition, through the quantification of the β-globin gene expression, 
it was possible to determine that, despite the fact that no silencing effect was 
noted, no clear relationship was evident between levels of gene expression and 
number of integration units. This is however expected, since transcription might 
depend also on the site of integration. Moreover, in β039-globin K562 cell clones 
the accumulation of β-globin mRNA sequences is affected by the known effect of 
nonsense mediated mRNA decay (NMD), which can significantly reduce but not 
totally eliminate the nonsense β039 transcripts. In fact, NMD does not completely 
ablate expression of mRNAs containing PTCs, and residual expression levels vary 
considerably between transcripts, cell types and even individuals [Holbrook et al, 
2004; Stalder and Mühlemann, 2008]. After comparative analysis of the RT-PCR 
data, clones wt3 (βwt-globin K562 cells) and m5 (β039-globin K562 cells) were 
selected for the experiments employing possible corrections with 
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aminoglycosides, due to the fact that, among the βwt-globin and β039-globin K562 
cell clone sets, they express similar, although not identical levels of β-globin 
mRNA molecules. Interestingly, clone m5 displays higher β-globin gene 
integration units and GFP production in respect to clone wt3 suggesting, as 
expected, NMD affecting β039-globin mRNA, although in this case the large 
number of mutated transgenes present into the cells may induce the saturation of 
the process, leading to the accumulation of a significant amount of nonsense 
transcripts. 
The positive results obtained in the characterization of the βwt-globin and 
β
039-globin K562 cell clones allow us to validate the βwt-globin expressing and 
β
039-thalassemia ex vivo cellular models. 
 
The second part of our work has been focused on the treatment of our cellular 
models with several aminoglycosides to characterize their read-through activity. 
As known, the aminoglycosides more effective in the translational read-through, 
for the treatment of genetic diseases, are geneticin or G418 [Howard et al, 1996; 
Bedwell et al, 1997, Lai et al, 2004; Pinotti et al, 2006] and gentamicin [Barton-
Davis et al, 1999; Keeling et al, 2001; Du et al, 2002; Wilshanski et al, 2003; 
Howard et al, 2004]. Given the ready availability of geneticin, we decided to start 
precisely with that compound. 
First of all, we performed control experiments, with the purpose to verify if 
geneticin was able to induce an increase of β-globin chains, due to the induction of 
β-globin gene expression. So, we treated original K562 cells with 400 ng/µl G418 
and wt3 βwt-globin K562 clone cells with scalar concentrations (100 ng/µl, 200 
ng/µl and 400 ng/µl) of the compound, which were decided depending on the 
inhibition curves performed on wt3 and m5 K562 cell clones. The samples were 
labelled with the βglobin-PE MoAb and the effects of geneticin on the β-globin 
production were determined by both FACS and immunohistochemistry analysis. 
The FACS data showed a not significant increase in the proportion of β-globin 
containing cells after treatment with geneticin using both the control cell lines. 
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Increase that was not demonstrated by immunohistochemistry analysis, due to the 
lower sensitivity of such technique compared to the flow cytometer. 
Once determined that G418 has no effects on the β-globin gene expression, we 
treated the m5 β039-globin K562 cell clone with increasing concentration (100 
ng/µl, 200 ng/µl and 400 ng/µl) of geneticin, analysing the effects by FACS and 
immunohistochemistry. The FACS data showed, in this case, a strong increase in 
the proportion of β-globin containing cells, proportionally to the geneticin 
concentration, reaching a maximum in the samples treated with 400 ng/µl G418, 
also demonstrated by immunohistochemistry. Since in control experiments only 
negligible increase of the proportion of β-globin containing cells was detected, we 
could conclude that the clear increase obtained in the case of m5 β039-globin 
K562 cell clone was due to the translational correction of the mutated transcript by 
the aminoglycoside.  
Several papers reported that treatment with aminoglycosides prevents or, at 
least, limits the degradation of nonsense transcript through NMD, because these 
compound, binding the decoding centre of the ribosome and decreasing the 
accuracy requirements for codon-anticodon pairing, suppress stop codons and, 
instead of chain termination, an amino acid is incorporated into the polypeptide 
chain, preventing the recognition of PTC containing mRNA by the NMD 
machinery [Bedwell et al, 1997; Holbrook et al, 2004]. For this reason, we decided 
to evaluate the effects of geneticin on the content of β-globin mRNA in both wt3 
and m5 K562 cell clones, by quantitative real time RT-PCR, performed using the 
Genotyping kit, so as to discriminate between βwt- and β039-globin mRNA 
sequences. This discrimination was particularly important in the case of m5 β039-
globin K562 clone cells, because it permited us to quantify only the amount of the 
mutated transcripts. The obtained results showed that the treatment with geneticin 
determined no significant increase in the β-globin mRNA content in wt3 clone 
cells, also at the greatest concentration, but a clear increment in the β-globin 
mRNA content in m5 clone cells, proportionally to the increased concentration of 
the aminoglycoside. Such result confirms that geneticin, suppressing the β039 
premature stop codon, prevents the decrease in β039-globin mRNA abundance 
attributable to NMD, leading to the production of full length proteins.   
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Since Manuvakhova et al [2000] demonstrated that the sequence context 
beyond the termination codon can influence the level of read-through induced by 
several aminoglycosides and other translation factors present in the complete 
translation system may also influence the overall efficiency of translation 
termination, we decided to evaluate if geneticin can affect the recognition by the 
ribosome of premature as well as normal stop codons, resulting in a substantial 
alteration of the protein expression. In this regard, some colleagues performed 
two-dimensional electrophoreses using cytoplasmic extracts from m5 β039-globin 
K562 clone cells untreated and treated with 400 ng/µl G418, obtaining that only 5 
out of 350 proteins significantly increase or decrease following treatment with 
geneticin, which therefore shows only negligible effects on protein expression in 
our m5 K562 clone. 
As geneticin, although shown to be an excellent translational corrector, has 
many disadvantages, in particular the high toxicity, we decided to check the read-
through activity of other aminoglycosides, first of all gentamicin. Thus, we treated 
original K562 cells with 1.2 µg/µl and 1.4 µg/µl gentamicin and wt3 βwt-globin 
and m5 β039-globin K562 clones cells with increasing concentrations of such 
aminoglycoside (600 ng/µl, 800 ng/µl, 1 µg/µl, 1.2 µg/µl and 1.4 µg/µl), decided 
depending on the inhibition curves performed on m5 K562 cell clone. Because the 
FACS analysis showed a greater sensitivity compared to the 
immunohistochemistry, we decided to limit ourselves to the first in determining 
the effects on β-globin chain production after treatment with the aminoglycoside. 
The treatment of control cells with gentamicin determined a not significant 
increase in the proportion of β-globin containing cells, furthermore not dependent 
to the concentration. On the contrary, treated m5 β039-globin K562 clones cells 
showed a clear increment in the proportion of β-globin containing cells, 
proportionally to the concentration of gentamicin, but much smaller than that 
obtained after treatment with geneticin, leading us to conclude that also if 
gentamicin presents an obvious read-through activity, G418 is a stronger 
translational corrector. Our data on these two aminoglycosides are consistent with 
those reported by Manuvakhova et al [2000], where geneticin and gentamicin 
showed a percentage of read-through equal to 22.1% and 4%, respectively, in the 
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presence of the tetranucleotide (comprised of the stop codon and the first 
nucleotide that follows) formed as a result of the β039 mutation.  
Unfortunately with the other aminoglycosides tested (neomycin, paromomycin, 
kanamycin, amikacin, streptomycin, tobramycin, higromycin), we did not achieve 
any results better than those previously obtained with G418 and gentamicin. In 
any case, our data allow us to conclude that aminoglycosides, to varying degrees 
depending on the compound, are indeed able to induce translational read-through 
of the β039-thalassemia mutation, leading to the production of full length β-globin 
chains. 
At this point, we decided to characterized the read-through activity of geneticin 
using a different cellular system, namely erythroid precursor cells isolated from 
β
039-thalassemia patients, whose growth in vitro represents more closely than cell 
lines the in vivo situation. In this regards, we sequenced the β-globin gene of 
several β0-thalassemia patients and isolated the erythroid progenitors from such 
individuals resulted homozygous for the β039 mutation. Due to the limited number 
of erythroid precursor cells obtained from each subject, we decided to treat the 
cells only with 200 ng/µl and 400 ng/µl G418. The FACS analysis of the treated 
β
039 progenitors showed a clear increase in the proportion of β-globin containing 
cells, dependently to the geneticin concentration. Because these cells produce only 
β
039-globin transcripts the yield of β-globin chains can be explained only by the 
translational read-through activity of the aminoglycoside, which prevents the 
recognition of the premature termination codon by the ribosome and rescues the 
nonsense mRNA from the NMD pathway.  
As known, the ribosome under the action of aminoglycosides cannot 
discriminate between the amino acids introduced at the premature stop codon, so 
amino acids very different from the correct one can be added to the polypeptide 
chain, leading to the production of not functional proteins. For this reason, we 
decided to verify if β-globin chains produced by β039 erythroid precursor cells 
treated with G418 were able to generate adult haemoglobin, performing a HPLC 
analysis, which can give us information about the relative concentration of HbA 
compared to total Hbs. The obtained chromatograms showed a significant increase 
in the proportion of HbA with a concomitant expected decrease in the proportion 
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of HbF and HbA2, respect to the total Hbs content, after treatment with geneticin. 
Such increase, however, was smaller than the increment of the proportion of β-
globin containing cells, detected by FACS analysis, due to fact that only a part of 
the amino acids incorporated by the ribosome at the premature stop codon gave 
rise to a protein able to interact with α-globin chains to yield a molecule of HbA.  
Finally, we decided to evaluate if also in the case of β039 erythroid precursor 
cells the treatment with G418 lead to an increase in the β-globin mRNA content 
respect to control cells, due to the rescue of the PTC containing transcripts from 
the degradation by NMD pathway. The results obtained by quantitative real time 
RT-PCR showed, after treatment with geneticin, increases in β-globin mRNA 
content even greater than those achieved in the case of the m5 β039-globin K562 
cell clone. Such increases, proportional to the aminoglycoside concentration, 
confirm the ability of G418 to reduce the recognition of the nonsense mRNA by 
the NMD machinery.  
 
In the final part of our work, we decide to verify the possible use of the 
pCCL.βwt.PGW lentiviral vector for gene therapy using β039 erythroid precursor 
cells. This vector, as already described, presents some important characteristics 
which make the integration of the transgene into the genome safe and efficient, 
minimizing the effects of the surrounding chromatin, which could silence its 
expression, and the enhancing effects of the contained promoters on oncogenes. 
Moreover, we decided to test the combined effects of gene therapy with the 
lentiviral vector and fetal haemoglobin induction by treatment with mithramycin, a 
potent HbF inducer [Bianchi et al, 1999; Fibach et al, 2003], to verify if the 
concomitant increases in HbA and HbF could lead to a haemoglobin content 
similar to that of a heterozygous subject.  
First of all, we quantified the copy number of vectors integrated into the 
cellular genome of transduced β039 erythroid progenitors, treated or not with 30 
nM mithramycin, by quantitative real time PCR. We achieved β-globin transgenes 
folds in transduced versus untransduced cells, varying from about 1.2 to 2. An 
expected result because of the low MOI used for the infection, with the purpose to 
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obtain limited introduction of exogenous sequences, mimicking the physiological 
situation. 
Once verified to have reached our goal regarding the number of vectors 
integrated, we evaluated the α-, β- and γ-globin mRNA content in transduced β039 
erythroid precursor cells treated or not with the mithramycin. In β-thalassemia, the 
synthesis of normal α-globin chains from the unaffected α-globin genes continues 
as normal, resulting in the accumulation within the erythroid precursors of excess 
unmatched α-globin. The free α-globin chains are not able to form viable tetramers 
and instead precipitate in red cell precursors in the bone marrow forming inclusion 
bodies. They are responsible for the extensive intramedullary destruction of the 
erythroid precursors and hence the ineffective erythropoiesis that underlies all β-
thalassemias [Thein, 2005]. For this reason, it is very important, for an effective 
therapy, that the increase in β-like globin genes expression does not coincide with 
an increase in α-globin genes expression, so as to reduce the precipitation of the α-
globin chains, ameliorating the viability of red blood cells. Our results showed that 
the α-globin mRNA content remained stable even after infection with 
pCCL.βwt.PGW vector and treatment with mithramycin, whereas the β-globin 
mRNA content clearly increased after transduction with the lentiviral vector, 
diminishing in the presence of mithramycin, which instead caused a significant 
increment in the γ-globin mRNA content. The reduction of the abundance of β-
globin transcripts following the treatment with mithramycin can be explained by 
the fact that this compound is a potent HbF inducer and affects transcription by 
moving toward the expression of fetal globin genes, reducing the production of β-
globin mRNA [Breveglieri et al, manuscript in preparation].  
Finally, we performed a HPLC analysis to evaluate the effective production of 
functional HbA and HbF following transduction with pCCL.βwt.PGW vector and 
treatment with mithramycin, using the erythroid progenitors isolated from two 
β
039-thalassemia patients. In the first case, the chromatogram showed a high 
proportion of HbF and a very low proportion of HbA in control cells. After 
infection with the lentiviral particles the relative concentration of HbA increased 
significantly whereas that of HbF remained stable, slightly increasing in presence 
of mithramycin, with a concomitant reduction of the HbA relative concentration. 
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On the contrary, in the second case, both the proportion of HbF and HbA were low 
in control cells, but the transduction with pCCL.βwt.PGW vector induced a clear 
increase in the relative concentration of HbA, which remained stable also in 
presence of mithramycin, which instead induced a strong increase in the 
proportion of HbF.  
From the result obtained on the globin transcripts content and the Hbs 
proportion, we can affirm that our lentiviral vector containing the βwt-globin gene 
is suitable to perform gene therapy of the β039-thalassemia, particularly when 
associated with the treatment with mithramycin.  
Concluding, we can assert that both the therapeutic approaches for the cure of 
β
0
-thalassemias analysed in this work, namely translational read-through and gene 
therapy, while still presenting many disadvantages, including toxicity of 
aminoglycosides and the uncertainty of the effects of lentiviral vector on 
endogenous genes, can be considered techniques with a high curative potential. Of 
course, in the case of translational read-through is hoped the identification of new 
compounds with a therapeutic effect similar to but greater than that of 
aminoglycosides, with less toxicity and oral bioavailability, while in the case of 
gene therapy, further investigations should be made to eliminate its well known 
disadvantages, primarily including the possible activation of oncogenes. In this 
respect, most investigators are studying the development of viral vectors 
increasingly safe and efficient. 
Finally, regarding the production of new translation correctors, in a recent 
paper by Welch et al. [2007], two high-throughput screens (comprising 800,000 
low molecular weight compounds) were performed to identify compounds that 
promoted UGA nonsense suppression. Chemical scaffolds were identified and 
optimized through extensive medicinal chemistry efforts. These analyses 
identified PTC124 (3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; 
C15H9FN2O3) as a candidate for further development. The selectivity of PTC124 
for premature termination codons, its well characterized activity profile, oral 
bioavailability and pharmacological properties indicate that this drug may have 
broad clinical potential for the treatment of a large group of genetic disorders with 
limited or no therapeutic options.  
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Table 1. Synthetic oligonucleotides used as primers in polymerization chain reactions (PCR).  
 
 
 
 
 
 
 
 
Name Strand Nucleotide sequence Length Tm (°C) 
BGF forward 5’-GTGCCAGAAGAGCCAAGGACAGG-3’ 23 72.1 
BGR reverse 5’-CACTGACCTCCCACATTCCCTTTT-3’ 24 69.8 
BGF1 forward 5’-AGACCTCACCCTGTGGAGCC-3’ 20 67.9 
BGR1 reverse 5’-AGTTCTCAGGATCCACGTGCA-3’ 21 67.1 
BGF2 forward 5’-CTTGATGTTTTCTTTCCCCTTC-3’ 22 62.5 
BGF3 forward 5’-ACAATCCAGCTACCATTCTGCTTT-3’ 24 65.7 
BGR3 reverse 5’-AGGCAGAATCCAGATGCTCAAG-3’ 22 66.6 
BGF4 forward 5’-GCATCTGGATTCTGCCTAATAA-3’ 22 61.8 
BGF5 forward 5’-GCCTGGCTCACCTGGACA-3’ 18 67.9 
BGF6 forward 5’-CGCTTTCTTGCTGTCCAATTTC-3’ 22 66.7 
BGR7 reverse 5’-CTGTCTCCACATGCCCAGTTT-3’ 21 66.3 
LV1F forward 5’-GGATCTCGACGGTATCGGTTAACT-3’ 24 66.9 
LV1R reverse 5’-GGGTGTGTGCCCAGATGTTCT-3’ 21 68.4 
LVA forward 5’-GGTGGTTGATGGTAACACTATGCT-3’ 24 64.7 
LVB reverse 5’-TTTTACGGCGAGATGGTTTCTC-3’ 22 66.0 
LVC forward 5’-GATTCCGGGTCACTGTGAGTG-3’ 21 66.8 
LVD reverse 5’-ATCCCAAAGCTGAATTATGGTAGAC-3’ 25 64.0 
LVE forward 5’-TCCTGGGAGTAGATTGGCCA-3’ 20 66.7 
LVF forward 5’-ATCCTCCTTTGCAAGTGTATTTACG-3’ 25 64.9 
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Table 1. Synthetic oligonucleotides used as primers and probes in real time quantitative PCR.  
 
 
 
 
 
 
 
 
 
 
 
 
Name Strand Nucleotide sequence Length Use 
PF forward 5’-CAGGCTGCTGGTGGTCTAC-3’ 19 Primer 
PR reverse 5’-AGTGGACAGATCCCCAAAGGA-3’ 21 Primer 
PFα forward 5’-CACGCGCACAAGCTTCG-3’ 17 Primer 
PRα reverse 5’-AGGGTCACCAGCAGGCAGT-3’ 19 Primer 
PFβ forward 5’-CAAGAAAGTGCTCGGTGCCT-3’ 20 Primer 
PRβ reverse 5’-GCAAAGGTGCCCTTGAGGT-3’ 19 Primer 
PFγ forward 5’-TGGCAAGAAGGTGCTGACTTC-3’ 21 Primer 
PRγ reverse 5’-TCACTCAGCTGGGCAAAGG-3’ 19 Primer 
Pβwt  5’-VIC-AAAGAACCTCTGGGTCCA-TAMRA-3’ 18 Probe 
Pβ039  5’-FAM-CAAAGAACCTCTAGGTCCA-TAMRA-3’ 19 Probe 
Pα  5’-FAM-TAGTGATGGCCTGGCTCACCTGGAC-TAMRA-3’ 25 Probe 
Pβ  5’-FAM-TAGTGATGGCCTGGCTCACCTGGAC-TAMRA-3’ 25 Probe 
Pγ  5’-FAM-TGGGAGATGCCATAAAGCACCTGG-TAMRA-3’ 24 Probe 
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Table 3. Endonucleases used in cloning experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nome 
Restriction 
site 
Conc. Buffer Temp. Company 
ClaI 
AT CGAT 
TAGC TA 10 U/µl 
Buffer Y+/Tango: 
33 mM Tris-acetato pH 7.9, 10 mM Mg-acetato, 
66 mM K-acetato, 0.1 mg/ml BSA 
37°C MBI Fermentas 
NcoI 
C CATGG 
GGTAC C 10 U/µl 
Buffer Y+/Tango: 
33 mM Tris-acetato pH 7.9, 10 mM Mg-acetato, 
66 mM K-acetato, 0.1 mg/ml BSA 
37°C MBI Fermentas 
PmeI 
GTTT AAAC 
CAAA TTTG 10 U/µl 
Buffer B+: 
10 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 
mg/ml BSA 
37°C MBI Fermentas 
SmaI 
CCC GGG 
GGG CCC 10 U/µl 
Buffer Y+/Tango: 
33 mM Tris-acetato pH 7.9, 10 mM Mg-acetato, 
66 mM K-acetato, 0.1 mg/ml BSA 
30°C MBI Fermentas 
SwaI 
ATTT AAAT 
TAAA TTTA 10 U/µl 
Buffer 0+: 
50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 100 mM 
NaCl, 0.1 mg/ml BSA 
30°C MBI Fermentas 
XbaI 
T CTAGA 
AGATC T 10 U/µl 
Buffer Y+/Tango: 
33 mM Tris-acetato pH 7.9, 10 mM Mg-acetato, 
66 mM K-acetato, 0.1 mg/ml BSA 
37°C MBI Fermentas 
SnaBI 
TAC GTA 
ATG CAT 10 U/µl 
Buffer Y+/Tango: 
33 mM Tris-acetato pH 7.9, 10 mM Mg-acetato, 
66 mM K-acetato, 0.1 mg/ml BSA 
37°C MBI Fermentas 
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